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iAbstract
The major event in relapsing remitting multiple sclerosis (MS) is the acute relapse. The 
majority of patients with MS present with such an event. Most early relapses are 
followed by complete or near complete recovery, however partial recovery or 
significant disability can result from an individual relapse. Study of relapses in vivo is 
therefore desirable. Magnetic resonance imaging (MRI) is very sensitive at detecting 
MS lesions. Unfortunately, in the brain and spinal cord, it has been difficult to reliably 
identify the lesion that is responsible for the symptoms of an individual relapse and 
most new brain lesions which are apparent on MRI are clinically silent.
Optic neuritis provides an attractive model to study the effects of relapses in MS. Optic 
neuritis is a frequent manifestation of MS and has been regarded as a forme fruste of the 
disease. The natural history of acute optic neuritis mirrors that of an acute MS relapse 
elsewhere in the central nervous system (CNS) and the response to corticosteroid 
therapy is the same. Visual function can be measured accurately in a rater-independent 
fashion and it is possible to measure the latency and amplitude of the visual evoked 
potential (VEP) which gives information about the integrity of the visual conducting 
pathways.
Developments in imaging technology and application now means that, potentially more 
pathologically specific imaging sequences can be applied to the study of the optic 
nerves. This thesis will investigate the application of these new imaging techniques, 
along with clinical and VEP measures, to the study of optic neuritis in order to gain new 
insights into the effect of individual lesions on structure and function in the CNS in the 
short- and long-term.
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Optic Neuritis 1
Chapter 1 Optic Neuritis
1.1 Anatomy and physiology of the optic nerve
1.1.1 Gross anatomy
The optic nerve is an offshoot of the brain and is covered by a sheath, made up of the 
full three layers of meninges in continuity with the leptomeninges of the brain, which 
transmits the cerebrospinal fluid (CSF) (Tamraz, 1994). Its blood supply comes from 
the ophthalmic artery, a branch of the internal carotid artery (Sadun, 1998). The optic 
nerve in adult humans is about 40-5Omm long and is subdivided into four parts with 
varying lengths and cross-sectional areas (Table 1.1 and Table 1.2). The two optic 
nerves fuse in the cranial cavity to form the optic chiasm where the nerve fibres from 
the nasal half of each retina decussate (Sadun, 1998).
1.1.2 Optic nerve head
The optic nerve head is approximately 1mm long (anterior-posterior) by 1.5mm 
horizontally and 1.8mm vertically. The anterior surface is the optic disc that is visible 
on fundus examination (Tamraz, 1994; Sadun, 1998).
1.1.3 Infraorbital optic nerve
The intraorbital optic nerve is 20-30mm long (Blinkov & Glezier, 1968; Tamraz, 1994; 
Sadun, 1998), and has a sinuous course from the back of the globe to the optic foramen. 
The intraorbital optic nerve is approximately 6mm longer than the distance it has to 
traverse to allow for movements of the eye (Williams et al., 1989). The nerve is 3mm 
in diameter at the globe, increasing to 4.5mm at the orbital apex (Sadun, 1998), with an 
average diameter in the globe of 3.5mm (Tamraz, 1994) and is circular in shape 
(Sylvester & Ari, 1961; Barker, 2000), The nerve is surrounded by the nerve sheath, 
containing the CSF, and then orbital fat containing the ciliary vessels and nerves 
(Williams et al., 1989). The dura fuses anteriorly with the sclera and posteriorly with 
the periosteum of the optic canal (Tamraz, 1994). At the orbital apex the optic nerve is
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surrounded by the annulus of Zinn, the origin of the four rectus muscles of the orbit 
(Sadun, 1998).
Portion of optic nerve Approximate anterior-posterior length
i) Optic nerve head 1mm
ii) Intraorbital optic nerve 20-30mm
iii) Intracanalicular optic nerve 4-10mm
iv) Intracranial optic nerve 3-16mm
Total optic nerve length 40-50mm
Optic chiasm 4-13 mm
Table 1.1: Approximate anterior-posterior length of adult human optic nerve
according to position within the nerve (Blinkov & Glezier, 1968; 
Williams etal., 1989; Tamraz, 1994; Sadun, 1998; Slamovits, 1998).
Portion of optic nerve Optic nerve mean cross-sectional area
Intraorbital 6.75-6.95mm2
(i) Anterior 6.16mm2
Intracanalicular (ii) Middle 6.66mm2
(iii) Posterior 7.71mm2
Intracranial 9.93-12.09mm2
Table 1.2: Optic nerve mean areas according to position within the optic nerve from
human adult autopsy studies (Donaldson & Bolton, 1891; Sylvester & 
Ari, 1961; Dolman et al., 1980; Jonas et al., 1990; Rimmer et al., 1993; 
Chou et al., 1995).
1.1.4 Intracanalicular optic nerve
The optic nerve enters the optic canal through the orbital foramen. The canal is formed 
by the union of the two roots of the lesser wings of the sphenoid bone. The canal is 4- 
10mm long (Blinkov & Glezier, 1968; Tamraz, 1994; Sadun, 1998), is approximately 
21mm in cross-sectional area anteriorly, narrowing to 16mm at its mid-point, and 
increasing again to 18mm2 posteriorly (Chou et al., 1995). Each canal runs posteriorly
Optic Neuritis 3
and medially. The sphenoid sinus and the posterior ethmoidal air cells lie medial to the 
optic canal. Infero-laterally the optic strut, which joins the lesser wing of the sphenoid 
bone to its main body, separates the canal from the superior orbital fissure (Sadun, 
1998). The optic strut joins with the anterior clinoid posteriorly (Goldberg et al., 1992). 
Superiorly is a plate of bone, over which lies the frontal lobe of the brain, although 
occasionally the frontal sinus extends this far back. Unlike the intraorbital optic nerve 
the intracanalicular portion is fixed and cannot move freely as the eye moves. The dura 
is adherent to the bones of the canal on one side and the optic nerve on the other (Sadun, 
1998). The limited space within the canal and its bony walls makes the optic nerve 
vulnerable to damage from blunt trauma (Chou et al., 1995) and from compression due 
to swelling of the optic nerve, possibly explaining the previous observation of a poorer 
prognosis when the intracanalicular optic nerve is involved in optic neuritis (Miller et 
al., 1988).
1.1.5 Intracranial optic nerve
The optic nerves exit the canal into the cranial cavity. The intracranial optic nerves are 
3-16mm in length and 4.5-5mm in diameter (Blinkov & Glezier, 1968; Tamraz, 1994; 
Sadun, 1998), but are elliptical in shape (Sylvester & Ari, 1961; Barker, 2000), and take 
a posterior, superior and medial course to join at the optic chiasm. The frontal lobes of 
the brain lie superiorly. The olfactory tracts here are separated from the optic nerve by 
the anterior cerebral and anterior communicating arteries. Laterally, lie the internal 
carotid artery and its branches. The ophthalmic artery is given off here and enters the 
canal infero-laterally to the optic nerve. Infero-medially lies the sphenoid sinus (Sadun, 
1998).
1.1.6 Optic chiasm
Within the optic chiasm nerve fibres from the nasal retina (serving the temporal visual 
field) cross to the contralateral optic tract, whereas temporal fibres (serving nasal 
vision) continue within the ipsilateral optic tract. The chiasm has a transverse diameter 
of 10-20mm, an anterior-posterior width of 4-13mm and is 3-5mm thick (Blinkov & 
Glezier, 1968; Tamraz, 1994; Sadun, 1998). The chiasm overlies the tuberculum sellae 
of the sphenoid bone and the pituitary gland, hence its vulnerability to damage from
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supra-sellar extension of pituitary tumours. In 79% of cases the chiasm is postfixed, 
overlying the posterior two-thirds of the sella. In 12% of cases it is over the middle 
sella, in 4% it is over and behind the dorsum sellae and in 5% it is in the chiasmatic 
sulcus. This explains the variation in position of the chiasm on imaging (Tamraz, 1994) 
and the differences in length seen in the intracranial optic nerves (Sadun, 1998). 
Inferolateral to the chiasm lies the cavernous sinuses and laterally are the supraclinoid 
portions of the internal carotid arteries. Posteriorly is the third ventricle, anteriorly the 
anterior communicating arteries, and superiorly lies the lamina terminalis (Sadun,
1998).
1.1.7 Optic nerve histology and physiology
The axons of the optic nerve start at the retinal ganglion cells and synapse in the lateral 
geniculate nucleus (LGN), either ipsilateral or contralateral depending on their path 
through the optic chiasm. Some fibres terminate in the optic tectum in the brainstem 
and may play a role in pupillary responses. There are in addition efferent fibres which 
are thought to terminate in the retina. These may be involved in a feedback system to 
modulate the visual response (Sadun, 1998).
As in the central nervous system (CNS) the nerve fibres are myelinated by 
oligodendrocytes rather than Schwann cells which myelinate peripheral nerves. 
Astrocytes are also present. All of the axons subserving vision are myelinated after they 
pass through the lamina cribrosa in the optic nerve head. In one study the optic nerves 
were reported to contain 1,010,000±84,000 myelinated fibres each, and in addition a 
large number of unmyelinated fibres which may be the efferent fibres mentioned above 
(Blinkov & Glezier, 1968). The presence of unmyelinated fibres is disputed (Anderson 
& Hoyt, 1969). Two further studies recorded mean fibre counts of 1,244,005±20,033 
(Balazsi et al., 1984) and 1,159,000±196,000 (Jonas et al., 1990) respectively. The 
cross-sectional area of the intra-orbital optic nerve is 6.75-6.95mm2 (Table 2) (Dolman 
et al., 1980; Jonas et al., 1990; Rimmer et al., 1993). The density of myelinated fibres 
is therefore approximately 150,000 per mm2.
The mean diameter of axons is 0.96±0.09/xm. 95% of axons are between 0.3 and 2pm 
across (Repka & Quigley, 1989). Mean axonal area is 0.644±0.361/zm2. The axons are
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about one tenth of the size of spinal ventral root axons with myelin sheaths 
approximately one half as thick (Kunii et al., 1999). There are two classes of retinal 
ganglion cells in humans. About 80-90% of them are small-to-medium sized, are 
concentrated in the macula and project to the parvocellular layers of the dorsal LGN. 
These P-cells have colour-opponent physiology and are thought to subserve high- 
contrast, high-spatial frequency resolution. In contrast, the remainder are large cells 
which project to the magnocellular layers of the LGN (the M-cells) and are primarily 
involved with non-colour information of high temporal and low spatial frequency 
(Sadun, 1998).
The inner layer of the meninges, the pia mater wraps around the optic nerve. From its 
inner surface fibrous septa, containing collagen, enter the nerve subdividing it into 
longitudinal polygonal sections occupied by fascicles of axons, approximately 1000 
fascicles in all (Williams et al., 1989). Separation is incomplete and communication 
between different fascicles without a connective tissue barrier can occur at different 
points along the nerve length (Anderson & Hoyt, 1969). With the exception of the 
central retinal vessels within a central connective tissue core most blood vessels in the 
optic nerve are very small. These arterioles, venules and capillaries all run in the 
connective tissue septa. The arterial input to the nerve derives chiefly from the 
surrounding plial plexus (Sadun, 1998). The presence of these septa distinguishes the 
optic nerve from other CNS white matter tracts.
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1.2 Optic neuritis
Optic neuritis is a common condition, having an incidence of 1-5 per 100,000/year 
(Rodriguez et al., 1995; Jin et al., 1998; MacDonald et al., 2000). The incidence is 
highest in Caucasians (Optic Neuritis Study Group, 1991), in countries from higher 
latitudes (Jin et al., 1998) and in spring (Jin et al., 1999). The age group principally 
affected is 20-49 years, females being more commonly affected (Jin et al., 1998). It 
usually presents as subacute unilateral loss of vision, although bilateral visual loss can 
occur, either simultaneous or sequential. Most cases of optic neuritis are due to 
idiopathic inflammatory demyelination, which may occur in isolation, or as a 
manifestation of multiple sclerosis (MS) (Optic Neuritis Study Group, 1997a). The 
causes of optic neuritis/MS are currently unknown. A genetic predisposition exits as 
suggested by the epidemiology of the condition, although the genetic component is not 
Mendelian and linkages have been proposed at chromosomes lp, 6p, lOp, 17q and 19q 
(Compston & Coles, 2002). Environmental factors, in particular exposure to viruses, 
are probably also important although, as yet, no reliable candidate has been identified.
1.2.1 Presentation of optic neuritis
The typical presenting features of optic neuritis are listed in Table 1.3 (Perkin & Rose, 
1979; Optic Neuritis Study Group, 1991; Beck, 1998). Optic neuritis usually presents 
as a painful subacute unilateral loss of vision, which progresses over a period of a few 
days to two weeks. In about 10% of cases no pain is reported. Phosphenes (photopsias) 
may be seen by the patient on eye movement (Davis et al., 1976). Clearly, subclinical 
cases are very common as some patients present with Uhthoff s phenomenon (visual 
deterioration on getting warm, or during exercise) (Selhorst & Saul, 1995) and delayed 
visual evoked potentials (VEP) are not uncommon in early MS, even without a previous 
history of optic neuritis (Feinsod & Hoyt, 1975).
The maximal visual loss varies from minor blurring to no perception of light (NPL) in 
the diseased eye. Abnormal colour vision, reduced contrast sensitivity, visual field loss 
and a relative afferent pupillary defect (RAPD) are usually present in the affected eye 
(Levatin, 1959; Perkin & Rose, 1979; Optic Neuritis Study Group, 1991). Whilst any 
type of visual field defect may be seen, and the type of defect may vary over time, the
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most characteristic finding is a central or para-central scotoma (Keltner et al., 1993). 
The presence of an RAPD is a useful objective sign of a unilateral optic neuropathy, 
although it is not specific for optic neuritis. The lack of an RAPD may reflect mild 
clinical involvement in the affected eye, previous optic neuritis in the contralateral eye 
or subclinical optic neuropathy in the contralateral eye (Cox et al., 1981).
Typical features of optic neuritis 
20-49 age group 
Female>male 
Caucasian
Peri-ocular pain and pain on eye movement
Pain may precede onset of visual symptoms
Progressive visual loss over a few days
Phosphenes (photopsias) provoked by eye movement
Previous history of multiple sclerosis or previous neurological
symptoms
Spontaneous improvement in vision
Uhthoff s phenomenon (usually not noticed until the recovery phase) 
Fading of vision (usually not noticed until the recovery phase) 
Pulfrich’s effect (usually not noticed until the recovery phase)
Typical signs of optic neuritis 
Decreased visual acuity 
Decreased colour vision 
Decreased contrast sensitivity 
Any type of visual field defect 
Relative afferent pupillary defect 
Normal or swollen optic disc 
Normal macula and peripheral retina 
Uveitis or retinal phlebitis may be detected
Table 1.3: Typical symptoms and signs of optic neuritis.
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Slit lamp examination occasionally reveals cells in the anterior chamber or vitreous but 
is usually normal (Lightman et al., 1987). However, intermediate uveitis, pars planitis, 
panuveitis and granulomatous uveitis have all been associated with optic neuritis and 
MS. The uveitis may be present for some years before the onset of optic neuritis or MS 
(Malinowski et al., 1993; Biousse et al., 1999). The optic disc appears swollen in 36- 
58% of cases at presentation (Perkin & Rose, 1979; Optic Neuritis Study Group 1991). 
Small flame-shaped haemorrhages or marked optic disc swelling with cotton wool spots 
on the retina are seen occasionally. In cases where there is no disc swelling the 
condition is often labelled retrobulbar neuritis. Retinal examination is usually 
unremarkable. However, in a series of 50 consecutive patients with optic neuritis, 
peripheral retinal peri-phlebitis (peri-venous sheathing) was seen in six patients and 
fluoroscein leakage was seen in 10 (Lightman et al., 1987). The presence of these 
abnormalities was linked with an increased risk for subsequent development of MS. 
Retinal peri-phlebitis can also be seen in MS in the absence of optic neuritis and on 
occasion it can be so severe as to cause retinal ischaemia and peripheral retinal 
neovascularisation (Vine, 1992). It is uncertain whether eyes affected by optic neuritis 
will show a higher incidence of retinal peri-phlebitis than eyes of MS patients which 
have not been affected by optic neuritis.
1.2.2 Fellow eye involvement
One of the most surprising aspects of unilateral optic neuritis is that asymptomatic 
deficits may be detected in the contralateral eye. In the North American Optic Neuritis 
Treatment Trial (ONTT) abnormalities were seen on visual acuity testing (logMAR 
>0.0) in 12.2%, contrast sensitivity testing (Pelli-Robson <1.67 log units) in 13.4%, 
colour vision testing (Farnsworth Munsell 100 Hue Test [FM 100] square root of error 
score >10.5) in 19.9% and visual field testing (Humphrey mean deviation <-3.0) in 
46.3% of patients without a previous history of optic neuritis in that eye (Beck et al., 
1993b). The presence of fellow eye abnormalities was not associated with previous MS 
or lesions on brain MRI suggesting that dissemination of the disease was not 
responsible. The Japanese Multicentre Treatment Trial discovered abnormal visual 
fields in 53%, abnormal colour vision ( >1 error using Ishihara pseudoisochromatic 
plates) in 7.7%, reduced contrast sensitivity at one or more spatial frequencies in 14.6% 
and critical flicker fusion frequency less than 35Hz in 16.1% of contralateral eyes
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(Wakakura et al., 1999b). Previous asymptomatic optic neuritis may account for some 
of these effects although the majority of fellow eyes with abnormalities in the ONTT 
recovered to normal after six months’ follow-up suggesting that acute inflammation in 
the fellow optic nerve was responsible (Beck et al., 1993b). Another possibility is that 
the effects are due to chiasmal or retro-chiasmal involvement in the symptomatic side. 
The ONTT demonstrated chiasmal or retro-chiasmal visual field defects in 13.2% of 
patients at least once during the first year of follow-up (Keltner et al., 1994).
1.2.3 Recovery
In optic neuritis the pain rarely lasts more than a few days and vision deteriorates over a 
period of a few days to two weeks before spontaneously improving (Beck, 1998). In the 
placebo group of the ONTT 79% had begun to show signs of improvement ( >  one line 
on chart) within three weeks of onset, and 93% by five weeks (Beck, 1998). The initial 
period of recovery is rapid. In one study (Perkin & Rose, 1979), at three weeks after 
onset -40% had a visual acuity of counting fingers or worse, -30% were 6/18 to 6/60 
and -30% were 6/12 or better. At four weeks -17% were counting fingers or worse, 
-33% were 6/18 to 6/60 and -50% were 6/12 or better. Amongst patients who were 
followed for at least six months 85.7% reached a final visual acuity of between 6/6 and 
6/12, 9.6% were between 6/18 and 6/60, and 4.7% between counting fingers and NPL. 
The mean period of recovery to 6/6 amongst those who reached this level was 8.1 
weeks, which was not affected by the severity of visual impairment at presentation. In a 
different series (Bradley & Whitty, 1967), vision had improved to normal (defined as 
Snellen acuity of 6/9 or better) in half of the patients after one month, and in three- 
quarters by six months. The recovery here was slower in those with poor vision at onset 
(6/60 or worse).
For most patients in the ONTT, recovery of visual acuity was nearly complete by five 
weeks after onset of symptoms. Further improvement however, was noted even up to 
one year after onset. The mean visual acuity at one year after entry into the study was 
20/15, with less than 10% having a visual acuity worse than 20/40 (Beck, 1998). The 
amount of visual improvement after optic neuritis does not seem to be related to age, 
gender, ethnicity, concurrent presence of multiple sclerosis, or abnormalities on brain 
magnetic resonance imaging (Beck et al., 1994). Severity of the initial visual loss in the
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ONTT was related to final visual outcome, although still most patients recovered well. 
Of 187 patients with visual acuity worse than 20/200 on admission to the ONTT, only 
6% had this level of acuity or worse at 6 months. Of 28 patients with light perception 
only or worse, 64% recovered to 20/40 or better (Beck & Cleary, 1993b). In another 
patient group, of 12 patients who presented with NPL in the diseased eye, five 
recovered to 20/20 or better, three to 20/40 or better and four had peripheral recovery 
but dense central scotomata and visual acuities of less than 3/60 (Slamovits et al.,
1991).
Other visual parameters tend to improve in parallel with the improvement in visual 
acuity, but subjective residual deficits are common (Beck, 1998). In one study of 58 
patients one year after untreated optic neuritis 59% reported that their vision had not 
returned to normal, although only 5 (8.0%) patients had a visual acuity in the diseased 
eye worse than 6/9 (Frederiksen et a l, 1997). The vision after optic neuritis may show 
marked variation during the day and from one day to the next (Wall et al., 1998) and 
may deteriorate in specific situations, for example Uhthoff s phenomenon (Selhorst & 
Saul, 1995) and fatigue or fading of vision (Enoch et al., 1979). Pulfrich’s phenomenon 
(misperception of the trajectory of moving objects) is also occasionally seen (Slagsvold,
1978).
The optic disc usually becomes pale, either diffusely or more often in the temporal 
region, despite improvements in vision (Beck, 1998). Abnormalities in the retinal nerve 
fibre layer (RNFL) have also been seen following optic neuritis and reflect axonal loss 
(Steel & Waldock, 1998). The RAPD may disappear on recovery although, particularly 
in cases where there is poor recovery, it may be persistent.
1.2.4 Differential diagnosis
The differential diagnosis of optic neuritis with appropriate investigations is considered 
in Table 1.4. Misdiagnosis of optic neuritis has been reported in clinical trials. Out of 
457 patients enrolled in the ONTT, three were subsequently diagnosed as having 
anterior ischaemic optic neuropathy, two had compressive lesions (one ophthalmic 
artery aneurysm and one pituitary tumour) and two had connective tissue diseases in 
addition to optic neuritis (Optic Neuritis Study Group, 1991; Beck et al., 1992).
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Diagnosis Usual clinical features Tests to consider
Corticosteroid responsive optic neuropathies 
Sarcoidosis
Systemic lupus erythematosus
Autoimmune optic neuritis
Chronic relapsing inflammatory optic
neuropathy
Optic peri-neuritis
Beh?et’s disease
Neuromyelitis optica (Devic’s disease)
Progressive severe visual loss 
May be very painful 
Often bilateral (simultaneous 
or sequential)
Isolated or as part o f a multi­
system disorder 
More common in Africans or 
Afro-Caribbeans (sarcoidosis) 
Corticosteroid dependent
Contrast-enhanced 
MRI orbits and brain 
Lumbar puncture 
ANA
serum ACE 
CXR
67Gallium scan 
Biopsy o f accessible 
tissue (sarcoid)
Other inflammatory optic neuropathies
Post-infectious
Post-vaccination
Acute disseminated encephalomyelitis 
Neuroretinitis
Bilateral and simultaneous 
Often in childhood 
Usually excellent prognosis
Swollen disc and macular star 
Spontaneous recovery
Contrast-enhanced 
MRI orbits and brain 
Lumbar puncture
Bartonella, borrelia 
and syphilis serology
Compressive optic neuropathies
Primary tumours, eg meningiomas, gliomas
and pituitary tumours
Metastases
Tuberculomas
Thyroid ophthalmopathy
Arterial aneurysms
Sinus mucocoeles
Painless (rarely painful, eg 
aneurysms and mucocoeles) 
Progressive visual loss 
Optic atrophy at presentation 
Past history of, or evidence for 
primary tumour (metastases)
Contrast-enhanced 
CT or MRI orbits 
and brain
Biopsy if  appropriate
Infectious optic neuropathies
Syphilis
Tuberculosis
Lyme disease
Viral optic neuritis
Progressive visual loss with 
exposure to infectious agent 
Severe optic disc oedema 
Cellular reaction in vitreous
Appropriate serology 
Lumbar puncture 
CXR
Tuberculin test
Ischaemic optic neuropathies 
Anterior ischaemic optic neuropathy 
Posterior ischaemic optic neuropathy (PION) 
Giant cell arteritis (GCA)
Diabetic papillopathy
Usually older age group 
Sudden onset 
Painless (except GCA) 
Swollen optic disc 
(except PION) 
Altitudinal field defect
ESR
Toxic and nutritional optic neuropathies
Vitamin B ]2 deficiency
Tobacco-alcohol amblyopia
Methanol intoxication
Ethambutol toxicity
Cuban and Tanzanian epidemic optic
neuropathies
Bilateral and symmetrical
Painless
Poor prognosis
Serum vitamin B 12
Inherited optic neuropathies 
Leber’s hereditary optic neuropathy Family history 
Sequential (or simultaneous) 
bilateral painless visual loss
Genetic testing for 
Leber’s mutation
Ocular causes 
Posterior scleritis
Maculopathies and retinopathies including 
and central serous retinopathy
Big blind spot syndrome and acute zonal 
occult outer retinopathy (AZOOR)
Severe pain
Less visual symptoms
Painless
Metamorphopsia 
Preserved colour vision
Visual field loss + photopsias 
Normal fundus
B mode ultrasound 
o f orbits
Electroretinogram
Fluoroscein
angiogram
Electroretinogram
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ACE = angiotensin converting enzyme 
CT = computerised tomography 
ESR = erythrocyte sedimentation rate 
Metamorphopsia = distorted vision
ANA = antinuclear antibodies
CXR = chest radiograph
MRI = magnetic resonance imaging
Photopsia = spontaneous showers of light
in vision
Table 1.4: Differential diagnosis of optic neuritis (Rosenberg et a l, 1984; Kansu et
al., 1989; Miller et al., 1995; Dunya et al., 1996; Miller & Newman, 
1998; McCluskey et al., 1999; Zajicek et al., 1999; Acheson, 2000; Gass, 
2000; Eggenberger, 2001; Purvin et al., 2001; Zacks & D'Amico, 2001; 
Kidd et al., 2002).
In a later study, out of 102 patients enrolled 17 were later excluded due to misdiagnosis 
(Wakakura et al., 1999b). The final diagnoses in these 17 were: rhinogenic optic 
neuropathy (sinus mucocoeles) (n=9); brain tumour (n=3); ischaemic optic neuropathy 
(n=2); Leber’s hereditary optic neuropathy (n=l); nutritional optic neuropathy (n=l); 
age-related macular degeneration (n=l).
Presentation with severe pain that restricts ocular movements or wakes the patient from 
sleep should alert to the possibility of posterior scleritis (McCluskey et al., 1999) or an 
infective or granulomatous optic neuropathy, such as sarcoidosis or chronic relapsing 
inflammatory optic neuropathy (CRION) (Zajicek et al., 1999; Kidd et al., 2002). 
Visual loss in infective and granulomatous optic neuropathy is usually more severe than 
in typical optic neuritis and does not spontaneously improve. In cases of optic 
neuropathy due to sarcoidosis there are usually systemic features of the disease that can 
be detected although it may be restricted, at least initially, to the optic nerve (Zajicek et 
al, 1999).
Children or adults may present with a typical history for optic neuritis but, on fundus 
examination, optic disc swelling and a macular star is seen leading to the diagnosis of 
neuroretinitis. This condition is usually idiopathic but may be associated with cat 
scratch disease, Lyme disease, syphilis, toxocariasis, toxoplasmosis or histoplasmosis 
(Eggenberger, 2001). Prognosis for recovery is good and there is no risk of developing 
MS following it (Beck, 1998). Sarcoid optic neuropathy, if it affects the anterior optic
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nerve can cause disc swelling and a macular star (Ray & Gragoudas, 2001), but the 
clinical course is more in keeping with that for sarcoidosis than typical neuroretinitis.
1.2.5 Investigations
Generally, optic neuritis can be diagnosed on clinical grounds (Table 1.3). If any 
warning signs or atypical features for optic neuritis occur leading to suspicion of an 
alternative diagnosis (Table 1.5) then prompt investigations are required (Lee et al., 
2000; Eggenberger, 2001).
Optic atrophy on presentation without previous optic neuritis or multiple sclerosis
Severe optic disc oedema with vitreous reaction
Optic disc haemorrhage
Bilateral loss of vision
Previous history of neoplasia
African or Afro-Caribbean patients with vision <6/12 and no early recovery
Loss of vision to no perception of light with no early recovery
Painless loss of vision to <6/60 with no early recovery
Severe or persistent pain for >2 weeks since onset
Visual loss progressing for >2weeks since onset of visual symptoms
Lack of any recovery >3 weeks after onset of visual symptoms
Worsening of vision after withdrawal of corticosteroids
Table 1.5: Warning signs in the presentation of optic neuritis that should prompt
further investigation to rule out alternative diagnoses.
The best management of some conditions, such as optic nerve compression by a sinus 
mucocoele or a tuberculous or granulomatous optic neuropathy, requires appropriate 
treatment within days of presentation as a significantly worse visual outcome may result 
if treatment is delayed. Thus, an expectant approach must not be adopted where clinical 
features are atypical.
Combined ophthalmological and neurological services is recommended to improve 
diagnostic accuracy and early review is important to ensure that visual recovery, either
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subjectively or objectively, has started to occur. A case o f optic neuropathy in which no 
spontaneous recovery at all has occurred is very unlikely to be optic neuritis.
Investigations should be guided by the clinical presentation (Table 1.4). It is important 
to have ready access to imaging facilities. Contrast-enhanced high resolution CT with 
fine cuts through the orbits will show up most compressive lesions (Acheson, 2000). 
Short tau inversion recovery (STIR) or fat-saturated fast spin echo (FSE) MRI is 
preferable in that it does not involve ionising radiation and can also demonstrate any 
intrinsic optic nerve lesions as in optic neuritis (Figure 1.1) (Gass & Moseley, 2000). 
Experimental study o f optic neuritis with MRI will be considered in the subsequent 
chapters.
Figure 1.1: Fat-saturated proton density FSE MRI in left-sided acute optic neuritis
(diseased optic nerve arrowed).
The VEP may not be helpful in differentiating between different causes o f  optic 
neuropathies in the acute phase (Acheson, 2000), although the combination o f VEP with 
pattern electroretinogram (PERG) may be useful in differentiating macular from optic 
nerve disorders. In retinal disorders both the P50 (early) and N95 (late) components of  
the PERG are abnormal, whereas in optic nerve disorders only the N95 component is 
abnormal (Acheson, 2000; Holder, 2001). In acute optic neuritis however, the P50 may 
be reduced as well in the acute phase, which normalises during recovery (Holder, 2001). 
In clinical practice, the presence o f a delayed but well preserved PI 00 wave o f the VEP 
is most useful in confirming a diagnosis of optic neuritis if  the presentation is delayed,
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or in supporting a diagnosis of MS by demonstrating dissemination in space in 
appropriately selected patients (Halliday et al., 1972; Halliday et al., 1973b). The 
insights that VEP studies have given about the pathophysiology of optic neuritis will be 
considered later.
If a corticosteroid responsive optic neuropathy is suspected then both conventional and 
gadolinium-enhanced MRI of the orbits and brain should be performed. In sarcoidosis, 
CRION and optic peri-neuritis optic nerve sheath enhancement is typical (Carmody et 
al., 1994; Purvin et al., 2001; Kidd et al., 2002). In addition, in sarcoidosis basal 
meningeal enhancement and enhancing cerebral lesions may be seen (Carmody et al., 
1994). White matter lesions on both T2 -weighted and gadolinium-enhanced MRI may 
be non-specific, occurring in both MS and other inflammatory conditions, although the 
former is much more common. The significance of white matter on T2 -weighted scans 
requires a careful consideration of the site and shape of the lesions and the age of the 
patient, recognising that age-related changes due to small vessel disease should not be 
misinterpreted as evidence for demyelination (Miller et al., 1998).
Serological and other evidence for sarcoidosis, vasculitis and syphilis should be sought 
and tuberculosis considered in appropriate patients. In cases of suspected infectious or 
corticosteroid responsive optic neuropathy a lumbar puncture should also be performed. 
The CSF examination can look for infections, hypercellularity, a raised protein level 
and local or systemic production of oligoclonal bands of immunoglobulins to try to help 
differentiate between demyelinating optic neuritis and other causes of inflammatory 
optic neuritis. In optic neuritis there may be no oligoclonal bands, or local intrathecal 
synthesis of immunoglobulins (unmatched bands compared with serum). In CRION, 
sarcoidosis, vasculitis or acute disseminated encephalomyelitis there may be no 
oligoclonal bands or systemic production of immunoglobulins (matched oligoclonal 
bands in both CSF and serum) (Zajicek et al., 1999; Kidd et al., 2002).
1.2.6 Treatment of optic neuritis
A number of therapeutic trials have attempted to improve the prognosis with respect to 
visual outcome in typical optic neuritis. Early, observational studies suggested that 
corticosteroids might be effective, although this view was controversial (Perkin & Rose,
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1979). Subsequent placebo-controlled trials of corticosteroids have been carried out and 
these are summarised in Table 1.6.
A meta-analysis of these trials showed that corticosteroids reduced the number of 
patients without clinical improvement at 30 days (odds ratio 0.60, range 0.42-0.85) but 
did not cause long-term improvement in visual outcome (odds ratio 0.96, range 0.71- 
1.31) (Brusaferri & Candelise, 2000). When the presenting visual acuity was 20/40 or 
better, then corticosteroids conferred no benefit in the ONTT (Beck et al., 1992).
There has been a suggestion that the failure to see a long-term beneficial effect in the 
treatment trials may be because the corticosteroids were given too late to provide 
neuroprotection (Compston & Coles, 2002). Treatment trials in the hyperacute phase 
are required to address this issue.
Corticosteroids can cause significant side-effects. Common minor side-effects reported 
include insomnia, mild mood changes, stomach upsets, facial flushing, acne, oedema 
and weight gain (Beck et al., 1992; Sellebjerg et al., 1999). More serious side-effects 
seen in the IVMP arm (n=151) of the ONTT include one patient developing psychotic 
depression and another developing pancreatitis (Beck et al., 1992). There have also 
been reports of avascular necrosis (osteonecrosis) of the femoral head (McKee et a l, 
2001) and deaths in children due to chicken pox following short-term corticosteroid 
therapy (Committee on Safety of Medicines, 1994; Reynolds et al., 1996).
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Study Entry criteria Treatment groups Visual outcome Comments
Rawson et al., 
1966.
Rawson &
Liversedge,
1969.
Treatment to 
commence within 
10 days o f onset of  
symptoms.
1) IM ACTH 40 
units/day for 30 
days (n=25).
2) IM placebo for 
30 days (n=25).
Faster recovery of 
VA in treatment 
group (p<0.01 at 
30 days) but no 
effect at 1 year.
All treated patients 
pain-free by 2 
days. Placebo 
group pain-free by . 
2 weeks.
Bowden et 
al., 1974.
Any patient 
regardless o f delay 
to the initiation o f  
treatment.
1) IM ACTH 40 
units/day for 30 
days (n=27).
2) IM placebo for 
30 days (n=27).
No significant 
treatment effect for 
any visual 
parameter at any 
time up to 2 years.
Mean delay to 
treatment o f 16.7 
days (ACTH 
group) and 18.5 
days (controls).
Gould et al., 
1977.
Treatment to 
commence within 
10 days. V A<6/9, 
abnormal colour 
vision, RAPD and 
central scotoma.
1) Retrobulbar 
triamcinolone 
40mg (n=31).
2) No injection 
(n=30).
Faster rate o f  
recovery o f VA in 
the treatment group 
(p=0.1 at 1 week). 
No difference seen 
at 2 and 6 months.
Single blind.
Trauzettal- 
Klosinski et 
al., 1993.
Randomisation 
within 21 days and 
before recovery. 
RAPD and >  2 of: 
abnormal VA; 
central scotoma; 
abnormal VEP 
and/or flicker test.
1) Oral MP 
tapering dose over 
24 days starting at 
1 OOmg/day (n= 16).
2) Oral thiamine
1 OOmg/day for 24 
days (n=34).
Trend for all the 
parameters tested 
to recover faster in 
the treated group 
but with no 
treatment benefit at 
12 months.
Not all patients 
blinded to 
treatment.
Optic Neuritis
Treatment
Trial
Beck et al., 
1992, 1993a, 
Beck & 
Cleary 1993a, 
Beck 1995, 
Optic Neuritis 
Study Group, 
1997a.
Treatment to 
commence within 
8 days o f onset o f  
symptoms.
RAPD and 
abnormal visual 
field in affected 
eye.
1) Oral prednisone 
lmg/kg/day for 14 
days (n=156).
2) IVMP 250mg 
QDS for 3 days 
then lmg/kg/day 
prednisone for 11 
days (n=151).
3 days o f dose 
tapering in both 
treatment groups.
3) Oral placebo for 
14 days (n=150).
Median VA 6/7.5 
by day 4 in IVMP 
group compared 
with day 15 in the 
other two groups. 
Minimal treatment 
benefit at 30 days 
and no effect seen 
after 1 and 5 years. 
No treatment 
benefit from IVMP 
if  VA > 6 /12 .
No benefit shown 
for prednisone.
No IV placebo 
group.
Increased risk o f  
recurrence o f ON 
after prednisone at 
5 years (p=0.003 
vs IVMP, /?=0.004 
vs placebo). 
Decreased 2-year 
(ARR 0.34, 95% 
Cl 0.16 to 0.74) 
but not 3-year rate 
o f CDMS after 
IVMP.
Kapoor et al., 
1998.
Randomisation 
within 30 days.
VA ^  6/9.
Optic nerve lesions 
classified as long 
( >  15mm) or short 
on STIR MRI.
1) IVMP lg/day 
for 3 days with no 
tapering dose 
(n=33).
2) IV saline for 3 
days (n=33).
Trend for increased 
rate o f  recovery o f  
VA after IVMP in 
all patients and in 
those with long 
lesions. No effect 
seen at 6 months.
No correlation 
between initial VA 
and initial lesion 
length. Treatment 
did not affect 6 
month lesion 
length on MRI.
Sellebjerg et 
al., 1999.
Treatment to 
commence within 
28 days o f onset o f  
symptoms.
VA < 0 .7 .
1) Oral MP 500mg/ 
day for 5 days with 
a tapering dose for 
10 days (n=30).
2) Oral placebo for 
15 days (n=30).
Improved spatial 
vision at 3 weeks 
in treatment group 
(p=0.03). No 
benefit after 8 
weeks and 1 year.
MP did not affect 
the conversion to 
CDMS at 1 year 
(p=0.S).
Wakakura et 
al., 1999a.
Treatment to 
commence within 
14 days o f onset o f  
symptoms.
RAPD in the 
affected eye.
1) IVMP lg/day 
for 3 days then oral 
taper for 7-10 days 
(n=33).
2) Mecobalamin 
500/ig/day IV for 3 
days then orally for 
7 days (n=33).
Faster visual 
recovery for all 
parameters tested 
after IVMP but no 
treatment effect 
seen after 12 weeks 
and 1 year.
Mecobalamin 
treatment used for 
comparison as 
placebo treatment 
considered 
unethical in Japan.
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ACTH = adrenocorticotrophic hormone (corticotrophin) ARR = adjusted rate ratio
VA = visual acuity
Table 1.6: Randomised controlled trials of corticosteroids in acute unilateral optic
neuritis.
(i) Recommendations for management
The recommendations of the Quality Standards Subcommittee of the American 
Academy of Neurology were that “oral prednisone in doses of lmg/kg/day has no 
demonstrated efficacy in the recovery of visual function in acute monosymptomatic 
optic neuritis, and therefore is of no proven value in treating this disorder. Higher dose 
oral or parenteral methylprednisolone or adrenocorticotrophic hormone may hasten the 
speed and degree of recovery of visual function in persons with in acute 
monosymptomatic optic neuritis. There is, however, no evidence of long-term benefit 
for visual function. The decision to use these medications to speed recovery but not to 
improve ultimate visual outcome should therefore be based on other non-evidence- 
based factors such as quality of life, risk to the patient, visual function in the fellow eye, 
or other factors that the clinician deems appropriate” (Kaufman et al., 2000).
When treatment is instigated lg/day IVMP for three days has become the preferred 
option (Trobe et al., 1999). For convenience, this tends to be given as a single daily 
dose which enables outpatient treatment. In the United States of America an oral taper 
of prednisolone following this remains popular, although it is less commonly used in the 
United Kingdom and Europe (Barnes, 2000). The rationale for the use of an oral taper 
is concern regarding suppression of the hypothalamic-pituitary-adrenal axis, although 
with the short treatment regimens used fast recovery of the axis is seen and the oral 
taper should not normally be needed (Wenning et al., 1994). Another concern is that 
after cessation of the IVMP worsening of symptoms may occur with recrudescence of 
inflammation as has been suggested from serial gadolinium-enhanced MRI studies of
CDMS = clinically definite multiple sclerosis 
IM = intramuscular
IVMP = intravenous methylprednisolone 
ON = optic neuritis
Cl = confidence intervals 
IV = intravenous 
MP = methylprednisolone 
QDS = 4 times per day
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the brain in MS (Miller et al., 1992), however there were no reports of recovery 
followed by deterioration of vision in the one study that did not use an oral taper 
(Kapoor et al., 1998), Appropriate precautions should be taken before starting 
treatment and all patients should be warned of the possible side-effects (British National 
Formulary, 2003).
If a corticosteroid responsive optic neuropathy is suspected then treatment should be 
with IVMP lg/day for three day followed by lmg/kg/day oral prednisolone. This is 
then slowly reduced by lOmg per month. If a relapse occurs on reducing the dose then 
high-dose treatment should be re-instigated and a corticosteroid-sparing agent such as 
azathioprine started before reducing the dose again. Protocols for osteoporosis 
prophylaxis need to be followed. Although these cases are rare they need to be 
recognised as management is entirely different from typical demyelinating optic neuritis 
in that early and continued treatment with corticosteroids is necessary to ensure a good 
visual outcome (Kidd et al., 2002). In optic neuritis associated with vasculitis (eg in 
systemic lupus eythematosus) the visual outcome may be improved if 
cyclophosphamide is given at an early stage but there are no published data on this.
At present there are no treatments that can reverse established poor visual outcome 
following typical optic neuritis. An early report suggested that intravenous 
immunoglobulin (IVIG) may be helpful in promoting remyelination and improving 
vision (van Engelen et al., 1992). A larger subsequent trial randomised 55 MS patients 
with persistent visual acuity loss after optic neuritis to receive either 0.4g/kg IVIG daily 
for five days followed by three single infusions monthly for three months, or placebo 
(Noseworthy et al., 2001). The trial was terminated early due to negative results.
Visual acuity was unchanged after six months’ follow-up (p=0.766), although there was 
a trend for improvement after 12 months (p=0.132). The improvement was however 
modest, amounting to a mean difference of two letters on the logMAR acuity chart with 
no improvement in VEP latency. The lack of significant improvement in these patients 
may imply that IVIG does not induce remyelination or that irreversible disability may 
be largely a result of axonal degeneration. Potential future therapies could include 
neuro-protective agents (Guy, 2000), strategies to induce remyelination (Compston & 
Coles, 2002), and optic nerve transplantation (Adachi-Usami, 2001), although all are at 
this time experimental.
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(ii) Management of bilateral optic neuritis
In cases of bilateral (simultaneous or early sequential with poor initial recovery) optic 
neuritis then patients should be investigated for the possibility of a corticosteroid 
responsive optic neuropathy. Treatment should be with parenteral followed by oral 
corticosteroids to hasten functional visual recovery. Patients should be followed closely 
as the oral prednisolone is tapered off to ensure that worsening vision does not occur.
(in) Management of childhood optic neuritis
Childhood cases are more commonly bilateral and simultaneous (Kriss et al., 1988), 
usually following viral infections (Morales et al., 2000). Visual recovery after optic 
neuritis in childhood is usually good. In one cohort 78% had a visual acuity of 6/6 or 
better after a mean follow-up of 8.8 years (Kriss et al., 1988). Another series reported 
better prognosis for unilateral optic neuritis than bilateral cases, although many of the 
bilateral cases suffered recurrent attacks of visual loss (Morales et al., 2000). Prompt 
response to corticosteroid therapy has been reported although there have been no 
treatment trials of corticosteroids in childhood optic neuritis (Brady et al., 1999).
1.2.7 Late outcome and the risk of recurrence of optic neuritis
The cumulative probability of having recurrent optic neuritis after five-year follow-up 
in the ONTT was 19% for the affected eye, 17% for the unaffected eye and 30% for 
either eye (Optic Neuritis Study Group, 1997b). The risk of recurrence was twice as 
high in patients who had developed MS and was also higher in those who were initially 
treated with oral prednisolone. The cumulative probability of recurrence at five years 
was 41% in the prednisolone group, 25% in the IVMP group (/?=0.003) and 25% in the 
placebo group (p=0.004). The increased risk was apparent throughout the period of 
follow-up in the study although there is not a convincing explanation for the underlying 
mechanism behind this association.
Ten-year follow-up figures have recently been reported for the ONTT (Optic Neuritis 
Study Group, 2004). The retention of patients in the study was very good with 319 out 
of the original 454 participants being seen. The median visual acuity in the originally
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affected eye at 10 years was logMAR -0.06 (Snellen 20/16) with only 33% having a 
visual acuity of worse than 0.0 (Snellen 20/20). Median Pelli-Robson contrast 
sensitivity score was 1.65 (33% <1.65) and median 30-2 Humphrey perimetry mean 
deviation was -1.25 (27% <-3.00dB). Recurrence of optic neuritis occurred in 35% 
(48% in those who had developed MS and 24% in those who had not). Only six 
patients (2%) had visual acuity of less than 20/40 in each eye, usually due to recurrence 
of the disease. The long-term visual prognosis following optic neuritis is therefore very 
good.
1.2.8 The association between optic neuritis and multiple sclerosis
The association between optic neuritis and MS has been apparent for many years 
(Perkin & Rose, 1979). MS is a clinical diagnosis based on the dissemination of CNS 
lesions in time and space i.e., the occurrence of a second clinical episode at a different 
site in the CNS. CDMS can be diagnosed when the episodes are confirmed by a 
Neurologist without the need for supporting investigations (Poser et al., 1983). The risk 
of developing MS increases with longer follow-up. In one series the 10 year risk of 
CDMS was 39%, the 20 year risk was 49%, the 30 year risk was 54% and the 40 year 
risk was 60% (Rodriguez et al., 1995). The risk is increased in females (Rizzo III & 
Lessell, 1988), (Sandberg-Wollheim et al., 1990), in those with retinal vascular 
abnormalities (Lightman et al., 1987), in those who are HLA-DR2 positive (Sandberg- 
Wollheim et al., 1990; Hauser et al., 2000), in those who have oligoclonal bands on 
CSF examination (Cole et al., 1998; Sandberg-Wollheim et al., 1990), and in those with 
serum antimyelin antibodies (Berger et al., 2003). The risk of MS developing following 
childhood and bilateral simultaneous optic neuritis is much lower (Parkin et al., 1984; 
Kriss etal., 1988).
The strongest predictor for the development of MS, that appears to exceed the factors 
just mentioned, is the presence of asymptomatic white matter lesions on brain MRI.
The five-year risk of CDMS in the ONTT was 16% in 202 patients with no brain 
lesions, but was 51% in the 89 patients with three or more lesions on entry to the study 
(Optic Neuritis Study Group, 1997a). The 10-year risk of CDMS in the ONTT was 
38%; 22% in 191 patients with no initial brain lesions, rising to 57% in 28 patients with 
nine or more baseline lesions (Optic Neuritis Study Group, 2003). In a different cohort
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CDMS developed in 37 out of 71 patients (52%) with one or more lesion after 10 years 
while no patient with a normal MRI developed CDMS (Ghezzi et al., 1999). The risk 
of early MS developing increases if asymptomatic spinal cord lesions are present at 
baseline in addition to brain lesions, reflecting increased dissemination in space in these 
patients. In a study of patients with clinically isolated syndromes suggestive of 
demyelination (CIS) (i.e. optic neuritis, spinal cord and brain stem syndrome patients) 
10/21 (48%) patients with abnormal brain and spinal cord imaging developed MS at one 
year compared to 3/17 (18%) with brain lesions alone (Brex et al., 1999). The risk of 
MS within one year also increased if new brain lesions were detected on repeat brain 
imaging after three months. MS occurred in 12/21 (57%) of patients with new lesions 
on T2 -weighted imaging and 7/11 (64%) of patients with new gadolinium-enhancing 
lesions, but only 1/20 (5%) of patients who had abnormal baseline imaging and no new 
lesions at three months.
Recently, The International Panel on MS Diagnosis published diagnostic criteria for MS 
(“McDonald criteria”) which suggested that MRI evidence of dissemination of CNS 
lesions in time and space was sufficient for the diagnosis of MS even before clinical 
dissemination had occurred (Figure 1.2) (Table 1.7) (McDonald et al., 2001).
These criteria clarify the role of MRI in clinical practice but have not been without 
controversy, principally regarding the reliance on imaging data when these findings on 
MRI can be non-specific (Poser & Brinar, 2001). However, when they have been 
applied to a cohort of CIS patients, the use of the criteria with repeat imaging after three 
months has shown a 93% specificity and an 83% positive predictive value for the 
development of CDMS at three years (Dalton et al., 2002).
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Baseline 3 months
Figure 1.2: Left - baseline proton density weighted FSE MRI (left) o f a 37 year-old
woman with left optic neuritis demonstrating asymptomatic brain lesions 
(arrowed). Right -  gadolinium-enhanced Ti-weighted spin echo image 
taken three months later demonstrating two new enhancing lesions 
(arrowed) sufficient to give a diagnosis o f  MS using the McDonald 
criteria.
Even if multiple sclerosis does develop following optic neuritis the prognosis for 
disability is usually good, it being more often associated with a benign course o f the 
disease (odds ratio 1.73, 95% Cl 1.27-2.35) (Ramsaransing et al., 2001). After five 
years only 17 o f the 105 patients who had developed CDMS (4% o f the entire cohort) in 
the ONTT had an expanded disability status scale (EDSS) score o f three or more, and 
only five had an EDSS o f six or more, although this did include one patient who died 
from MS (Optic Neuritis Study Group, 1997a). As well as predicting an increased risk 
for the development o f MS, brain MRI lesion load can also help to predict the 
probability o f developing disability following a CIS. In a cohort o f patients followed 
for 14 years following a CIS, EDSS correlated with both baseline lesion volume 
(r=0.48) and change in lesion volume in the first five years (r=0.61), suggesting that 
early inflammatory activity in MS is related to the later development o f disability (Brex 
etal., 2002).
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MRI dissemination in space consisting o f 3 out o f 4 o f the following:
1. One gadolinium-enhancing lesion or nine T2 hyperintense lesions if  no enhancing 
lesion.
2. At least one infratentorial lesion.
3. At least one juxtacortical lesion.
4. At least three periventricular lesions.
One spinal cord lesion may be substituted for one brain lesion.
or
Two or more MRI-detected lesions consistent with MS plus positive CSF (oligoclonal bands
different from any such bands in the serum and/or the presence o f an elevated IgG index)
and
MRI dissemination in time
First scan 3 or more months after the clinical event.
1. A gadolinium-enhancing lesion (not at the site implicated in the first clinical event) is 
sufficient evidence to demonstrate dissemination in time.
2. If there are no gadolinium-enhancing lesions a second scan is required more than 3 
months later. A new T2 or gadolinium-enhancing lesion is sufficient evidence for 
dissemination in time.
First scan less than 3 months after the clinical event.
1. A second scan done 3 or more months after the optic neuritis showing a gadolinium- 
enhancing lesion is sufficient evidence for dissemination in time.
2. If no enhancing lesion is seen on the second scan, a further scan performed not less than 
3 months after the previous scan that shows a new T2 or enhancing lesion will suffice.
or
A  second clinical attack
Table 1.7: Diagnostic criteria to allow multiple sclerosis to be diagnosed following
a monosymptomatic clinical event such as optic neuritis (McDonald et 
a l, 2001).
1.2.9 Treatments to delay the onset of multiple sclerosis after optic neuritis
Are there any treatments that alter the risk for the development of MS following 
clinically isolated optic neuritis? Post hoc analysis from the ONTT suggested that there 
was a decreased risk for the development of CDMS in the IVMP group (10 patients, 
7.5%) compared to the other two groups (19 patients, 14.7% in the prednisolone group 
and 21 patients, 16.7% in the placebo group) after a follow-up period of two years in
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patients with clinically isolated optic neuritis on entry to the study (n=389) (Beck et al., 
1993a). The adjusted rate ratio for the development of CDMS in IVMP group was 0.34 
(95% Cl 0.16 to 0.74) compared with the placebo group. Most of the treatment effect 
was seen in patients with an abnormal brain MRI on entry to the trial. The findings 
however, were based on a retrospective analysis with an open-label treatment (there was 
no intravenous placebo arm) with only small numbers developing MS. Also, data were 
not available for 50 of the patients, which may have had a confounding effect. The 
beneficial effect was lost by three years with a cumulative incidence of CDMS of 17.3% 
in the IVMP group, 24.7% in the prednisolone group and 21.3% in the placebo group 
(Beck, 1995). The significance of these findings remains uncertain. If benefit from 
IVMP exists to delay the onset of CDMS it is short-lived and does not affect either the 
eventual risk of CDMS or the development of disability (Optic Neuritis Study Group, 
1997a).
Two recent trials have addressed whether /3-interferon can slow down the progression 
from CIS to CDMS. The CHAMPS study recruited 383 patients following their first 
demyelinating event (192 with optic neuritis) who, in addition, had two or more 
clinically silent brain lesions on MRI (Jacobs et al., 2000). Half the patients received 
once weekly 30/xg intramuscular interferon /3-la and half placebo injections. The trial 
was stopped early after an interim analysis since the cumulative probability of the 
development of CDMS during the three-year follow-up period was significantly lower 
in the interferon group than in the placebo group (rate ratio 0.56; 95% Cl 0.38-0.81; 
p=0.002). There was also a relative reduction in new lesion activity on MRI in the 
interferon group (p<0.001). The ETOMS study took a similar group of patients (n=309, 
98 with optic neuritis) but four asymptomatic white matter lesions (or three if one was 
enhancing after administration of gadolinium) were required for entry (Comi et al., 
2001). Half the patients received once weekly subcutaneous 22/ig interferon /3-la and 
half placebo injections. After two years the odds ratio for conversion to CDMS was 
0.61 (95% Cl 0.37-0.99; /?=0.045) in the treatment group compared to the placebo 
group, again with less new lesion formation in the treatment group (p<0.001). The 
treatments were well tolerated with no excess major adverse events due to the 
interferons. Significant minor adverse events included influenza-like symptoms (both 
trials), depression (CHAMPS) and injection site reactions (ETOMS).
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These results are not surprising because in essence the interferons are reducing the 
relapse rate, which is a well-known effect from the previous studies in relapsing 
remitting MS (RRMS). These patients were at high risk for the development of MS in 
view of the abnormal baseline brain imaging. Pooling the results with results from 
studies in RRMS, the interferons reduce the relapse rate by a third. The annual relapse 
rate in these patients is approximately 0.5/year. Interferon treatment therefore has to be 
given for six years to prevent one relapse in this group of patients (Ebers, 2001). There 
are also no long-term data that can say whether, by reducing inflammatory activity, the 
interferons prevent the development of disability due to MS.
(i) Recommendations for management
Brain MRI at presentation can give an indication for the prognosis for the development 
of MS, and if a high lesion load is present then this gives further information concerning 
the probability of later disability, although the association is not strong. A significant 
number of patients with CIS and brain lesions have a benign long-term course (Brex et 
al., 2002).
In the UK, the Association of British Neurologists’ guidelines currently recommend 
disease modifying drugs (DMDs) only in established MS, therefore brain imaging at 
presentation with optic neuritis will not alter initial treatment decisions. In the absence 
of evidence that earlier treatment of patients with CIS has a greater long-term effect on 
prognosis for disability, current UK practice is to treat only ambulant patients with 
clinically active, established RRMS, or secondary progressive MS (SPMS) with 
superimposed disabling relapses. In countries where DMDs are available for use after a 
CIS if asymptomatic brain lesions are present, baseline brain imaging may be useful to 
guide the treatment decision.
Repeat imaging of CIS patients may, however, establish an earlier diagnosis using the 
McDonald criteria. In some patients this will be worthwhile in order to enable a more 
informed discussion of diagnosis and prognosis. Further studies are needed to 
determine whether the subgroup of CIS patients who develop MS using the McDonald 
criteria will benefit usefully from long-term treatment with DMDs.
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It is important that the diagnosis of optic neuritis is secure before treatment with a DMD 
is commenced as there has been a report of three patients with anterior ischaemic optic 
neuropathy and incidental white matter lesions of presumed vascular origin who were 
commenced on interferon /3-la on the erroneous assumption that the cause of visual loss 
was optic neuritis (Horton, 2002).
1.2.10 Optic neuritis pathology
There are a limited number of studies on the pathology of optic neuritis, due to the 
absence of autopsy material from the acute inflammatory phase of the illness. This 
reflects the fact that optic neuritis generally affects a young patient group and the lack 
of data from biopsy of lesions, unlike the situation with MS lesions in the brain. Human 
autopsy material has been available from patients with established multiple sclerosis, 
but the studies that have used this need to be interpreted with caution. The results 
probably represent both episodes of acute optic neuritis as well as possible insidious 
damage either as part of MS, or as a long-term consequence of acute episodes.
Samuel Gartner in 1953 published the first systematic study of the optic nerve in MS 
(Gartner, 1953). He examined under the light microscope the optic nerves of 10 MS 
patients who had had visual symptoms in life. Six of them had had definite or probable 
optic neuritis. He described atrophy of nerve fibres, particularly in the papillomacular 
bundle but also extending to other areas, as well as increases in glial cells, fibroblasts 
and lymphocytes. Atrophy of nerve fibres and ganglion cell bodies was also seen in the 
retina and the optic disk showed extensive gliosis with new connective tissue formation.
The introduction of electron microscopy allowed more thorough investigation, de 
Preux and Mair (1974) carried out a combined light and electron microscopy study of 
the optic nerves of patients affected by Schilder’s disease, Devic’s disease and 
disseminated sclerosis (MS). The patient with disseminated sclerosis had died due to 
the condition and had documented visual impairment during life. The optic nerves in 
Devic’s disease had extensive destruction of myelin and axons with astrocytosis, absent 
oligodendrocytes and infiltration of the nerve bundles and fibrous septa by 
macrophages. The destruction of axons and myelin was mild in Schilder’s disease with 
oligodendrocyte preservation but some astrocytosis. Myelin breakdown in the optic
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nerves of the patient with disseminated sclerosis was patchy with parts showing 
complete demyelination and other areas only patchy demyelination. Where there was 
complete demyelination oligodendrocytes were absent but macrophages were present 
and there was an intense astrocyte proliferation around naked axons. Axonal 
destruction was present but not as severe as in the patient with Devic’s disease. The 
connective tissue septa contained blood vessels with endothelial hypertrophy and 
hyperplasia (also seen in the other two conditions). In the partially demyelinated 
regions there were some degenerating demyelinated fibres with an excess of fibroblasts 
and frequent macrophages. Oligodendrocytes were present almost as frequently as in 
normal optic nerves. The myelin of degenerating fibres showed concentric splitting or a 
lattice pattern.
In another study, the length of plaques seen on post mortem examination from the optic 
nerves of 14 patients who died of MS varied from 3mm to 3cm with a mean of 10.5mm 
and plaques contained increased fibrillary astrocytic processes (McDonald, 1977; 
McDonald, 1986). Plaques in MS show a classical peri-venular distribution and peri­
vascular cuffing has been observed in the peripheral retina, at a site where there are no 
myelinated nerve fibres, suggesting that primary autoimmune demyelination is not the 
only process occurring in MS (Fog, 1965).
Ulrich and Groebke-Lorenz (1983), in another autopsy study of MS patients, discussed 
some of the clinico-pathological implications of optic nerve demyelination in MS.
There was a significant correlation between visual acuity taken from retrospective 
records before death and the rank preserved myelin (rs -0.668,/K0.001). They also 
confirmed the earlier finding of areas of partial and complete demyelination and the 
presence of astrocytosis. They were unable to quantify the extent of axonal loss due to 
technical problems with the stains used. The interesting observation was that it was still 
possible to have a reasonable level of visual acuity despite a long segment of 
demyelination covering the whole cross-section of the nerve for more than one 
centimetre. This suggested that useful conduction of nerve impulses was possible along 
demyelinated nerves (this phenomenon will be discussed further in the pathophysiology 
of optic neuritis).
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A later study further demonstrated the variable size of plaques in the optic nerves of MS 
patients, from 5-90% of the cross-sectional area (Mogenson, 1990). The plaques were 
typically coniform, with bases at the periphery. Three out of ten nerves examined also 
had areas with periphlebitis.
A further way of investigating the functional significance of damage to the optic nerves 
in MS is to investigate the differential loss of fibres in the magnocellular and 
parvocellular pathways. Evangelou et al. (2001) studied the optic nerves and LGNs 
from eight patients with MS and eight non-neurological controls. They found that the 
optic nerve cross-sectional area from the intracranial portion of the optic nerve was non- 
significantly reduced in the patients with MS to a median 6.44mm compared to 
9.25mm2 in controls (p=0.08). Axonal density was also reduced from a median 
170,118mm'2 in controls to 108,912mm'2 (p=0.05) giving a total estimated axonal 
number of 1,407,711 in controls and 808,003 in the patients with MS (p=0.05). In the 
LGN there was not a decrease in size of the nucleolated magnocellular neurons whereas 
there was for the parvocellular neurons: median 226/mi2 compared with 230/xm in 
controls (p=0.001), suggesting that transynaptic atrophy had occurred. The skewness of 
parvocellular cell distribution correlated with axonal density in the optic tract. These 
observations suggest that the parvocellular nerves are damaged preferentially in MS. 
These observations confirm the clinical finding that parvocellular cells (providing 
colour vision and high spatial frequency resolution) are damaged preferentially in optic 
neuritis compared with magnocellular cells (responsible for low spatial frequency 
resolution) (Wall, 1990).
All the above studies rely on autopsy material from patients with long established MS. 
Histopathological examination of patients with acute optic neuritis has usually not been 
possible due to the obvious hazards from biopsy of the optic nerve. There is one report 
in the literature of a 50 year old woman who presented with progressive monocular 
visual loss (Rush et al., 1982). There was a history of retrobulbar pain and blurred 
vision in that eye several months previously. Visual acuity was counting fingers at 5 
feet, with defective colour vision, a relative afferent pupillary defect and a pale optic 
disk. A computed tomography scan showed diffuse enlargement of the affected optic 
nerve with no enhancement. There was a positive anti-nuclear antibody titre at a 
dilution of 1:100 (speckled pattern) and a monoclonal immunoglobulin G band in her
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serum. CSF examination showed 27mg/100ml protein, 54mg/100ml glucose, ten 
lymphocytes and one monocyte. Due to increasing pain and decreasing visual acuity to 
hand movement perception a frontotemporal craniotomy was performed. The 
intracranial optic nerve and anterior chiasm looked yellow, indurated and swollen. 
Biopsy of the intracranial optic nerve showed a perivascular lymphocytic infiltration, 
multifocal demyelination, and reactive astrocytosis. Electron microscopy examination 
revealed dense bundles of reactive astrocytes, encompassing lymphocytes with 
plasmacytic features (probably B lymphocytes). Axonal integrity was not commented 
on. No visual recovery occurred after two years follow-up despite post-operative 
corticosteroids. It is not definite that this case represents optic neuritis given the 
progressive history with no visual recovery and abnormal blood test results but it 
represents the only human biopsy study of possible optic neuritis.
A way around this lack of data from human cases is to use animal models. Caution 
needs to be taken when trying to extrapolate the results to humans in that experimental 
allergic optic neuritis may not be a completely accurate model for human optic neuritis.
Rao et al. (1977) developed a model for acute allergic optic neuritis, which they 
discovered in adult guinea pigs that developed experimental allergic encephalomyelitis 
(EAE) following sensitisation with intracutaneous injections of isogenic spinal cord 
emulsion in complete Freund’s adjuvant. Two patterns of disease were observed. One 
group with absent pupillary light responses and normal fundi were classified as having 
“retrobulbar optic neuritis”. Lesions were localised to the orbital and intracranial 
portions of the optic nerves with foci of mononuclear cell infiltration in the pial septa, 
adjacent axonal bundles and occasionally in a perivascular distribution. Demyelination 
was present with disrupted myelin sheaths, phagocytosis of myelin fragments and 
moderate axonal swelling. The other group had absent pupillary light responses with a 
swollen disc and oedema of the surrounding retina. These were described as suffering 
from “neuroretinitis”. Inflammation and demyelination was observed here just posterior 
to the lamina scleralis. Axonal swelling was seen at the lamina retinalis, which 
extended into the juxtapapillary retinal nerve fibres. Foci of mononuclear cell 
infiltration were present in the choroid and meninges.
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The pattern of acute EAE is usually that of an illness leading to the death of the animal 
within four to six weeks although recovery is possible. Sensitisation of juvenile guinea 
pigs in later experiments produced a more chronic illness with death after several 
months and variation of the clinical findings, including pupillary changes, suggesting a 
relapsing remitting course (Rao, 1979). Multiple foci of mononuclear cell infiltration 
and demyelination in the optic nerve were again present but gliosis was now frequently 
seen. Non-myelinated axons appeared normal except at sites of active inflammation 
where axonal swelling was observed. Raine et al. (1980) later questioned the validity of 
the chronic model for human optic neuritis as part of MS. Although active optic nerve 
lesions were seen up to four months after inoculation they did not observe new 
spontaneous lesions spread over a number of years without re-inoculation, in contrast to 
the situation they observed in the spinal cord. At the periphery of chronic demyelinated 
lesions in the optic nerve, remyelination was seen with thinly myelinated fibres and an 
increase in densely staining cells, presumed to be oligodendrocytes. Axonal loss was 
not commented upon, although optic nerve atrophy was not seen.
Guy et al. (1992) carried out orbital gadolinium enhanced Ti-weighted fat suppressed 
MRI and T2 -weighted fat suppressed MRI on adult guinea pigs with EAE. The 
ultrastructure of the optic nerves was then investigated with transmission electron 
microscopy in order to correlate the imaging and histopathological findings.
Gadolinium enhancement of the optic nerve near the globe was seen early, within three 
days of sensitisation, before clinical signs of EAE appeared, consistent with previous 
observations that blood-brain barrier breakdown is the first event in an MS relapse 
(Kermode et al., 1990). After 10 to 14 days a longer segment of the optic nerve was 
enhancing and this persisted at 30 days. Gadolinium enhancement preceded high signal 
becoming apparent on T2-weighted images. The nerves showed perineural and 
perivascular demyelination, axonal degeneration and decreased axonal density with 
expansion of the extravascular space. Inflammatory cells infiltrated the perivascular 
space. Expansion of the extracellular space and the inflammatory infiltrate was 
associated with the intensity of the gadolinium enhancement and the T2 -weighted signal 
aberration tied in with observed demyelination.
Hayreh et al. (1981) were able to record VEPs from rhesus monkeys with EAE using a 
flash stimulus and correlate these with histological findings. In early EAE no gross
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VEP change was detectable despite a cellular infiltration of the optic nerve, mild focal 
demyelination and optic disk oedema. Later on in the disease evolution a flat VEP was 
observed in association with optic atrophy on fundus examination and extensive 
demyelination and axonal loss on histological examination. Pattem-reversal VEPs 
would have been more sensitive but it was not possible to use them in this experimental 
model.
Further work on the integrity of the blood-brain barrier in the optic nerve was performed 
by Hu et al. (1998) in a rat EAE model. Microglia became activated, MHC class 11^  
cells increased and horseradish peroxidase leakage was visible from day seven to eight 
post injection. On day eight, Monastral blue leakage was present in the myelinated 
parts of the optic nerve with infiltration of EDI+ macrophages and aj3TCR+ 
lymphocytes. Significant clinical symptoms became apparent at day 10. Oedema was 
detectable on transverse sections of the optic nerve between days 10 to 14. The 
intensity of the leakage, cellular infiltrate and MHC class II expression was maximal at 
day 12 and predominantly in the myelinated region of the optic nerve. At day 10 CD4+ 
lymphocytes predominated over CD8+ cells, however this situation was reversed at day 
28. In control rats MHC class 11+ cells were found in the meninges surrounding the 
optic nerve and the lamina cribrosa. The presence of these cells may contribute to the 
development of optic neuritis. The first features of acute EAE were therefore activation 
of microglia, increasing MHC class II expression and breakdown of the blood-brain 
barrier in line with earlier observations. Calcium activated neural proteinase (calpain) 
expression was found to be increased in the activated microglia and macrophages from 
the optic nerves of rats with EAE in a later study (Shields et al., 1998). Calpain may 
play a role in degradation of myelin basic protein and other myelin proteins during 
phagocytosis.
In a mouse model of demyelination induced by Semliki Forest virus (SFV), Ikeda and 
Tansey (1986) observed early (1-2 weeks post-inoculation) demyelination with peri­
vascular lymphocyte cuffing, a moderate lymphocytic infiltration of the meninges, 
microglial proliferation and some astrocytic hypertrophy. At this time fast axonal 
transport, measured by [3H]proline uptake in the brain after ocular injection, was 
increased. The height of demyelination occurred 18-21 days post-inoculation. Most 
demyelinated fibres were found at the periphery of the optic nerve, closest to the larger
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blood vessels. There was a significant loss of small (<7jum) myelinated fibres with a 
corresponding increase in unmyelinated fibres compared with control optic nerves, 
suggesting that the smaller fibres were more susceptible to demyelination. Slow axonal 
transport peaked at this time and there was also a suggestion that axonal sprouting had 
occurred as a possible response to the injury.
Axonal cytoskeleton changes have also been observed early on in the course of acute 
EAE in rats induced by optic nerve microinjection of polyclonal rabbit ant- 
galactocerebroside antibody with guinea pig complement (Zhu et al., 1999). On day 
one post injection moderate neurofilament and microtubule disassembly was seen in the 
local demyelinated area with again an increase in microglia but before any cellular 
infiltration was seen. From day three onwards there was an increasing inflammatory 
cell infiltrate of predominantly macrophages, coinciding with more axonal cytoskeleton 
changes. There was then more extensive demyelination, axonal swelling and loss, and 
subsequent gliosis. Some of the axonal swellings may have represented the occurrence 
of axonal transection. Axonal loss was seen in demyelinated areas with few or no 
inflammatory cells, suggesting that inflammation-independent mechanisms were at 
work. However, axonal cytoskeleton changes and axonal loss were most apparent in 
areas with high levels of cell infiltration in agreement with recent biopsy studies of 
brain MS lesions in humans (Ferguson et al., 1997; Trapp et al., 1998). Acute 
demyelination may therefore induce local axonal cytoskeleton changes, which are then 
further enhanced by inflammation. The cytoskeleton changes may be amongst the 
earliest events in the course of acute axonal loss that occurs in acute EAE/optic neuritis. 
From day seven axons frequently showed thin myelin sheaths, possibly representing 
attempts at remyelination, although partial demyelination could also have been 
responsible. Wallerian degeneration of axons was only occasionally observed.
Active remyelination has been observed after anti-galactocerebroside antibody mediated 
demyelination and oligodendrocyte destruction in the cat optic nerve (Carroll et al., 
1990). This was thought to be due to a new population of small glial cells, possibly 
derived from dedifferentiated astrocytes or progenitor cells, which differentiate to 
become oligodendrocytes. Bipotential glial progenitor cells have been previously 
identified in the rat optic nerve (ffrench-Constant & Raff, 1986). Almost complete
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remyelination occurs in this model unlike in human optic neuritis suggesting that repair 
mechanisms in human optic neuritis may be impaired.
The above animal models demonstrate that there may be very early axonal changes with 
an increase in microglia and breakdown of the blood-optic nerve barrier followed by 
cellular infiltration. Demyelination of axons occurs focally initially but then spreads 
over time. Early axonal swelling may indicate acute axonal transection. The amount of 
axonal loss is related to the degree of inflammation, although inflammation-independent 
mechanisms of demyelination and axonal loss may also occur. Early remyelination by 
oligodendrocytes possibly derived from progenitor cells may then start. The 
predilection of MS to affect the optic nerves is uncertain but a possible mechanism is an 
inherent weakness of the blood-brain barrier in the optic nerve (Tso et al., 1975). The 
animal studies may provide good models for early acute inflammatory changes in optic 
neuritis but they provide little information about the causes and effects of recurrences 
(relapses) of optic neuritis, which may be more akin to the human situation. More 
studies are also required to follow the course of EAE optic neuritis into the chronic 
phase to investigate the complex interplay between degeneration and repair that may be 
occurring following optic neuritis. In human optic neuritis remyelination is thought to 
occur, as witnessed by the progressive shortening of VEP latency (Jones, 1993; 
Frederiksen & Petrera, 1999), although its frequency and extent is unknown. It is 
difficult to measure visual function in animals and therefore correlate clinical findings 
with radiological and histological results in order to understand the functional 
significance of any changes observed. The pathophysiology of the acute deficits, 
subsequent recovery and persistent disability in optic neuritis will be discussed in the 
next section.
1.2.11 The pathophysiology of optic neuritis
A coherent account of the pathophysiology of optic neuritis has to include the 
mechanisms behind both relapse and recovery including the causes of incomplete 
recovery from an individual attack. Insight into these mechanisms has come from study 
of optic neuritis and MS in vivo and laboratory studies.
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From studies of the pathology of optic neuritis and MS it is clear that demyelination of 
axons is a significant and consistent feature within all types of MS lesions (Lucchinetti 
et al., 2000). Demyelination occurs due to breakdown of the ability of regulatory 
systems to prevent auto-reactive T cells from causing autoimmune damage (Compston 
& Coles, 2002). In optic neuritis and MS, T cells auto-reactive to myelin, access the 
central nervous system by expressing adhesion molecules to allow their passage through 
the blood-brain barrier. Once there, they recognise myelin and cause microglia to 
express major histocompatibility complex class II to present myelin to T cells. A pro- 
inflammatory loop is therefore set-up and an inflammatory demyelinating plaque 
results.
From experiments with demyelination induced by direct micro-injection of diphtheria 
toxin into the posterior columns of cat spinal cords, McDonald and Sears (1970) first 
demonstrated that demyelination can cause conduction block in axons, suggesting the 
cause for clinical relapse. Contributory evidence came from the development of 
electrophysiological studies in vivo.
Stimulation of the eye produces a cortical response. When appropriate averaging 
techniques are used, this visual evoked response (VER) or VEP can be measured 
(Halliday et al., 1972). Two principal methods can be used as a stimulus: a flash of 
light, typically of peak intensity 1.25xl06cd/m2 and a time constant of 20/xs; or pattem- 
reversal of a checkerboard pattern with individual black-and-white squares subtending 
50 minutes and having a luminance of 8.6 and 110xl06cd/m2 respectively. In studies of 
optic neuritis, flash responses are not able to differentiate accurately between diseased 
and healthy nerves (Halliday et al., 1972). Pattern reversal VEPs in optic neuritis 
usually show a characteristic delay and often a reduction in the amplitude of the 
response. Halliday et al. (1972) observed delayed responses from 120ms to 155ms 
using pattern-evoked visual responses from eyes affected by optic neuritis compared to 
controls, probably due to slowing of conduction within the affected optic nerve (Table
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Study Subjects Results Comments
Halliday et 
a l,  1972.
17 controls
17 acute optic 
neuritis
( <  29 weeks after 
onset)
2 chronic optic 
neuritis
(21 months and 5 
years)
Diseased eyes where a 
response could be measured 
Mean lat. 155.1 ± 20.0ms 
Mean ampl. 3.68 ± 1.63fiV 
Healthy unaffected eyes 
Mean lat. 121.1 ± 5.9ms 
Mean ampl. 8.22 ± 4.43/iV 
Controls
Mean lat. 120.1 ± 4.0ms 
Mean ampl. 7.74 ± 3.26pV
5 patients <  2 weeks o f onset, 
with visual acuity <  6/60, 
showed no response 
4 o f these were re-measured 
subsequently and low  
amplitude, delayed responses 
were recorded 
8 patients seen median 19.5 
weeks after onset (range 7 
weeks to 5 years)
Median latency 151.5ms 
(range 132-206)
Median visual acuity 6/6 
(range 6/5 to 6/9)
Halliday et 
a l ,  1973a.
53 patients 
recovering from optic 
neuritis
Correlation between VEP 
amplitude and visual acuity 
(pO.OOl)
No correlation between VEP 
latency and visual acuity
Halliday et 
a l,  1973b.
51 patients with MS 
24 o f which having a 
past history o f optic 
neuritis
All patients with previous 
optic neuritis had delayed 
VEPs
25/27 MS patients without 
previous optic neuritis had 
delayed VEPs
96% o f MS patients had a 
delayed VEP
93% o f MS patients without 
previous optic neuritis still 
had a delayed VEP
Feinsod and 
Hoyt, 1975.
25 patients with MS 
15 o f which had no 
visual symptoms or 
signs
Flash-evoked latency and 
amplitude abnormal in all 
subjects 
Three patterns:
i) Prolonged peak latency
ii) Breakdown of first 
negative component into 2- 
4 sub-components
iii) Very low amplitude 
response
Responses due to varying 
degrees o f conduction delay in 
demyelinated axons and 
depletion o f axons in the optic 
pathways
Harding and 
Wright, 1986.
22 patients <  3 days 
from onset o f acute 
optic neuritis
At 3 days
Mean P I00 amplitude <l/xV  
Mean latency unmeasurable 
At 1 week
Mean P I00 amplitude ~3pV  
Mean latency unmeasurable 
At 3 weeks
Mean P I00 amplitude ~5fiV  
Mean latency ~ 160ms 
A t 4 weeks
Mean P I00 amplitude ~4/rV 
Mean latency ~130ms
Amplitude o f PI 00 VEP but 
not flash VER correlated with 
visual acuity
Over next 12 months VEP 
latencies decreased and 3/22 
returned to normal
Kriss et a l ,  
1988.
20 childhood optic 
neuritis patients 
(4 unilateral and 16 
bilateral) out of a 
cohort examined a 
mean 8.8 years after 
attack
45% had delayed VEP 
including one absent 
response
All unilateral cases remained 
abnormal.
55% o f  cases overall had a 
normal response
CF = central field, WF = whole field, SD = standard deviation
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Study Subjects Results Comments
Youl et al., 
1991.
11 patients (2 with 
bilateral optic 
neuritis) recorded a 
mean 6.4 (range 2- 
13) days after onset 
o f acute optic neuritis 
9(1  bilateral) o f  
whom re-examined a 
mean 27.8 (range 20- 
32) days later
Acutely (13 eyes)
Absent VEP in 3 eyes 
Delayed + low ampl. in 6 
Delayed only in 3 
Low amplitude only in 1 
Follow-up (10 eyes) 
Delayed VEPs only in 6 
Delayed + low ampl. in 2 
Normal in 2
VER amplitude significantly 
larger at follow-up (p=0.02) 
and associated with resolution 
o f optic nerve gadolinium 
‘leakage’ on STIR MRI
Jones, 1993. 376 patients 
examined at differing 
time points following 
acute unilateral optic 
neuritis
1-4 weeks (n=64)
89.1% abnormal, 21.8% 
absent
5-8 weeks (n=78)
93.6% abnormal, 6.4% 
absent
9-13 weeks (n=64)
93.7% abnormal, 1.6% 
absent
14-26 weeks (n=55)
92.7% abnormal, 0% absent 
27-104 weeks (n=59)
79.7% abnormal, 0% absent 
105-990 weeks (n=56) 
71.4%  abnormal, 0% absent
Most apparent improvement 
in VEP latency between 6 
months and 2 years after optic 
neuritis
Latencies in patients with MS 
were prolonged at 4 weeks, 
but significantly shorter 
between 8-104 weeks, 
compared with isolated optic 
neuritis
Brusa et al., 
1999.
12 patients who were 
part o f the Kapoor et 
al. 1998 IVMP trial, 
re-examined after 3 
years
Clinically affected eye 
Shortening o f mean latency 
between 6 months and 3 
years
Whole field: 131 to 123ms 
Central field: 136 to 125ms
Clinically unaffected eye 
Prolongation o f mean latency 
over same time period 
Whole field: 110 to 113ms
Fredericksen 
and Petrera, 
1999.
90 patients with acute 
optic neuritis, with 
follow-up after 2 ,4 , 
12 and 52 weeks
Baseline
69 (77%) - abnormal VEP 
Follow-up 
13 (19%) normalised 
11 o f the initially normal 
VERs became abnormal
Baseline abnormalities seen in 
35% o f clinically unaffected 
eyes (not including MS)
Brusa et al., 
2001.
31 patients, examined 
3, 6, 9, 12, 18 and 24 
months after acute 
optic neuritis
At 3 months 
All responses abnormal 
WF ampl. = 5.79 SD 3.6/iV  
WF lat. = 129.8 SD 13.5ms 
CF ampl. = 4.42 SD 3.4pV  
CF lat. = 129.8 SD 10.1ms 
At one year
WF ampl. = 6.99 SD 3.5f*V 
WF lat. = 122.7 SD 13.4ms 
CF ampl. = 4.63 SD 2.9/iV  
CF lat. = 122.4 SD 12.1ms
At two years
WF ampl. = 6.91 SD 3.5/iV  
WF lat. = 119.7 SD 12.8ms 
CF ampl. = 4.5 lSD 2.4/iV  
CF lat. = 118.4 SD 11.0ms
Most significant shortening 
between 3 and 6 months 
(p<0.001 for WF and CF) 
Between 1 and 2 years less 
marked shortening (p<0.05 for 
WF)
Table 1.8: Studies of pattem-reversal (unless indicated) VER in optic neuritis and
MS.
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Delayed visual evoked, somatosensory evoked and brainstem evoked responses have 
also been seen in the absence of clinically definite relapses in these systems and these 
investigations have been used to provide confirmatory evidence of other silent areas of 
demyelination and so assist in making the diagnosis of MS by confirming dissemination 
in space (McDonald, 1998).
The presence of demyelination enables some of the phenomena that some optic neuritis 
patients experience to be explained.
(i) Phosphenes
Spontaneous oscillatory bursts of action potentials have been observed in 
experimentally demyelinated optic nerves induced in mice by SFV which may be the 
electrophysiological representation of phosphenes seen by some optic neuritis patients 
(Tansey & Ikeda, 1986). This spontaneous firing, often induced by movement is 
thought to be analogous to Lhermitte’s phenomenon in the spinal cord (Davis et al., 
1976).
(ii) Uhthoff s phenomenon
VEP experiments have been performed on patients who experience Uhthoff s 
phenomenon, before, during and after exercise (Persson & Sachs, 1981) and during 
heating in a hydrotherapy bath (Saul et al., 1995). These experiments showed that both 
exercise and heat principally caused decline in VEP amplitudes, particularly in patients 
who showed symptomatic visual loss. The mechanism behind Uhthoff s phenomenon 
is thought to be the induction of conduction block in demyelinated nerve fibres by the 
increased temperature (Rasminsky, 1973). Demyelination is thought to reduce the 
ability of the nerve fibre to conduct repetitive impulses by increasing the refractory 
period (Schauf & Davis, 1974). Hence the safety factor for conduction is reduced.
(iii) Pulfrich’s phenomenon
Pulfrich’s phenomenon may be explained by a delay in the visual impulse from one eye 
being delayed in reaching the brain compared with the other. To measure the effect
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Rushton (1975) arranged a pair of oscilloscopes with one screen being presented to each 
eye, so that each subject saw a fused image. A spot oscillated to and fro on the screen. 
The subject was asked to vary the phase angle, and hence the time lead or lag, in order 
to produce a fused image. The inter-ocular latency could then be calculated. In a series 
of patients with MS inter-ocular delays of up to 30ms were recorded. VEPs were more 
sensitive at detecting delayed conduction because the Pulfrich test could only detect 
inter-ocular delay and many of the MS patients had abnormal conduction in both eyes. 
This phenomenon has also been measured in patients who had recovered from optic 
neuritis (Slagsvold, 1978). All patients tested were however, asymptomatic for 
Pulfrich’s phenomenon and in clinical practice it is much rarer than Uhthoff s 
phenomenon.
(iv) Fading of vision
Fading of vision in bright environments is thought to be due to fatigue or a saturation 
effect in the conduction of demyelinated optic nerves which occurs over minutes 
(Campos et al., 1980). This effect may be due to a progressive failure to conduct nerve 
impulses at high firing rates (McDonald & Sears, 1970).
Remyelination can occur in optic neuritis and multiple sclerosis lesions however the 
new intemodes are thought to be shorter and thinner than normal (Prineas & Connell, 
1979). Restoration of central conduction via these new intemodes however, was 
demonstrated, suggesting a mechanism for recovery from clinical relapses (Smith et al., 
1979; Smith et al., 1981). Further evidence for the existence of remyelination after 
acute demyelinating events comes from VEP studies. Normalisation of the VEP latency 
has been shown to occur after optic neuritis in 0% to 38% of cases (Frederiksen & 
Petrera, 1999), and continues for up to two years after the acute event (Bmsa et al., 
2001). A study of childhood optic neuritis found that normalisation occurred in 55% of 
cases, suggesting that remyelination may be more extensive in children (Kriss et al., 
1988).
However, remyelination as the mechanism for remission from relapses cannot explain 
completely the mechanism of recovery from a relapse. Prineas et al. (1993) concluded 
from observation of lesions from post mortem material from cases of early MS that the
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interval from the beginning of a new lesion to commencing remyelination is 
approximately one month. From their experimental observations on cat spinal cords 
Smith et al. (1981) concluded that remyelination commences during the second week 
following micro-injection of lysophosphatidyl choline, with recovery of conduction 
stretching over three months. This is therefore too long to explain the rapid recovery in 
function that can sometimes be seen with relapses, particularly in optic neuritis (Youl et 
al., 1991). Furthermore, the remyelination may only occur at the edge of lesions and is 
often incomplete (Prineas & Connell, 1979). There is also evidence to suggest that 
function is possible despite complete or almost complete demyelination of axons within 
lesions. Wisniewski et al. (1976) described: (i) two patients with functional vision 
who, on post mortem examination, had very long segments of optic nerves showing 
complete demyelination, and (ii) four animals in remission from EAE despite having 
spinal cords displaying large stretches of demyelination. Recovery of good visual 
acuity is also possible despite persistent increased latency of the visual evoked response 
(Halliday et al., 1973a). In a mouse model of demyelination induced by Theiler’s 
murine encephalomyelitis virus, normal function was possible even though there was 
nearly complete demyelination of the spinal cord (Rivera-Quinones et al., 1998). These 
findings support the assertion by Charcot (1877) that “patches of sclerosis have been 
found, after death, occupying the whole thickness of the nerve-trunk, in the optic 
nerves, in cases where, during life, an enfeeblement of sight simply had been noted.
This apparent disproportion between the symptom and the lesion constitutes one of the 
most powerful arguments which can be invoked to show that the functional continuity 
of the nerve-tubes is not absolutely interrupted, although these, in their course through 
the sclerosed patches, have been despoiled of their medullary sheaths and reduced to 
axis-cylinders.” Conduction of nerve impulses must therefore show some recovery very 
quickly and be possible even in the presence of demyelination or only partial 
remyelination.
Youl et al. (1991) observed that both clinical improvement and increased P I00 
amplitude of the VEP occurred rapidly after acute optic neuritis. This was associated 
with the cessation of gadolinium “leakage” visible on STIR MRI after administration of 
dimeglumine gadopentate. The leakage was thought to be due to acute inflammation 
causing a breakdown in the blood-optic nerve barrier. Acute inflammation alone could
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therefore have been responsible for conduction block and its resolution an important 
step in remission, prior to any significant remyelination.
Nitric oxide (NO) and the inducible form of NO synthase (iNOS) have been found in 
elevated concentrations in the central nervous system in MS and experimental allergic 
encephalomyelitis. Increased iNOS expression can be seen in activated macrophages 
and astrocytes. NO is thought to be an important inflammatory mediator. In 
experiments, Redford et al. (1997) observed that NO donors cause reversible 
conduction block in axons from both the peripheral and central nervous systems. 
Demyelinated and early remyelinated axons were particularly were particularly 
susceptible. This therefore gave experimental evidence for how inflammation can cause 
conduction block. It is now thought that other compounds may also be involved in 
producing conduction block. Brinkmeier et al. (2000) discovered an endogenous 
pentapeptide in the cerebrospinal fluid of patients with MS and Guillain-Barre 
syndrome, which was able to act as a sodium channel blocker and could therefore also 
be involved in the pathophysiology of optic neuritis and MS.
Restoration of conduction in a demyelinated axon is also thought to be due to increased 
expression of sodium channels along the demyelinated segment allowing continuous 
(albeit slowed) conduction instead of the fast saltatory conduction that occurs in 
normally myelinated axons (Smith & McDonald, 1999). Saxitoxin is a neurotoxin that 
binds and blocks sodium channels. Increased saxitoxin binding has been demonstrated 
in human multiple sclerosis lesions by Moll et al. (1991) although the resolution was 
not sufficient to permit differentiation of the binding into glial or axonal tissue 
components. More recently, Felts et al. (1998) showed an increase in sodium channel 
immunoreactivity on experimentally demyelinated axons, with an even distribution on 
some, but discrete foci on others. The relevance of these foci is unclear but as they 
occur at a time when conduction is possible their presence may be important (Smith & 
McDonald, 1999). Restoration of conduction in demyelinated axons has been 
demonstrated experimentally using intra-axonal recording. Conduction was possible 
over segments of demyelination exceeding several intemodes although with a reduced 
conduction velocity and increased refractory period (Felts et al., 1997). These 
mechanisms could therefore explain the basis of recovery of function despite evidence
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of persistent demyelination and the presence of asymptomatic lesions causing delay of 
the visual evoked response (Halliday et al., 1973a; 1973b).
The recovery from a relapse is therefore probably a combination of resolution of 
inflammation, increased expression of sodium channels in a demyelinated segment and 
the formation of new intemodes by remyelination (Smith & McDonald, 1999). 
Inflammation may be important in the repair process. A number of inflammatory 
cytokines may be involved in inducing remyelination (Sharief, 1998). Interleukin-1/3 is 
a potent inducer of remyelination. It also induces astrocytes to produce other cytokines, 
including interleukin-6 which is involved in oligodendrocyte differentiation, migration 
and survival, and ciliary neurotrophic factor, which may protect oligodendrocyte 
precursors from cell death caused by tumour necrosis factor-a and neurotoxins. 
Inflammation and repair may therefore be in complex balance and governed by the 
availability of oligodendrocytes and their precursors and the temporal and spatial effects 
of inflammatory cells and their associated cytokines.
Remyelination may fail for a number of reasons. Oligodendrocyte precursors may be 
depleted by the inflammatory process (Franklin, 2002). In chronic plaques gliosis may 
act as a physical barrier to remyelination (Compston & Coles, 2002). Astrocytes have 
been demonstrated to express Jagged 1 in active lesions. Jagged 1 can inhibit 
oligodendrocyte differentiation and process production via the Notch pathway (John et 
al., 2002). Also, axons in demyelinated plaques re-express PSA-NCAM (polysialylated 
form of neural cell adhesion molecule) which may inhibit remyelination (Charles et al., 
2002).
The failure of complete recovery from a relapse may be in part due to axonal 
degeneration. Axonal loss has been demonstrated to occur in acute MS lesions with the 
degree of axonal damage related to the amount of inflammation present (Ferguson et al., 
1997; Trapp et al., 1998). NO may be important here. Smith et al. (2001) exposed 
axons to pathophysiological concentrations of NO for two hours and demonstrated that 
persistent conduction block occurred associated with axonal degeneration 
morphologically. The axons were vulnerable at lower concentrations of NO if they 
were also made to conduct impulses at 50 or 100Hz (physiological frequencies). NO 
may inhibit mitochondrial function and hence axons will be more susceptible to damage
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if put under some metabolic stress (Smith & McDonald, 1999). It was possible to 
protect the axons from degenerating by preventing sodium entry into the axons or 
inhibiting sodium/calcium exchange using appropriate channel blocking drugs (Kapoor 
et al., 2003). Direct autoimmune T cell axonal damage (Medana et al., 2001) and 
glutamate excitotoxicity may also be important in the pathogenesis of acute axonal 
degeneration (Pitt et al., 2000).
Halliday et al. (1973a) observed a clear relationship between the mean amplitude of the 
VEP and visual acuity (p<0.001), but not between the mean latency and visual acuity 
following optic neuritis. This suggested that axonal loss could have functional 
significance following a single episode of acute inflammation and this could explain 
some of the mechanisms behind the failure to recover completely from a relapse. 
Normal visual acuity is however possible despite abnormal VEP results following optic 
neuritis (Halliday et al., 1973a; Frederiksen & Petrera, 1999). There may therefore, be 
redundancy in the number of axons required hence large numbers may need to be lost to 
be clinically significant. Frisen and Quigley (1984) obtained nerve fibre counts from 
the temporal quadrants of optic nerves with optic atrophy. The temporal quadrant was 
measured as it was felt that this portion of the nerve was most likely to subserve foveal 
vision. This was compared to the visual acuity to give an indication of the functional 
fraction of neural channels. This produced a parabolic relationship and the suggestion 
that normal (Snellen 6/6) vision can remain despite the loss of 40% of the neural 
substrate. Visual acuity of 6/15 seemed possible with 10% remaining of the neural 
substrate and 6/60 with only 1%. The recovery and/or retention of function despite 
continued axonal dysfunction or loss within the optic nerve may also be as a 
consequence of plasticity and functional remodelling within the visual system and 
higher centres, perhaps by utilising the redundant capacity (Sabel et al., 1997; Werring 
et al., 2000). In a series of experiments, reviewed in (Sabel et al., 1997), it has been 
demonstrated that recovery of visual function in rats to near-normal levels was possible 
within two weeks despite only 10% of nerve fibres remaining following graded optic 
nerve crush. The remaining nerve fibres were measured by looking at the number of 
retinal ganglion cells that had taken up horseradish peroxidase after injection in the 
contralateral superior colliculus. The other neural connections of the optic nerve, 
including the lateral geniculate nucleus were therefore not included in assessing nerve 
viability and therefore it is not certain whether other pathways had nerve fibres that
Optic Neuritis 44
were less vulnerable to injury and contributed to the visual recovery. Measurement of 
vision was by a behavioural task involving orienting towards a visual stimulus or ability 
to perform visual tests in a Y-maze. The tests were therefore examining behavioural 
adaptation rather than visual recovery per se. Nevertheless, whatever the mechanism 
recovery of function was possible despite significant axonal loss. Werring et al. (2000) 
observed extraoccipital activation on functional magnetic resonance imaging (fMRI) 
using periodic monocular 8Hz photic stimulation in seven patients with optic neuritis 
who had recovered back to normal visual acuity (Snellen 6/6 or better). Whilst this 
study demonstrates that altered cortical responses occur following optic neuritis, their 
functional significance in contributing to recovery of vision is unknown.
There is evidence that a more chronic process of ongoing axonal loss also occurs in MS 
and this may explain the development of irrecoverable disability and secondary 
progression in MS (Smith & McDonald, 1999). Abnormalities in the retinal nerve fibre 
layer in patients with MS have been seen in the absence of previous optic neuritis and 
visual complaints suggesting that insidious axonal loss can occur in the optic nerves 
(Frisen & Hoyt, 1974). Early visual evoked response abnormalities in the absence of 
optic neuritis have also been recorded in MS patients including both increased latency 
and reduction of amplitude (Feinsod & Hoyt, 1975). Other studies have shown that 
progressive atrophy of the brain and spinal cord occurs in MS, measured using MRI 
techniques. Correlations with disability have been shown in most of these studies 
(particularly cross-sectional studies) again providing evidence for axonal loss in MS and 
its functional significance (Losseff & Miller, 1998).
The amount of axonal degeneration in MS appears in part related to the amount of 
preceding inflammation. After administration of Campath-IH, a humanised anti­
leucocyte (CD-52) monoclonal antibody Coles et al. (1999) observed almost complete 
suppression of new gadolinium enhancing lesions in patients with MS for at least 18 
months. Disability progression and increasing brain atrophy still occurred in about half 
the patients and was correlated to the magnetic resonance imaging inflammatory load 
present before treatment (p<0.001). These progressive changes may be as a result of 
Wallerian degeneration of axons (Waller, 1850) becoming apparent radiologically over 
time (Simon et al., 2000). That increased cerebral atrophy indicated axonal 
degeneration could be deduced from its strong correlation with decreased TV-acetyl
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aspartate concentration detected using magnetic resonance spectroscopy (Coles et al.,
1999).
Axonal loss in chronic plaques also occurs. The axonal loss is greater in areas of 
demyelination than remyelination (Komek et al., 2000). Oligodendrocytes are thought 
to secrete trophic factors to help maintain axonal integrity (Scolding & Franklin, 1998; 
Wilkins et al., 2003). Remyelinated axons may not, however, be totally immune from 
degeneration. Raine and Cross (1989) observed axonal loss in both demyelinated and 
remyelinated plaques. The mechanism of damage may be related to the observation that 
remyelinated axons may be vulnerable to damage from physiological impulse 
transmission (Samtani & Smith, 1999) Axonal damage due to low-grade ongoing 
inflammation in chronic plaques has also been proposed as a mechanism of chronic 
damage (Smith & Lassmann, 2002).
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Chapter 2 Magnetic Resonance Imaging in Optic Neuritis
MRI allows in vivo examination and there is therefore the potential o f gaining valuable 
insights into the pathophysiology o f optic neuritis. This potential will be discussed 
along with results o f previous MRI studies in optic neuritis. The theory o f MRI will be 
considered followed by the technical difficulties to be overcome in order to image the 
optic nerves.
2.1 Theory of magnetic resonance imaging
The basis o f MRI (Hendrick, 1994; Horowitz, 1994; Hashemi & Bradley jr, 1997), is 
the utilisation o f the properties o f the nuclei o f atoms. Nuclei contain protons which are 
positively charged particles. Each proton behaves as though it was spinning and so 
generates an electro-magnetic field (Figure 2.1).
Magnetic field direction
Proton
Proton spin 
direction
Figure 2.1: The spin o f a proton will generate a magnetic field.
Depending on the number o f nucleons (protons and neutrons), the nucleus may show an 
overall “spin”, which may be an integer or a half-integer. Hence the nucleus may have 
a net magnetic field or magnetic dipole moment (MDM). The principal element o f  
interest for biological MRI is hydrogen because a hydrogen atom’s nucleus contains a 
single proton and hence an MDM, it is found in abundance in biological tissues 
(approximately 1019 hydrogen nuclei per mm3 o f tissue, principally in water and fat) and 
can provide a means o f differentiating normal from diseased tissue as the water content 
often changes due to disease.
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If a nucleus with an MDM is placed in an external magnetic field (the Bo field) then the 
spins of its protons will line up with the magnetic field. The spin direction is not 
usually exactly perpendicular to the “vertical” axis (defined by the main magnetic field). 
The spin and hence the MDM precesses in a motion identical to a spinning top. The top 
spins around its axis, while the axis of the spinning top precesses (more slowly) around 
the vertical axis.
For MRI the magnetic field strengths used are tens of thousands of times stronger than 
the Earth’s magnetic field (1.5 Tesla [T] *30,000 x Earth’s magnetic field strength). If 
radiofrequency (RF) energy appropriate to that nucleus (at the Larmor or precession 
frequency, which is proportional to the magnetic field) is applied (generating the Bi 
magnetic field) some protons will change the direction of their spins, or precession, to 
line up with the new magnetic field. The change in angle of the spins of the protons is 
called the “flip angle”. It is proportionate to the strength and duration of the RF pulse. 
Commonly used flip angles are 90° and 180°. Partial flip angles (of use in gradient 
echo [GE] imaging, see later) of less than 90° can be achieved by lowering the strength 
or duration of the RF pulse. When the RF pulse is switched off the spins will return to 
align with the Bo field. The magnetisation precessing in the x-y plane can induce a 
detectable current in a surrounding coil. This signal oscillates at the precessional 
frequency which can be described as a sine curve and its amplitude decays away to give 
the “free induction decay” or “T2 * curve”.
If the signals from different protons are out of alignment such that one has a negative 
vector whereas another has a positive vector, although they may be precessing at the 
same frequency, they will not be in phase. The individual signals will therefore tend to 
cancel each other out. Immediately after the RF pulse, the vectors are in phase and 
hence the signals are additive. The decay in the T2 * curve is due to dephasing of the 
individual proton MDM vectors. The dephasing is caused by inhomogeneities in the 
external magnetic field which will change the precession frequency and by spin-spin 
interactions between neighbouring protons.
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2.1.1 Ti and T2 relaxation
Relaxation is the term used to describe the realignment of proton spins back to their 
equilibrium state after the RF pulse is turned off.
The Ti relaxation time is the time constant for the rate of growth of magnetization 
back along the longitudinal (z) axis (Ti is the time for the signal to recover to l-(l/e), 
approximately 63% of original value). The T2 relaxation time, which is more rapid, is 
the time constant for the rate of decay of the spins (hence magnetization) in the x-y 
(transverse) directions (T2 is the time for the signal to decay to 1/e, approximately 37% 
of original value). Ti and T2 relaxations are two independent processes occurring at two 
different rates and both vary according to the environment the protons lie within, ie the 
nature of the tissue being examined.
The T2 decay depends on the spin-spin interactions. T2 is therefore fixed and depends 
upon the properties of the tissue whereas T2 * depends on the homogeneity of the 
external magnetic field.
2.1.2 The spin echo pulse sequence
The spin echo pulse sequence consists of a 90° RF pulse followed by one or more 180° 
pulses (Figure 2.2). The 180° pulse is a rephasing or refocusing pulse which eliminates 
dephasing between protons caused by external magnetic field (Bo) inhomogeneities. A 
new T2 * decay occurs after each refocusing pulse, each with a lower amplitude due to 
dephasing from spin-spin interactions that cannot be corrected for and it is this decay 
that produces the T2  decay curve. The time from the 90° pulse to the 180° pulse must 
equal the time from the 180° pulse to the measurement of the signal. This allows time 
for the proton spins to get back in phase before the signal is measured.
In order to produce an image the RF pulse with relaxation and signal measurement need 
to be repeated many times. The TR is the “repetition time” or the time interval between 
RF pulses. The TE is the “echo time” or the time between the RF pulse and signal 
measurement. Both Ti and T2 are sensitive to the macromolecular environment of the 
protons and are inherent properties of the tissue being examined. Ti and T2 vary
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depending on the tissue type and between normal and diseased tissue and by varying TR 
and TE the required image contrast can be produced to display the tissue and detect 
disease effects.
180c 180c
90c 90c
measurementmeasurement
TE, Time
TE,
TR
Figure 2.2: The spin-echo pulse sequence.
In order to produce a more “Ti-weighted” image in which the intensity contrast is due 
mainly to the Ti relaxation properties o f the tissue a short TR and a short TE are 
required to allow for differences in the longer T\ times o f tissues whilst minimising the 
effects o f  T2 . In order to produce a more “T2-weighted” image longer TR and TE are 
required to minimise the effect o f Ti differences between tissues (to allow the 
longitudinal relaxation to be virtually complete in all tissues) whilst allowing more time 
for transverse decay. If a long TR and very short TE sequence is chosen then this will 
negate the effects o f both T 1 and T2 relaxation. The main factor left that can affect the 
signal produced by a tissue is the proton density, hence the images produced in this way 
are called “proton density” (PD) weighted images. The above effects are all relative as 
there is a spectrum from Ti- to T2 - and PD-weighted images.
If two 180° pulses are used with a long TR (usually around 2000-3000ms), two signal 
outputs can be measured: one with a short TE (usually around 20ms) and one with a 
long TE (usually around 80ms). Thus, two sets o f  images can be produced, one that is 
mildly Ti-weighted (called “PD”) and one that is more T2 -weighted.
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Ti relaxation curves show the strength o f the magnetisation in the z direction (Mz 
vector) as a function o f time (Figure 2.3) given by the equation:
Mz = Mo[l-<?('t/Ti)]
GM CSFWM
Mz
WM = white matter 
GM = grey matter
Time since RF pulse stopped
Figure 2.3: Ti relaxation curves.
Examining the graph shows that CSF has a longer Ti time than white matter. If a signal 
is measured with a short TR and TE then white matter will give high signal intensity, 
grey matter will give an intermediate signal and CSF will give low signal intensity. The 
maximum magnitude o f the magnetisation is also directly proportional to the proton 
density.
The T2 decay curve is a graph o f the signal intensity versus TE for a given tissue. If the 
T2 decay curve is considered (Figure 2.4) and a signal is measured with a long TE then 
CSF will give high signal intensity, grey matter will give intermediate signal intensity 
and white matter low signal intensity.
a
a
<d
>
CSF 
’ GM 
—WM
Time since RF pulse stopped
Figure 2.4: T2 decay curves.
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Acute MS lesions in cerebral white matter contain high amounts o f oedema and have 
varying amounts o f demyelination. The lesions have long Ti relaxation curves and T2 
decay curves (although not as long as CSF). Acute lesions therefore give low signal 
intensity on Ti-weighted images and high signal intensity on T2 -weighted images.
There may not be high contrast at a long TE between CSF and the lesion. On long TR/ 
relatively short TE (PD-weighted, although not true PD) images the lesions usually, 
because o f the properties o f their T2 decay curves, give higher signal intensity than CSF. 
As the acute lesion resolves and the oedema subsides the Ti relaxation speeds up.
Figure 2.5: a) T2 -weighted b) PD-weighted c) Ti-weighted conventional spin echo
images from a patient with SPMS demonstrating hyperintense lesions on 
T2 /PD-weighted images and hypointense lesions (black holes) on Ti- 
weighted images.
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The lesions still give high signal intensity on T2 - and PD-weighted images due to 
demyelination and gliosis and isointensity on Ti-weighted images. However, a chronic 
lesion with axonal loss will have increased extracellular water and will again give low 
signal intensity on Ti-weighted images whilst continuing to give high signal intensity 
on T2 - and PD-weighted images (Figure 2.5). T2 - and PD-weighted images are very 
sensitive to detecting MS lesions however there is low pathological specificity for the 
nature of the lesions so detected (Grossman et al., 2000).
2.1.3 Generating the image in space
In MRI the Bo field is usually generated by coils of superconducting wire. Gradient 
coils can change the Bo field. A transmitter coil transmits the RF pulse and receiver 
coils detect the RF pulses generated by the relaxing protons. The transmitter and 
receiver coils may be combined together (eg head coils). The gradient coil generates an 
intentional inhomogeneity in the Bo field which allows spatial information to be 
deciphered. Three orthogonal gradient coils are used to allow three-dimensional spatial 
encoding in the x, y and z directions and hence the image can be constructed. The 
gradients are referred to as the:
1) slice-select gradient
2) phase-encoding gradient
3) frequency-encoding gradient.
The vector of application of these three gradients can be varied to vary the plane of 
imaging to suit the tissue being investigated (axial, sagittal, coronal or oblique).
Oblique planes can be obtained by combining gradients.
2.1.4 The slice-select gradient
The slice-select gradient is produced by varying the magnitude of the Bo field in a 
particular direction. The Larmor frequency of the protons therefore varies with the 
slice-select gradient. By using different RF pulse frequencies then different protons 
along the slice-select gradient can be flipped, hence an image plane can be selected. 
Usually a range of frequencies (the “bandwidth” of the pulse) are used. The thickness 
of the image slice can be varied by changing the bandwidth of the RF pulse or by 
changing the amplitude of the slice-select gradient. Mostly the latter is varied as there is
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a limitation as to how much the bandwidth can be decreased. If contiguous slices are 
imaged then the edges of the consecutive slices may overlap causing interference or 
cross-talk. This can be overcome by having gaps between slices or by using an 
acquisition that images consecutive slices at different times and then interleaves them 
when the image is constructed. The slice-select gradient is only turned on during the 
application of the RF pulses.
2.1.5 The frequency-encoding gradient
Each image slice is composed of a grid of pixels. Each pixel will have its own signal 
intensity. In MRI the signal recorded is the sum of all the pixels. The signal intensity 
of each individual pixel needs to be reconstructed to generate the image. To distinguish 
points along the frequency-encoding gradient (or read-out gradient) a magnetic field is 
applied in this direction and therefore the Larmor frequency of the protons varies. The 
frequency-encoding gradient is applied only when the signal is measured. The signal 
strength at each frequency can be measured. To extract this information a Fourier 
transform is needed. The Fourier transform is a continuous frequency distribution curve 
that plots amplitude of the signal against frequency.
2.1.6 The phase-encoding gradient
Phase-encoding occurs by applying a gradient in the phase-encoding direction for a 
short period after the RF pulse, usually between the 90° pulse and the 180° pulse or 
between the 180° pulse and signal measurement. Protons at different positions in this 
gradient will therefore precess at a different frequency. When the gradient is switched 
off all protons will again precess at the same frequency but they will no longer be in 
phase. Differences in spatial position are therefore “phase-encoded”. The number of 
repetitions of the pulse sequence equals the number of rows of pixels in the image. For 
each repetition, the phase-encoding gradient is applied with increasing amplitude and 
therefore the effect of phase-encoding is greater.
Most imagers use 256 or 512 frequency gradations in the frequency-encoding direction 
and a multiple of 64 phase-encoding rows (128, 192, 256). When the signal is recorded 
the frequency-encoding gradient is applied hence the protons in each pixel will have a
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distinct frequency and a distinct phase, which are unique and encode the x and y 
coordinates for that pixel.
2.1.7 Image processing
The signal produced from each phase-encoding step is in the form of a set of sine waves 
comprising a composite of the signal from each pixel. The imager records the 
amplitude of the signal at equally-spaced intervals in time called sampling points. This 
is stored as a matrix of data. Each row of numbers represents a set of sampled points 
for each phase-encoding step and each column represents a point in time. This matrix 
of data can be thought of in terms of “k-space” and contains the same number of points 
as the final image. Each point in the image though arises from all points in k-space.
The centre of k-space contains the phase-encoding steps with the weakest gradients and 
therefore with the highest signal. This area provides contrast. The periphery of k-space 
contains the phase-encoding steps with the largest gradients and hence the least signal. 
This area gives information about boundaries and gives sharpness to the final image.
By a mathematical transformation (Fourier transformation) the sine waves are converted 
into a matrix of data consisting of individual pixels. Each pixel has x and y coordinates 
and an intensity value (representing the amplitude of the signal at that point). The 
image can therefore be reconstructed.
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2.2 Optic nerve imaging
MRI of the optic nerve is challenging for many reasons (Barker, 2000). These 
principally are:
1) Its small size and tortuosity
2) Its mobility
3) The surrounding CSF
4) Orbital fat
5) The bones of the orbital canal and air-fluid interfaces from the adjacent sphenoid 
and ethmoid sinuses
The optic nerves are approximately 40-50mm long and 3-5mm in diameter (Williams et 
al., 1989; Tamraz, 1994; Sadun, 1998). Resolution of the small structures or lesions 
contained within the nerves is dependent upon the voxel size. If the voxel size is too 
large then resolution will be impaired due to partial volume effects (ie mixing of signal 
from neighbouring structures). The voxel size can be reduced by increasing the matrix 
size, however if the voxel size is too small then there may not be enough signal resolved 
to produce an image because the signal-to-noise ratio (SNR) is reduced. Resolution and 
SNR can be increased by increasing the acquisition time or by increasing the magnetic 
field strength. Increasing the magnetic field strength however will increase the 
longitudinal relaxation time of the tissue being imaged, also potentially leading to 
increased acquisition time. There is also the possibility of more susceptibility artefacts 
(see later) from surrounding tissues at higher field strengths leading to worsening of the 
SNR (Horsfield, 2000). Signal averaging can also improve the SNR and thereby 
improve the resolution, again at the expense of increased acquisition time (Barker, 
2000). Increasing acquisition time will lead to more movement artefact, particularly in 
the mobile optic nerve. Fast imaging techniques are therefore required to give high 
SNR with an acceptable acquisition time (Gass et al., 1995).
The optic nerves are surrounded by a CSF-filled nerve sheath and, in the orbit, by lipid 
(Williams et al., 1989; Sadun, 1998). Due to its high PD lipid typically gives high 
signal intensity on both Ti- and PD/T2 -weighted imaging (Figure 2.6). CSF gives high 
signal intensity on PD- and T2 -weighted imaging. This may cause problems due to 
obscuring the edge of the optic nerves and hence CSF suppression may be desirable. In
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certain circumstances however the bright CSF may assist in identification o f the nerve 
(Barker, 2000).
Optic nerve 
Orbital fat 
Sphenoid sinus 
Optic canal
Figure 2.6: Axial PD-weighted FSE image demonstrating optic nerve anatomy.
2.2.1 Artefact
There is also a considerable potential for artefact in optic nerve imaging, more so than 
in the brain. The most important sources o f artefact with possible solutions are 
discussed below:
(i) Chemical shift artefacts
As has been discussed, the optic nerves are surrounded by lipid in the orbits. Orbital fat 
produces a signal that is much more intense than the water signal leading to excessive 
partial volume effects. In addition chemical shift artefacts can occur at lipid-water 
boundaries. Due to their differing chemical environments protons in lipid have a lower 
precession frequency than protons in water. The lipid protons are therefore 
misregistered relative to the water protons in the frequency encoding direction (Soila et 
al., 1984). This can lead to decreased signal where the lipid is displaced away from 
water and high signal where lipid and water overlap. This chemical shift artefact is 
more prominent at higher field strengths (Barker, 2000). High signal and chemical shift 
artefacts from orbital fat can be suppressed using STIR imaging (Johnson et al., 1987)
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or a frequency-selective fat saturation excitation pulse prior to imaging time (Gass et 
a l , 1995).
(ii) Motion artefacts
Motion in a structure causes image blurring in the direction of movement and “ghost” 
artefacts in the phase-encoding direction due to the signal being reconstructed over and 
over. The major motion problem in optic nerve imaging is random motion due to eye 
movements. On ocular movement the intra-orbital portion of the optic nerve shifts 
against the direction of gaze with an increasing extent from the relatively fixed posterior 
part at the orbital apex anteriorly (Liu et al., 1992). Motion artefacts can be reduced by 
using fast imaging techniques with multiple signal acquisitions and signal averaging or 
by using GE rather than spin echo techniques because a 180° refocusing pulse is not 
required in GE imaging (mobile protons may have moved before the 180° pulse has 
been applied (Taber et al., 1998; Barker, 2000). Subjects undergoing optic nerve 
imaging can also be encouraged to relax, close their eyes and avoid deliberate eye 
movements. Taping down the eyelids has been suggested (Iwasawa et al., 1997), 
although this seems a little extreme.
(iii) Susceptibility artefacts
Susceptibility artefacts occur at interfaces between different tissues, due to the different 
magnetic properties of the tissues. It is more apparent at higher field strengths and can 
cause rapid dephasing of spins with signal loss and mismapping artefacts (Hashemi & 
Bradley jr, 1997). It is a particular problem in the canalicular portion of the optic nerves 
due to the bony cavity of the optic canal and air from the adjacent sphenoid and ethmoid 
sinuses. Metals, particularly iron, can cause a lot of image distortion and subjects 
should be carefully screened for metal in clothing before imaging commences. 
Susceptibility artefacts can be reduced by using spin echo rather than GE or echo planar 
imaging (EPI) because the spin echo sequence includes a refocusing pulse (Barker, 
2000).
Imaging of the optic nerves is therefore a trade-off between imaging time, resolution, 
SNR and the amount of artefact induced.
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2.3 Magnetic resonance imaging in optic neuritis
MRI provides a valuable opportunity for in vivo study of the pathological evolution of 
optic neuritis and, by inference, other central nervous system inflammatory 
/demyelinating lesions with clinical and electrophysiological correlation. There follows 
a summary of the studies and pulse sequences used in optic neuritis.
2.3.1 Short tau inversion recovery imaging
The first imaging technique used to investigate optic neuritis was the STIR sequence. 
This utilises a 180° RF pulse prior to the excitation pulse to invert the net magnetisation. 
A short inversion time (TI) is then used so that the lipid signal is approximately zero 
(due to its short Ti relaxation time) whilst other tissues continue to give a negative 
signal (Johnson et al., 1987; Brown & Semelka, 1999). Thus when the 90° excitation 
pulse is applied these tissues will be flipped whereas the fat signal will remain zero.
This suppresses the fat signal relative to, in particular, water. The images are displayed 
with reversed polarity to make most tissues appear bright and lipid dark.
In a study of 37 patients following an episode of optic neuritis using STIR imaging (TR 
1500ms, TE 40ms, TI 150ms, matrix 256x256, field of view [FOV] 15cmxl5cm, 
number of excitations [NEX] 2, 5mm contiguous slices, Picker 0.5T imager) lesions 
were detected in 84% of symptomatic nerves and 20% of asymptomatic nerves (Miller 
et al., 1988). Slow (>4 weeks for vision to improve to 6/9) or poor (<6/9 at 6 months) 
visual recovery was associated with longer lesions (mean number of abnormal 5mm 
coronal slices 3.50 versus 1.84, p<0.01) although there was no correlation between 
lesion length and latency or amplitude of the PI 00 response of the VEP. Eleven out of 
15 patients (73%) with lesions involving the optic canal also had a poor recovery which 
was thought to be due to compression of the swollen optic nerve within the tight 
confines of the bony canal. These findings were confirmed by Dunker and Wiegand 
(1996). They examined 22 patients acutely and again after a mean of 4.7 years (range 
2.5-8 years) with STIR MRI of the optic nerves (TR 1800ms, TE 35ms, TI 140ms, 
Siemens 0.5T imager at baseline; TR 2100ms, TE 20ms, TI 150ms, Siemens 1.0T 
imager at follow-up). Lesions less than 17.5mm long either acutely or chronically were 
correlated with complete visual recovery (visual acuity >20/25, no visual field, colour
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vision or contrast sensitivity defect). Intracanalicular lesions correlated with incomplete 
visual recovery (visual acuity >20/25 but other deficits present).
Kakisu et al. (1991) demonstrated that although the lesion length on STIR (TR 1500ms, 
TE 40ms, TI 100ms, Picker 0.5T imager) was not correlated with pattem-reversal VEP 
findings in the acute phase, there was a significant correlation in the chronic phase 
(r=0.68,/?<0.005). There was however, no correlation between lesion length and visual 
acuity.
High signal in optic nerves following optic neuritis remains chronically despite 
improvements in vision and VEP findings (Youl et al., 1996) and may be seen in MS in 
the absence of acute attacks of optic neuritis (Davies et al., 1998).
Subsequently a study was performed to see whether STIR MRI of the optic nerves 
could help to predict whether corticosteroids could be targeted more effectively in optic 
neuritis (Kapoor et al., 1998). Sixty-six patients with acute unilateral optic neuritis had 
their optic nerves imaged with the STIR sequence (TR 2500ms, TE 40ms, TI 175ms, 
matrix 256x128, FOV 16cmxl6cm, NEX 2, 5mm contiguous slices, General Electric 
1.5T imager). They were then randomized to receive either lg/day IVMP for three days 
or placebo. Patients were stratified into those with short or long (>  3 involved coronal 
slices) lesions. The presence of canalicular involvement was also noted. Patients with 
longer lesions tended to present earlier (mean 8.4 versus 12.1 days,/?<0.05) however 
there was no correlation between initial visual acuity and initial lesion length. Treatment 
with IVMP was not associated with improved visual outcome at six-months in those 
patients with long or canalicular lesions and treatment did not affect six month lesion 
length on repeat imaging. An association between initial canalicular involvement and 
poor recovery was not seen, however after six months canalicular involvement was seen 
in all 16 patients with a poor visual recovery compared with only 31 out of 45 patients 
with a good recovery (p<0.01).
The STIR sequence has some drawbacks. A long TR is required to enable all the Ti 
relaxation to occur in the different tissues prior to the next inversion pulse, leading to an 
increased acquisition time. Tissues with Ti similar to fat will have their signal 
suppressed and the contrast between other tissues may be reduced. There may also be a
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signal void at fat-water interfaces. Care must be taken when interpreting images after 
administration of gadolinium as this is a Ti contrast agent. The STIR sequence will 
result in decreased signal from tissues that have taken up the contrast agent rather than 
enhanced Ti signal that is normally expected and easier to depict (see later) (Brown & 
Semelka, 1999).
2.3.2 Chemical shift imaging
This technique involves a spin echo acquisition followed by a sequence with the read­
out timing adjusted to vary the relative amounts of water and fat signal in each voxel. 
The images are combined so that images containing only water or fat can be produced 
(Brown & Semelka, 1999). Optimisation of the field homogeneity is crucial for 
consistent image appearance. This method however doubles the imaging time and 
requires post-processing. A derivation of this technique using chopper fat suppression 
has been reported (Lee et al., 1991). Here normal signal averaging is employed with the 
first acquisition having the 90° and 180° pulses in phase and the second reversing the 
phase of the 90° and having the 180° pulse offset by a delay. With pre-saturation of fat 
and subtraction of the second data set from the first during signal averaging, a fat- 
suppressed single image dataset is produced with no increase in imaging time. Using 
this sequence (TR 2000-2500ms, TE 30-35 or 70-80ms, 128 phase steps, FOV 
20cmx20cm, 3mm slices with 1-1.5mm intersection gap, Signa 1.5T imager) the 
sensitivity for detecting optic neuritis lesions was 89% with 100% specificity and 86% 
accuracy.
2.3.3 Frequency selective fat saturation
By applying a narrow bandwidth RF pulse centred at the precession frequency of fat in 
the absence of a gradient the resulting transverse magnetisation can be dephased by 
spoiler gradients. Any imaging sequence can then be used including Ti- or T2 -weighted 
images and after the administration of contrast signal enhancement results leading to 
easier to interpret images. The suppression of fat signal is not as high as with STIR 
imaging due to Ti relaxation occurring between the fat saturation pulse and the imaging 
pulse. The degree of suppression will also be affected by magnetic field
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inhomogeneities as the precession frequency varies with magnetic field strength (Brown 
& Semelka, 1999).
2.3.4 Fat saturated fast spin echo imaging
The major disadvantage of spin echo imaging is the poor resolution possible within an 
acceptable acquisition time (Barker, 2000). Imaging time can be decreased using 
multiple echoes to reduce the number of excitation pulses required. The rapid 
acquisition with relaxation enhancement sequence, now more commonly known as 
FSE, uses multiple echo trains from a single TR, each using slightly different amount of 
phase encoding gradient to build up the image in k-space, rather than each line in k- 
space coming from different TRs as in spin echo imaging (Hennig et al., 1986; Brown 
& Semelka, 1999). The amplitude variations between the echoes are due to both the 
phase-encoding amplitude and the TE. The effective TE (TEef) is recorded as this is the 
TE of a multi-echo sequence at the centre of k-space where image contrast principally 
occurs. The echo train length (ETL) is the number of echoes delivered for each TR.
For optic nerve imaging with fat saturation the FSE sequence allows for increased 
resolution and image quality with an acceptable acquisition time. In a study comparing 
STIR (TR 2000ms, TE 50ms, TI 175ms, NEX 1, matrix 256x256, FOV 20cmx20cm, in­
plane resolution 0.8x0.8mm, 5mm slices with 0.5mm inter-slice gap, 2 acquisitions, 
General Electric 1.5T imager with 13min acquisition time) with fat-saturated FSE (TR 
3250ms, TEef 68ms, ETL 16, NEX 4 , 512x512 matrix, 24cm rectangular FOV, in­
plane resolution 0.5x0.5mm, 3mm interleaved contiguous slices, General Electric 1.5T 
imager with 1 lmin acquisition time) lesions were detected in 18 out of 21 symptomatic 
optic nerves with acute optic neuritis using STIR compared with 20/21 using FSE (Gass 
et al., 1996). Mean lesion length was 15.4mm on STIR images and 17.3mm on FSE 
images. Using fat-saturated FSE dual echo imaging is possible giving both PD- and T2- 
weighted images from the same acquisition if appropriate TEefs are chosen (Barker,
2000). It is not yet known how results of imaging using FSE in optic neuritis relate to 
visual impairment in the acute phase and prognosis for recovery of vision.
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2.3.5 Combined fat and water suppression imaging
On FSE and, particularly the lower resolution STIR, CSF gives high signal which may 
obscure the signal from the optic nerves (Gass et al., 1996). It is possible to suppress 
the signal from CSF using fluid-attenuated inversion recovery (FLAIR) techniques.
The FLAIR sequence uses an inversion pulse with a long TI for CSF suppression which 
increases the acquisition time. For optic nerve imaging fat saturation and fast 
acquisitions are required hence a combined selective partial inversion recovery pre­
pulse with a FLAIR sequence and FSE acquisition (SPIR-FLAIR) has been developed 
to try to achieve these aims (Jackson et al., 1998). SPIR-FLAIR (TR 8000ms, TE 
120ms, TI 2200ms, ETL 21, matrix 256x256, FOV 16cmxl6cm, 3mm slices with 1mm 
intersection gap, 2 acquisitions, Philips 1.5T imager with 4min acquisition time) was 
compared with both SPIR (TR 3085ms, TE 120ms, ETL 12, matrix 512x512, FOV 
18cmxl8cm, 3mm slices with 1mm intersection gap, 2 acquisitions, Philips 1.5T imager 
with 4min 25s acquisition time) and STIR (TR 1560ms, TE 50ms, TI 165ms, ETL 4, 
matrix 256x256, FOV 18cmxl8cm, 3mm slices with 1mm intersection gap, 2 
acquisitions, Philips 1.5T imager with 2min 41s acquisition time) imaging in the 
assessment of optic neuritis. Both SPIR-FLAIR and SPIR detected lesions in all 21 
symptomatic optic nerves imaged whereas STIR imaging detected only 20/21. Lesion 
lengths were also longest on the SPIR-FLAIR images (17.2mm on SPIR-FLAIR, 
15.8mm on SPIR and 13.8mm on STIR,/?<0.01) even though the in-plane resolution 
was less than with SPIR imaging.
2.3.6 New pulse sequences and methods of analysis
Although the above conventional MRI techniques are sensitive in detecting the lesions 
of optic neuritis there is a lack of pathological specificity to allow prediction of the 
chronological age of these lesions. This is because oedema, demyelination and gliosis 
all demonstrate high signal on T2 -weighted images (Miller et al., 1998). As has been 
discussed imaging of the optic nerves is particularly limited by issues of poor 
resolution. Increasing the SNR requires very large increases in acquisition time. Using 
conventional imaging techniques at present is therefore limited by the technology 
available (Horsfield, 2000). The only pointers to age the lesion have been a subjective 
impression of optic nerve swelling in the acute phase and atrophy in the chronic phase
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(Miller et al., 1988; Gass et al., 1996; Jackson et al., 1998; Kapoor et al., 1998). Other 
techniques have been developed which are able to study the optic nerves in order to 
understand better the pathophysiology of optic neuritis. These have principally been 
applied in brain imaging in MS but, with recent technological advances, optic nerve 
imaging using these techniques has also been possible.
2.3.7 Gadolinium “enhancement”
Dimeglumine gadopentate is the most common contrast agent used in MRI as 
gadolinium is a paramagnetic substance. In areas of acute inflammation where there is 
blood vessel wall leakage gadolinium will accumulate and show up as high signal on 
Ti-weighted imaging due to shortening of Ti. Optic nerve imaging imposes some 
constraints due to the need for fat suppression. If STIR imaging is used then the signal 
from gadolinium is also suppressed hence a drop in signal is indicative of acute 
inflammation and gadolinium “leakage” rather than gadolinium enhancement (Brown & 
Semelka, 1999). In a study of 18 patients with acute optic neuritis (2 with bilateral 
simultaneous disease) STIR imaging (TR 2000ms, TE 40ms, TI 150ms, 5mm 
contiguous slices, Picker 0.5T imager) was performed before and after injection of 
0.02mmol/kg dimeglumine gadopentate (Youl et al., 1991). Ten of the patients (one 
with bilateral simultaneous optic neuritis) had MRI twice, once a mean 6.4 days (range 
2-13 days) after onset of symptoms and again a mean 27.8 days (range 20-32 days 
later). Clinical and electrophysiological examination was also performed at each 
occasion. Of the 31 examinations in total, gadolinium leakage was seen in 6/6 lesions 
where the time since onset of optic neuritis was less than seven days, in 7/8 lesions 
where time since onset was 7-13 days but in only 5/17 lesions where the age of the 
lesion was at least 14 days. Gadolinium leakage in the hyper-acute phase was 
associated with decreased visual acuity, pain on eye movement, an RAPD, swelling of 
the optic disc (p=0.001 for each clinical feature compared with the asymptomatic optic 
nerves) and decreased amplitude of the P100 component of VEP (p<0.001). There was 
a trend for patients with longer lesions to have worse visual acuity (acuity <6/9 in 4/5 
patients with gadolinium leakage on > 3 slices, compared with 4/8 studies with leakage 
on 1-2 slices, p=0.1). In those patients who had a follow-up MRI gadolinium leakage 
had ceased in 9/11 symptomatic optic nerves. This was associated with an 
improvement in all the above clinical features and increased P I00 amplitude (p=0.02)
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compared with the first examination. It was concluded that acute inflammation is 
associated with conduction block in the optic nerve and that resolution of inflammation 
plays an important role in the recovery process. As has been discussed these findings 
have been supported by work performed in vitro.
A recent report confirmed that gadolinium enhancement is a consistent feature of acute 
optic neuritis and that the lesion length had clinical significance at presentation 
(Kupersmith et al., 2002). In this retrospective series 101/107 (94%) symptomatic optic 
nerves demonstrated enhancement following gadolinium on fat saturated Ti-weighted 
imaging. Optic nerves with > 17mm enhancing segment on axial images had poorer 
baseline Snellen visual acuity (p=0.02), Humphrey 24-2 threshold perimetry (p=0.009) 
and colour vision on Ishihara plates (p=0.01). Canalicular involvement was associated 
with poorer colour vision (p=0.04). The location and length of the initial lesion 
however, was not predictive of the degree of visual recovery in the 93 patients (68 
treated with corticosteroids) with clinical follow-up after six months.
Further studies are required to give a more accurate view of the temporal relationship 
between enhancement, visual impairment, and electrophysiology. The previous studies 
on optic neuritis used single- or double-dose gadolinium. Triple-dose (0.03ml/kg 
dimeglumine gadopentate) gadolinium increases the sensitivity for detecting enhancing 
lesions in MS by 66-75% compared with the use of single-dose gadolinium (Filippi et 
al., 1996; Silver et al., 1997). The sensitivity is further increased by introducing a delay 
between the injection and imaging and by using magnetisation transfer (MT) imaging 
(Silver et al., 1997). It is not known yet whether the use of triple-dose Gd will add 
more information about prognosis in optic neuritis.
2.3.8 Optic nerve size
Optic nerve size can be judged on MRI both subjectively and objectively.
(i) Optic nerve swelling
Optic nerve swelling, suggesting the presence of acute inflammation and oedema, on 
STIR MRI was reported in three out of 37 cases (8%) of acute optic neuritis in the first
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major imaging study performed that investigated the condition (Miller et al., 1988). It 
had been thought to be a rare occurrence in optic neuritis and if swelling was present 
then a glioma or meningioma should be suspected (Comblath & Quint, 1997).
However, in a further study of acute optic neuritis using STIR imaging, swelling was 
reported in 12 out of 40 cases (40%) with, and in four out of 26 cases (15%), without 
canalicular involvement (Kapoor et al., 1998). Also, using formal measurement of 
optic nerve size with callipers from the intraorbital optic nerve on hard copy STIR 
images (TR 2000ms, TE 40ms, TI 150ms, matrix 128x256, FOV 15cmxl5cm, Picker 
0.5T imager) from 10 patients Youl et al. (1996) reported that the mean area of 
symptomatic optic nerves with acute optic neuritis (mean disease duration 6 days) was 
20.0 (standard deviation [SD] 2.7)mm2 compared with 14.4 (SD 3.5)mm2 for 
asymptomatic contralateral optic nerves (p=0.001). After a mean follow-up period of 
28 days the mean area of the symptomatic optic nerves had decreased to 15.5 (SD 
4.6)mm (p=0.01) whereas the asymptomatic optic nerves had a mean area of 14.1 (SD 
4.1)mm2 (p=not significant [NS]). Both visual acuity and VEP amplitudes improved on 
follow-up whereas VEP latencies did not improve significantly. This suggested that 
resolution of acute inflammation was associated with resolution of optic nerve swelling.
(ii) Optic nerve atrophy
An expected end result of demyelination and axonal loss is atrophy of tissue. 
Measurements of CNS atrophy are used increasingly to monitor disease progression in 
both natural history studies and therapeutic trials (Miller et al., 2002). Atrophy of tissue 
in MS could potentially result from both demyelination and axonal loss. However, 
axons contribute almost twice as much to the bulk of white matter as myelin (Miller et 
al., 2002) and axonal loss would seem likely to be the more important determinant of 
atrophy. There have been many studies of brain and spinal cord atrophy in MS using 
MRI. These measures are either of the whole brain or a representative part, for example 
brain lateral ventricle volume or spinal cord area at C2/3. They tend to represent the 
global effects of disease rather than the effect of lesions on a single pathway. The latter 
could, in principle, be assessed in the optic nerve. Being able to quantify the degree of 
optic nerve atrophy following optic neuritis would be useful since, as already discussed, 
optic neuritis is a model for the effects of lesions in MS. This is technologically very 
demanding for a number of reasons. An appropriate fast pulse sequence with fat
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saturation is required to produce high resolution images. The positioning of the patient 
and has to be reproducible for serial studies so that the scan-rescan variation is low and 
the measurement method has to be robust with low variation on repeat measurement.
Youl et al. (1996) also studied 22 patients with a mean disease duration of 60 days. 
Optic nerve area in both symptomatic and asymptomatic nerves was 16.8mm . After a 
mean of 405 days the patients were re-imaged. The mean area of symptomatic nerves 
decreased to 12.8 (SD 4.2)mm2 (p<0.001) and the asymptomatic nerves to 16.3 (SD 
3.3)mm (p=NS). This was despite improvement in visual acuity, VEP amplitude 
(p=0.03) and VEP latency (p=NS) in the affected eyes. The STIR sequence Youl et al. 
used had the disadvantages of low resolution (pixel size 1.2x0.6mm), the presence of 
high signal from CSF obscuring the edge of the optic nerve and the inclusion of optic 
nerve sheath leading to an overestimation of optic nerve area.
FSE images have also been assessed for optic nerve atrophy by manual measurement of 
nerve diameter in papilloedema and autosomal dominant optic atrophy but as with 
STIR, high signal from CSF within the nerve sheath mitigates against accurate 
delineation of the nerve itself (Mashima et al., 1996; Votruba et al., 2000).
The combined CSF and fat suppression of SPIR-FLAIR imaging has allowed optic 
nerve atrophy to be detected qualitatively following optic neuritis. Inter-observer 
assessment of optic nerve size was 1.0 using a weighted Cohen k  test for SPIR-FLAIR 
compared with 0.85 for SPIR and 0.61 for STIR (sequences which were not CSF 
suppressed) (Jackson et al., 1998).
Recently, Inglese et al. (2002) imaged 30 patients with RRMS and SPMS who had had 
a previous episode of optic neuritis. A Ti-weighted spin echo (TR 500ms, TE 14ms, 
matrix 224x512, FOV 15.6cmx25cm, 3mm slices with 0.3mm gap, 1.5T imager) 
sequence was used. The mean volume of the optic nerves was calculated from the mean 
areas from 11 slices using a local thresholding segmentation technique. The mean 
volume was 93.3 (SD 3.5)ml in 18 age-matched controls, 89.2 (SD 9.8)ml for clinically 
healthy nerves (n=18), 89.4 (SD 11.0)ml for diseased optic nerves with visual recovery 
to at least 20/25 (n=20) and 79.0 (SD 9.8)ml for diseased optic nerves with vision worse 
than 20/25 (n=22) (p=0.002, versus optic nerves with good recovery). Optic nerve
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volume was correlated with both visual acuity (rs=0.39, jo=0.01) and VEP P100 latency 
(>s=-0.31,/>=0.05). The functional significance of optic nerve atrophy was therefore 
apparent although the correlations were modest. Formal measures of reproducibility 
were not included in this study.
A formal quantitative study is required to assess whether a CSF and lipid suppressed 
sequence is of use in the detection of optic nerve atrophy. For quantitative assessment it 
would be helpful if high signal from affected optic nerves is also suppressed - to enable 
more accurate blinding between affected and unaffected nerves and between patients 
and controls. It would also be of benefit for signal-intensity based automated 
contouring techniques to avoid potential bias in manual outlining. The SPIR-FLAIR 
sequence would not be suitable as it is T2 -weighted and optic nerve lesions give high 
signal. A fat-saturated fast FLAIR sequence that is less T2 -weighted may be of use here 
and would warrant investigation.
The relationship between optic nerve swelling and atrophy needs elucidating further, 
combining this with other imaging modalities such as fat saturated post-gadolinium Ti- 
weighted spin-echo imaging. The temporal and functional relationship between 
gadolinium enhancement, optic nerve swelling and optic nerve atrophy can then be 
elucidated.
2.3.9 Magnetisation transfer imaging
MT imaging provides a means by which tissues can be examined in more detail, going 
beyond the Ti and T2 characteristics. There follows a description of its physical basis 
(Wolff & Balaban, 1989; McGowan, 1999; Barker, 2000; Van Buchem & Tofts, 2000). 
In tissues water can be thought to exist in two states: “free” as in intra- and extracellular 
fluid and “bound” which consists of water involved in cellular membranes and myelin 
sheath. As has been discussed the relaxation characteristics of protons depends in part 
on the macromolecular environment (tissue) in which the protons lie. The bound water 
has restricted motion, short T2 relaxation (~20/zs compared to 80ms for free water), a 
resonant frequency close to that of free water and is present at a much lower 
concentration than free water in most tissues such that, when using conventional 
imaging techniques, signal from this pool is not included. The bandwidth for the bound
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water is however much broader than for free water ( >  10kHz compared with ~200Hz) 
(Figure 2.7)
-25 0 +25
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Figure 2.7: Simulated spectrum for bound (fine line) and free water (bold line). The
areas under the curves are in the ratios o f the water concentrations.
If an RF pulse is applied in the absence o f a gradient with a frequency that includes the 
bound protons but not the free protons (ie an appropriate offset frequency) the bound 
protons can be partially saturated. There then follows an exchange o f energy 
(magnetisation transfer) between the bound and free protons by chemical exchange or 
spin-spin interaction (cross-relaxation). If an attempt is then made to image the free 
protons, the signal from them will be reduced in proportion to the degree o f exchange 
that has occurred with the bound protons. Use o f MT therefore allows the hitherto 
invisible bound water to be examined and provides a means o f increasing contrast. It 
also provides a means o f producing quantitative images by calculating the degree o f  
exchange between bound and free protons. If images are produced o f the same slice 
both with and without an MT pre-pulse the MT ratio (MTR) can be calculated which is 
an indication o f the amount o f signal reduction that has occurred due to the MT pulse.
It is calculated using the formula:
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MTR = [(Mo-Ms) / Mo] x 100 percent units
Where Mo is the signal intensity in absence of the MT pre-pulse and Ms is the signal 
intensity in the presence of the MT pre-pulse. By custom the MTR is expressed as 
percent units (pu). The higher the MTR, the greater the reduction in signal and hence 
the greater the bound water pool is. It is not an absolute measure but is dependent on 
the amplitude and frequency offset of the MT pulse as well as the time delay between 
the MT pulse and the excitation pulse. It also varies between imagers and in the same 
imager due to coil non-uniformity, thus requiring accurate repositioning of patients in 
serial studies.
The MT sequence for MTR calculation requires low Ti-weighting (as the MT pulse 
shortens the Ti time of tissues) and minimal motion between the Mo and Ms images. 
GE imaging is usually used due to its low Ti-weighting (Barker, 2000). It does not 
include a 180° refocusing pulse, instead the signal is produced following a reversal of 
the gradient pulses (Brown & Semelka, 1999). Usually flip angles <90° are used with 
short TR which decreases imaging time and power deposition to the patient.
Analysis of the images to give the MTR can be done in two ways. The conventional 
approach is to examine an ROI placed manually or using semi-automated techniques. 
This is useful when examining a particular tissue or a lesion. The positioning of the 
ROI is important to avoid partial volume pixels contaminated from adjacent tissues. 
The ROI also has to be accurately re-positioned both on the same image and in serial 
studies to ensure reproducibility and confidence that any changes detected are real and 
not artefactual due to variation in ROI placement. An alternative approach is to 
generate histograms containing information from all the pixels in the tissue to be 
examined. This can give an indication of the global burden of disease and can detect 
subtle changes in what appears to be normal tissue. Again reproducible segmentation 
and the avoidance of partial volume pixels are important.
MT imaging has been combined with histopathological examination to give an 
indication of the physical basis of the MT effect:
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(i) Magnetisation transfer imaging in experimental allergic encephalomyelitis
MTR calculation has been performed on lesions in guinea-pigs due to EAE in 
combination with histological analysis (Dousset et al., 1992). The MTR of two 
identified acute lesions from two animals decreased over the first 12 days following 
immunisation with homologous spinal cord in Freund’s adjuvant by 6-7% (p<0.001), 
although in one animal there was an initial early rise in MTR. Symptoms appeared 
around day 10. Clinical decline mirrored the decline in MTR. Histological examination 
was performed on day 14. The lesions were oedematous with a mononuclear cell 
infiltrate but had no demyelination.
The experiments were repeated in a relapsing EAE model in macacas fascicularis 
monkeys (Brochet & Dousset, 1999). The MTR decreased initially but then 
progressively increased. The degree of demyelination was related to the decrease in 
MTR. Remyelination was associated with a restoration of MTR to normal, although 
resolution of oedema was also thought to play a role. After repeated attacks the MTR 
did not return to the normal. This was related to mild astrogliosis.
Lesions produced by direct injection of lysophosphatidylcholine into the centrum 
semiovale of macacas fascicularis monkeys can produce both myelin and axonal 
damage. The MTR in these lesions showed a larger decrease than in the relapsing EAE 
model (Brochet & Dousset, 1999).
(ii) Magnetisation transfer imaging in a Wallerian degeneration model
Lexa et al. (1994) surgically ablated the visual cortices from one hemisphere of 10 cats. 
MT imaging was then performed at varying intervals with histological analysis. In the 
first two weeks following the ablation the MTR in the optic radiations were higher on 
the ablated side compared to the contralateral hemisphere (p<0.02) followed by a fall in 
MTR over the next two weeks (p<0.01). The initial rise in MTR was associated with 
the early phase of Wallerian degeneration with axonal collapse, increased axoplasmic 
density and collapse of myelin tubes. Later on demyelination occurred with gliosis.
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These studies indicate that early changes due to inflammation and Wallerian 
degeneration may be associated with an early rise in MTR, possibly due to exposure of 
myelin fragments to extracellular tissue increasing the exchange of magnetisation. Low 
MTR results from a decreased capacity for exchange due to oedema, demyelination and 
gliosis. Axonal loss combined with demyelination results in even greater falls in MTR. 
Remyelination can result in restoration of MTR.
(iii) Magnetisation transfer imaging combined with histopathological examination in 
multiple sclerosis
In a post mortem study van Waesberghe et al. (1999) demonstrated a strong correlation 
(rs=0.71) between MTR and axonal density but a weaker correlation between MTR and 
myelin density (rs=0.45) in active demyelinating lesions. In all regions MTR correlated 
strongly with axonal density (rs=0.83,/?<0.0001).
(iv) Magnetisation transfer imaging in optic neuritis
Optic nerve MT imaging requires high resolution and a fast imaging sequence to 
minimise motion artefacts between the Mo and Ms images. The optic nerve is small and 
therefore imaging does not produce enough pixels for meaningful histogram analysis. 
An ROI-based approach is therefore required. All the studies to date of MTR in the 
optic nerves have relied on manual placement of small ROIs, typically only of 4-8 
pixels. This risks the exclusion of important information if the optic nerves are swollen, 
as in acute optic neuritis and the inclusion of partial volume pixels containing CSF and 
orbital fat in the presence of optic atrophy. Also, none of the studies have included an 
indication of reproducibility of the results. For these reasons the results should be 
viewed with some caution.
In a study of 39 patients with acute optic neuritis and 50 controls (selected from patients 
having brain imaging for other indications) Boorstein et al. (1997) placed 8 pixel ROIs 
in the intraorbital portions of optic nerves on MT images (TR 106ms, TE 5ms, flip 
angle 12°, matrix 256x192, FOV 16cmxl6cm, 3mm slices, 1.5T imager, acquired both 
with and without a 19ms saturation pulse, amplitude 3.7jLtT, offset frequency 2kHz).
The MTR was 41.1 (SD 1.2)pu in control optic nerves, 30.6 (SD 2.4)pu in 22 optic
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nerves in which either a high signal lesion was present on T2 -weighted images or 
contrast-enhancement was seen and 36.3 (SD 1.6)pu in 12 of the remaining 18 patients 
who had no high signal lesion but who demonstrated a reduction in MTR. MTR was 
therefore more sensitive than conventional imaging at detecting abnormalities in 
diseased optic nerves although no clinical or electrophysiological correlations were 
presented.
Thorpe et al. (1995) imaged six controls and 20 patients between three months and 16 
years following optic neuritis (five of whom had MS, three with both eyes affected). 
One slice was acquired in the intraorbital portion of each optic nerve incorporating a 
lesion where possible (TR 180ms, TE 8ms, flip angle 40°, matrix 256x256, FOV 
16cmxl6cm, 3mm slice, 1.5T imager, acquired both with and without a 64ms saturation 
pulse, effective bandwidth 78Hz, amplitude 14.5/xT, offset frequency 1kHz). The MTR 
was calculated as described above and recorded from a four pixel ROI placed in the 
centre of the nerve. The mean MTR was 49pu in controls, 48pu in clinically healthy 
nerves and 42pu in diseased nerves (p<0.005 versus healthy nerves and control nerves). 
The MTR was correlated with VEP whole field latency (rs=-0.554,/?<0.01) but not 
Snellen visual acuity. Lesion length on T2 -weighted FSE images was correlated with 
visual acuity (p<0.02). The negative correlation between MTR and VEP latency 
supports the idea that MTR reduction may be due to demyelination. The lack of 
correlation with clinical measures is consistent with the complex relationship between 
demyelination and conduction discussed in the previous chapter.
In addition to the optic nerve atrophy measurements in MS described above Inglese et 
al. (2002) also measured MTR in the optic nerves using a four pixel ROI from the 
whole length of the optic nerve from a two-dimensional (2D) GE sequence (TR 640ms, 
TE 12ms, flip angle 20°, matrix 256x256, FOV 25cmx25cm, 15 contiguous 5mm slices, 
1.5T imager, acquired both with and without a saturation pulse, Gaussian envelope 
duration 7.68ms, offset frequency 1.5kHz, flip angle 500°). The mean MTR was 35.3 
(SD 2.4)pu in 18 age-matched controls, 35.1 (SD 4.7)pu for clinically healthy nerves 
(n=18), 34.6 (SD 3.6)pu for diseased optic nerves with visual recovery to at least 20/25 
(n=20) and 29.6 (SD 4.1)pu for diseased optic nerves with vision worse than 20/25 
(n=22) (p<0.001, versus optic nerves with good recovery). When MTR was correlated 
with clinical and electrophysiological tests opposite results to Thorpe et al. (1995) were
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obtained. MTR correlated with visual acuity (>s=0.49,/?=0.01) but not VEP P I00 
latency (rs=-0.10). A possible explanation for the latter finding was that the cohort was 
biased towards those with a limited visual recovery, over 50% having a visual acuity 
worse than 20/25. Axonal loss in the optic nerve may have been more pronounced in 
this group
The above studies used 2D GE imaging. It would be desirable to use a three- 
dimensional (3D) sequence to minimise partial volume effects by having the highest 
resolution possible. Partial volume voxels at the junction between the nerve and 
surrounding CSF cause a particular problem for MTR measurement. The optic nerve 
has a much greater surface area/volume ratio than the brain and therefore greater 
proportion of partial volume voxels. The proportion increases with atrophy and there is 
therefore a danger in studies of optic nerve MTR chronically after optic neuritis to be 
measuring decreased MTR due to increased measurement of these voxels rather than 
due to changes in the nerve substance itself. The segmentation technique, as well as the 
acquisition sequence, should be selected with care.
The temporal evolution of MTR changes after an acute attack of optic neuritis and the 
relationship with imaging, clinical and electrophysiological parameters needs to be 
clarified. It would be desirable to confirm by imaging the electrophysiological 
observation of remyelination in the recovery process.
2.3.10 Diffusion-weighted imaging
Diffusion of water molecules in vivo is affected by the structure of the tissue. In white 
matter tracts, of which the optic nerve is an example, the structure is in the form of 
tightly packed axons. Diffusion occurs preferentially along the orientation of the axons. 
In the direction orthogonal to the axons, cellular membranes act as a greater barrier to 
the water molecule, hindering and restricting the process of water diffusion. Because of 
the complexity of the diffusion mechanism in tissue in vivo the measurements are 
dependent on the observation time, ence the term “apparent diffusion coefficient” 
(ADC) was introduced to indicate this dependency and its difference from the free 
diffusion coefficient of water. The directional dependence of the ADC in vivo is called 
anisotropy and is one of several parameters which can be derived from the diffusion
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tensor (Basser et al., 1994). If the white matter tracts are disrupted or the permeability 
of axonal membranes is increased then the ADC will increase and the fractional 
anisotropy (FA), a measure of the alignment of tissues, will decrease.
Diffusion-weighted imaging (DWI) refers to any MRI technique which has been made 
sensitive to the properties of molecular motion. Usually a spin-echo pulse sequence is 
applied both with and without extra magnetic field gradient pulses, for diffusion 
encoding. The applied gradients do not affect stationary molecules but causes an un­
refocused phase shift and hence loss of signal from molecules that move during the 
measurement period relative to the signal acquired when no diffusion gradient is 
applied. The amount of signal loss that can be measured in each voxel is determined by 
the average diffusion coefficient in that voxel.
Studies in MS have revealed increased ADC values and decreased FA values in both 
lesions and normal appearing white matter (Ciccarelli et al., 2001; Filippi & Inglese, 
2001). DWI of the optic nerves in optic neuritis presents many challenges, as 
previously reported (Wheeler-Kingshott et al., 2002) and for the reasons discussed 
above. The optic nerves are small and mobile, therefore rapid high-resolution single­
shot techniques would be desirable to reduce motion artefacts within and between each 
image (Barker, 2000). CSF contamination of the optic nerves may lead to artificial 
elevation of the ADC and orbital fat may cause chemical shift artefacts. Furthermore, 
the bones of the orbital canal and air-fluid interfaces from the adjacent sphenoid and 
ethmoid sinuses are sources of susceptibility artefacts, potentially causing severe image 
distortions when employing single-shot DW techniques such as EPI sequences.
To sample the full diffusion tensor it is necessary to acquire a minimum of seven 
images: one without any diffusion weighting and six with diffusion weighting applied 
along six non-colinear directions (Basser & Pierpaoli, 1998). This makes it very 
sensitive to motion occurring between each acquisition. Ideally, one would wish to 
implement a registration algorithm capable of correcting the possible variable spatial 
position of the ON. An alternative is to acquire several images with the same diffusion 
weighting and average them after reconstruction to determine the central position of the 
optic nerve, with the drawback of longer acquisition times. Hence, most DWI studies of 
optic nerve have concentrated on measuring the ADC along fewer directions (rather
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than the full diffusion tensor) as fewer acquisitions are required (Iwasawa et al., 1997; 
Freeman et al., 1998; Wheeler-Kingshott et al., 2002).
Iwasawa et al. (1997) studied the optic nerves with a spin-echo sequence which had low 
diffusion weighting (“b-factor” of 262.05s/mm2) and cardiac gating for a single slice 
through the orbital optic nerve. Three acquisitions were performed with the diffusion 
gradients in the x, y and z directions respectively. Due to motion artefacts the ADC 
could only be measured in the y and z directions, and not always reliably then. The 
ADC was measured from a 1mm diameter circular region-of-interest (ROI) placed in 
the centre of the nerve. In seven controls the mean ADC was 982 (SD 741) x 10'6mm2/s 
in the y direction and 1559 (SD 675) x 10‘6mm2/s in the z direction. In four nerves with 
acute optic neuritis the mean ADC was 843 (SD 742) x 10"6mm2/s in the y direction and 
941 (SD 431) x 10‘6mm2/s in the z direction. In nine nerves with previous optic neuritis 
the mean ADC was 1560 (SD 690) xl0 '6mm2/s in the y direction and 4180 (SD 1130) x 
10'6mm2/s in the z direction (p<0.001 versus controls and acute optic neuritis).
EPI is a single-shot multi echo imaging technique, which allows high resolution with 
high SNR per unit time, but at the expense of susceptibility and chemical shift artefacts. 
For optic nerve DWI a fat- and CSF-suppressed zonal oblique multi-slice EPI (ZOOM- 
EPI) sequence has been recently developed (Wheeler-Kingshott et al., 2002). This 
sequence uses a limited field-of-view along the phase-encoding direction, shortening the 
echo train length, which reduces susceptibility artefacts and therefore image distortions. 
In a pilot study ZOOM-EPI DWI was carried out on three controls. After off-line post­
processing with magnitude signal averaging (and correction for the effects of the 
Raleigh noise distribution) the mean ADC from the optic nerves as a combination of the 
x, y and z gradients could be calculated over the length of the optic nerves and was 
found to be 1058 (SD 101) x 10'6mm2/s.
Recently, Chabert et al. (2002) developed an axial fast spin-echo acquisition which 
could measure the ADC and FA in individual optic nerves. In four volunteers the mean 
diffusivity was 1670 (SD 450) x 10'6mm2/s with a mean FA of 0.59 (SD 0.08), 
reflecting strong anisotropy in the optic nerve. The fibre directions followed the 
expected nerve fibre directions on anisotropy maps. The sequence was free of
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susceptibility artefacts however it was neither fat- nor CSF-suppressed and so the 
results should be interpreted with caution.
DWI offers the potential to offer pathologically specific imaging with measures that are 
thought to be sensitive to changes in nerve structure, particularly axonal disruption.
DWI will not be considered further in this work although application of DWI in both 
patients acutely affected by, and recovering from, optic neuritis would be of interest.
The functional significance of any changes measured would need to be elucidated with 
reference to clinical and electrophysiological tests.
2.3.11 Functional magnetic resonance imaging
The above studies have all focused on the imaging properties of the optic nerves and the 
structural changes that have occurred due to optic neuritis. An alternative approach is to 
study the effect of optic neuritis on brain function. fMRI allows the study of brain 
function as it utilises the differing T2 * decay properties of oxygenated and de­
oxygenated haemoglobin (Simon & McDonald, 2000). Increased activity in a certain 
area of the brain will cause increased blood flow in that area. The increased oxy- 
haemoglobin/deoxy-haemoglobin ratio causes a transient increase in signal on T2 *- 
weighted images, the BOLD or blood oxygen level dependent effect. Changes over 
time for each voxel can be measured. In a study of patients with unilateral optic neuritis 
an average 33% decreased activation in the occipital cortex was seen upon stimulation 
of the affected eye with red lights flashing at 8Hz compared with controls and 61% 
decreased activation upon stimulation of the contralateral unaffected eye (Rombouts et 
al., 1998).
In a subsequent study, Werring et al. (2000) recruited seven patients who had recovered 
vision to 6/5 following unilateral optic neuritis and had no brain lesions on imaging. In 
controls, stimulation of either eye just led to activation in the occipital cortex. In 
patients, stimulation of the previously affected eye resulted in activation in the insula- 
claustrum, thalamus, lateral temporal and posterior parietal cortices as well as the 
occipital cortex. Stimulation of the clinically unaffected eye led to activation of the 
occipital cortex and right insula-claustrum only. The extra-occipital activation appeared 
delayed compared with the occipital activation. The volume of extra-occipital
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activation correlated with VEP latency (>s=0.71,/?=0.005). These extra-occipital areas 
are known to have extensive connections with the visual system. It was therefore 
concluded that part of the recovery process following optic neuritis may be due to 
functional reorganisation of the cerebral response to visual stimulation.
Serial changes in occipital cortex activation have also been measured in the recovery 
period following acute optic neuritis (Langkilde et al., 2002). Eleven patients with 
untreated monosymptomatic optic neuritis were imaged with fMRI using 8Hz pattern 
reversal checkerboard stimulation serially from a mean of 10 days after symptom onset, 
and again at 34, 70 and 461 days. The number of activated voxels and the median 
BOLD signal increased, when stimulating the affected eye, with recovery and correlated 
with Snellen visual acuity (p=0.014 and /?=0.001 respectively). On binocular 
stimulation the BOLD signal peaked at day 30, in parallel with the period of largest 
functional recovery. These changes suggested that dynamic adaptive changes may 
contribute to recovery.
The dynamic changes in the recovery process in the extra-occipital areas need to be 
elucidated. Whole brain coverage of the acquisition would be desirable for this. A key 
question is whether the observed occipital and extra-occipital responses are necessary 
for recovery. The responses in patients with good versus poor recoveries, and how the 
responses relate to structural and electrophysiological changes in the optic nerves, need 
further investigation.
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2.4 Aims of this thesis
The aims of the series of studies outlined in this thesis are to elucidate further the 
pathophysiology of optic neuritis and so gain further insights into the mechanisms 
behind relapse, recovery, partial recovery and persistent disability in MS.
2.4.1 Optic neuritis as a model for multiple sclerosis relapses
The major event in RRMS is the acute relapse. The majority of patients with MS 
present with such an event. Most early relapses are followed by complete or near 
complete recovery, however partial recovery or significant disability can result from an 
individual relapse, and is often seen in patients with established relapsing remitting 
disease. Study of relapses in vivo is therefore desirable. MRI provides a non-invasive 
means of study of patients and is very sensitive at detecting MS lesions (Miller et al., 
1998). It would be desirable to be able to study of individual lesion responsible for a 
relapse in order to understand better the pathophysiology of the condition. This should 
make prediction of the prognosis for recovery from a relapse better and could provide a 
means of monitoring treatment effects in future therapeutic trials of novel agents in 
acute MS relapse. Unfortunately, in the brain and spinal cord, it has been difficult to 
reliably identify the lesion that is responsible for the symptoms of an individual relapse 
(Behan et al., 2000) and most new brain lesions which are apparent on MRI are 
clinically silent (Miller et al., 1998). New methods of MRI acquisition and analysis in 
the brain have also been better at studying the global burden of the disease and its 
effects on disability and progression than in studying individual lesions.
There are also difficulties when trying to study disability and impairment in MS. The 
most commonly used test is the EDSS (Kurtzke, 1983). This is a 10-point ordinal scale 
combining observer-derived scores for visual, brainstem, pyramidal, cerebellar, sensory, 
sphincter and cerebral function with walking ability. The EDSS is simple to perform, 
but at lower scores it is weighted towards impairment and at higher scores it is weighted 
towards disability, particularly walking ability (Thompson & Hobart, 1998). It is also 
rater-dependent. Inter-rater reliability is reasonable with an intraclass correlation 
coefficient (ICC) of 0.78 but intra-rater reliability is variable (ICC 0.62-0.94) (Hobart et 
al., 2000). The EDSS has limited use in monitoring individual relapses, being a
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composite scale. The multiple sclerosis functional composite (MSFC) combines scores 
for 25-foot timed walk, 9-hole peg test and paced auditory serial addition test. It is less 
rater-dependent than EDSS with inter- and intra-rater ICC of 0.95 and 0.97 respectively 
(Cohen et al., 2000). The MSFC is now used alongside the EDSS in clinical studies of 
MS, but again is less useful for investigating the effects of a single lesion. Arm 
function can be assessed using the Medical Research Council 0-5 scale of muscle 
strength and the Ashworth or the modified Ashworth spasticity scale (Sloan et al., 
1992). These also have the disadvantage of being rater-dependent. The 9-hole peg test 
and box-and-block tests are more responsive to change than use of the composite scores 
alone and can be used to monitor arm function serially (Goodkin et al., 1988).
However, the manual dexterity required to perform the test reflects motor, sensory and 
cerebellar function in the arm and makes study of a single system harder if impairments 
exist in other modalities.
In comparison with single symptomatic lesions elsewhere in the CNS, optic neuritis 
provides a more attractive model to study the effects of relapses in MS. As has been 
discussed, optic neuritis is a frequent manifestation of MS and has been regarded as a 
forme fruste of the disease (Ebers, 1985). The natural history of acute optic neuritis 
mirrors that of an acute MS relapse elsewhere in the CNS and the response to 
corticosteroid therapy is the same (Brusaferri & Candelise, 2000). The optic nerves can 
also be affected by chronic damage, seen with the loss of the nerve fibre layer in the 
retina in MS patients (Frisen & Hoyt, 1974) and STIR MRI signal change in the optic 
nerves of SPMS patients in the absence of previous episodes of optic neuritis (Davies et 
a l , 1998).
Patients with optic neuritis often seek medical attention early in the course of their 
illness and therefore, with appropriate access to eye hospitals, good case ascertainment 
is possible. Visual function can also be measured accurately in a rater-independent 
fashion. The full range of acuities from 6/6 or better through to NPL has been reported 
in approximately equal proportions (Perkin & Rose, 1979; Optic Neuritis Study Group,
1991). Reliance cannot, however be made solely on visual acuity as abnormalities 
using other visual tests can be detected in patients with acute optic neuritis and 
“normal” visual acuity of 6/6 (Frederiksen et al., 1991) and on recovery visual acuity 
alone may be less sensitive than other visual tests to detect abnormal vision
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(Frederiksen et al., 1997). However, the use of logMAR visual acuity does allow for 
parametric statistical analysis (Ferris III et al., 1982). The figure given is the logarithm 
of the minimum angle of resolution. The chart allows for testing of vision at non­
standard distances giving scores up to +1.68, approximately 6/300 Snellen equivalent 
(one letter read at lm distance). The worst score is +1.70 (no letters read) and therefore 
logMAR acuity cannot differentiate between patients with counting finger acuity or 
worse.
Visual field testing gives extra information about vision outside the macula. It was 
initially thought that the predominant defect was a central or paracentral scotoma 
(Perkin & Rose, 1979) however it has become apparent that any type of field defect may 
be possible (Beck, 1998). The principal means of testing visual field are with either the 
Humphrey visual field analyser (Allergen Humphrey, San Leandro, CA, USA) or 
Goldmann perimeter. For studies of optic neuritis the 30-2 programme (testing the 
central 30° of vision) of the Humphrey visual field analyser is used more often as it is 
automated, and with use of the company-supplied software, deviation of the patient’s 
results from expected age-matched normal results can be derived. This is given in 
decibels (a logarithmic scale) and again, like logMAR acuity, allows for parametric 
statistical analysis. Although the test is rater-independent, results from patients with 
recovered optic neuritis do show increased variability compared with controls. Wall et 
al. (1998) recorded a mean within-subject SD for mean deviation of 0.46dB for same- 
day measurements and 0.36dB for weekly measurements in 10 healthy volunteers 
compared with 1.35dB and 3.10dB in 17 patients with recovered optic neuritis 
respectively. A number of factors may have been responsible including temperature 
effects and fatigue. There is also some evidence to suggest that response variability in 
visual field testing worsens with decreased sensitivity due to loss of functioning neural 
channels (Henson et al., 2000).
Colour vision can be examined using Ishihara pseudoisochromatic colour plates 
(Kanehara and Co. Ltd., Tokyo, Japan) or the FM 100 test (Farnsworth, 1943). The 
Ishihara plates provide a useful and rapid screening test for the presence of an optic 
neuropathy (Sloan, 1942), however parametric analysis is not possible. The FM 100 
test takes longer but allows for parametric analysis. It is not, however, reliable in 
patients with a visual acuity of worse than 6/60 (Katz, 1995).
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Contrast sensitivity can be measured using spatial frequency gratings with 98% of optic 
neuritis patients showing decreased sensitivity at 6 cycles per degree (CPD) ranging 
down to 80% at 18 CPD (Wakakura et al., 1999b). Pelli-Robson charts allow for more 
rapid assessment (Pelli et al., 1988) and 98.2% of patients at presentation in the ONTT 
demonstrated some abnormality although again, parametric analysis is not possible 
(Optic Neuritis Study Group, 1991).
As well as accurate and reliable tests of visual function across a spectrum of different 
parameters it is also possible, as has been discussed, to measure the latency and 
amplitude of the VEP which gives information about the integrity of the visual 
conducting pathways (Halliday et al., 1972). Finally, MRI, with appropriate fat 
saturation techniques, enables the symptomatic lesion in optic neuritis to be visualised 
(Gass et al., 1996).
Developments in imaging technology and application now means that, potentially more 
pathologically specific imaging sequences can be applied to the study of the optic 
nerves (Barker, 2000). This thesis will investigate the application of these new imaging 
techniques, along with clinical and VEP measures, to the study of optic neuritis in order 
to gain new insights into the effect of individual lesions on structure and function in the 
CNS in the short- and long-term.
It will show that optic neuritis is a useful model to study some of the main features on 
MS namely relapse, remission, partial recovery and persistent disability. The study 
concentrates on the use of MRI in optic neuritis and the relationship between imaging 
results and clinical and electrophysiological measurements. At present there are poor 
predictors of recovery in optic neuritis. The use of new MRI sequences to aid in the 
prediction will be assessed. To combine the different parameters and to follow them 
over time multiparametric analysis will be needed. The aim will be to describe the 
natural history and to see what factors are important in predicting prognosis for 
recovery.
Magnetic Resonance Imaging in Optic Neuritis 82
This thesis will concentrate on structural imaging of the optic nerve in optic neuritis.
The cortical response to optic neuritis is being investigated in a parallel study in the 
NMR Research Unit by Dr. A.T. Toosy.
2.4.2 Magnetic resonance imaging in optic neuritis
Optic nerve MRI, especially quantitative MRI using the parameters mentioned in earlier 
sections, presents considerable difficulties. The sequences need careful setting up. 
Subject motion, especially optic nerve motion is a particular problem. Subjects need to 
be selected who can tolerate the moderately long acquisition times that are necessary for 
high resolution imaging. They need to be instructed to keep as still as possible and to 
avoid deliberate eye movements. Fixation on one spot for acquisitions of up to 20 
minutes is not possible. Most success has been achieved by asking patients to close 
their eyes and to avoid deliberate eye movements as much as possible. Subjects are not 
discouraged from sleeping as the onset of rapid eye movement (REM) sleep usually 
occurs later then 60-100 minutes after sleep onset (Lesch & Spire, 1990).
Optic nerve imaging has the potential for poorer reproducibility compared to brain 
imaging, as a result of movement artefacts causing poor scan-rescan reproducibility and 
because of difficulty in segmenting the optic nerves from images due to their small size 
leading to poor measurement-remeasurement reproducibility.
Quality assurance is important, particularly in serial imaging studies, to ensure that the 
output from the imager remains stable. This takes two principal forms. The first is by 
serial imaging of phantoms to ensure that the gradients are stable (Barker & Tofts,
1992). This is useful for MT imaging and DWI. For atrophy measurements serial 
imaging of healthy controls will give an indication of the stability of the measurements 
over time (Leary et al., 1999).
In addition the small size of the optic nerves means that there will be a greater 
proportion of partial volume voxels compared with other structures as the surface area 
to volume ratio increases as an object gets smaller. It should be borne in mind that 
measured changes may be as a result of this phenomenon rather than pathological 
changes in the nerve itself, for example when measuring MTR.
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In summary, a thorough evaluation of optic nerve imaging requires that the 
reproducibility, accuracy and stability of the imaging measures be carefully considered 
and understood. Such a methodological approach is needed to ensure a sound 
interpretation of the results in patients with optic neuritis.
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Chapter 3 Studies of Optic Nerve Atrophy Following Optic Neuritis
3.1 Detection of optic nerve atrophy following a single episode of unilateral 
optic neuritis by magnetic resonance imaging using a fat saturated short echo fast 
fluid-attenuated inversion recovery sequence.
3.1.1 Introduction
In MS, atrophy of the brain and spinal cord correlates with clinical progression and may 
indicate axonal loss (Losseff et al., 1996a; Losseff et al., 1996b; Simon et al., 1999).
As has been discussed optic neuritis provides an excellent model for studies to elucidate 
the pathogenetic mechanisms of disability in demyelinating diseases and development 
of a reliable imaging technique for quantifying atrophy in the optic nerve would 
facilitate such studies. However, MRI of the optic nerve presents many problems due to 
its size and tortuosity, the presence of high signal from orbital fat and the CSF-filled 
sheath around the nerve, and the potential for motion artefact due to eye movement 
(Gass et al., 1995). A new imaging sequence is evaluated here: fat saturated short echo 
fast FLAIR (sTE fFLAIR) which suppresses the high signal from fat and CSF and 
demonstrates both optic nerves with in-plane resolution of 0.5mm2 and 3mm slice 
thickness in I 3 V2 minutes. This has enabled quantification of optic nerve atrophy 
following a single episode of unilateral optic neuritis.
3.1.2 Patients and methods
17 patients were recruited following a single episode of unilateral optic neuritis at the 
Neuro-ophthalmology clinic at Moorfields Eye Hospital, London and Neurology and 
Ophthalmology clinics at Addenbrooke’s Hospital, Cambridge. Optic neuritis was 
diagnosed using previously agreed clinical criteria (Compston et al., 1978). No patient 
had a history of visual disturbance affecting the contralateral eye, although two patients 
had clinically probable MS (CPMS) and five CDMS by the Poser criteria (Poser et al., 
1983). The remainder were classified as having a CIS. The patients’ median age was 
40 years (range 23-51 years) with a median time since the onset of optic neuritis of 21 
months (range 3-81 months) (Table 3.1).
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Subject Gender
Age at 
assessment 
(years)
Time since 
onset 
(months) Clinical status
1 F 23 21 CIS
2 M 34 24 CIS
3 F 51 81 CPMS
4 F 41 67 CPMS
5 F 44 66 CIS
6 M 42 27 CIS
7 F 40 50 CIS
8 F 43 3 CIS
9 F 29 29 CIS
10 F 29 3 CIS
11 F 25 10 CDMS
12 F 50 5 CIS
13 F 47 9 CDMS
14 M 36 5 CIS
15 F 28 13 CPMS
16 M 25 26 CDMS
17 M 50 7 CDMS
Table 3.1: Subject, gender, age at assessment, time since onset of optic neuritis and
clinical status.
Ethical approval was obtained for the study from the joint ethics committee of the 
Institute of Neurology and the National Hospital for Neurology and Neursurgery; 
informed consent in writing was obtained from each subject, according to the 
Declaration of Helsinki. A clinical assessment was carried out including Snellen visual 
acuity and 24-2 or 30-2 Humphrey perimetry (Allergan-Humphrey Inc., San Leandro, 
CA, USA).
Optic nerve MRI was performed on a Signa 1.5T imager (General Electric, Milwaukee, 
Wise., USA) with coronal-oblique sTE fFLAIR (TR=2740ms, TE=16ms, TI=1072ms, 
NEX 6, ETL 6, matrix size 512x384, FOV 24x18cm, 3mm contiguous slices) and 
coronal-oblique fat suppressed dual echo FSE (TR=2300ms, TEef=58/145ms, NEX 2, 
ETL 8, matrix size 512x384, 24x18cm rectangular FOV, 3mm contiguous slices) 
sequences. Eleven patients had axial-oblique dual echo FSE brain imaging
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(TR=2400ms, TEef 15/105ms, NEX 2, ETL 8, matrix size 256x256, 24x18cm 
rectangular FOV, 5mm contiguous slices). We also studied 30 control subjects, median 
age 27 years (range 21-48 years), using the sTE fFLAIR sequence only. Repeat 
imaging was performed on 18 of the controls at a later date to determine the acquisition- 
reacquisition reproducibility. Control subjects had to be free of significant 
ophthalmological or neurological disease and were recruited by the use of advertising 
posters. During optic nerve imaging all subjects were asked to close their eyes and 
avoid eye movements if possible.
The images were analysed on Sun workstations (Sun Microsystem, Mountain View, 
CA., USA) using the Displmage display tool (Plummer, 1992). On the sTE fFLAIR 
images, the mean cross-sectional area of the intra-orbital portion of each optic nerve 
from patients and controls was calculated by a blinded observer from five consecutive 
3mm slices from the orbital apex forwards using a computer-assisted contouring 
technique as previously described (Grimaud et al., 1996). This portion of the optic 
nerve was chosen because of the ease of identification of the orbital apex, the fact that 
the nerve lies approximately orthogonal to the imaging plane and to allow comparison 
of a representative length of the optic nerve between subjects, given that there is 
variation in the length of the intra-orbital portion of the optic nerve between individuals 
(Blinkov & Glezier, 1968; Williams et al., 1989; Tamraz, 1994; Sadun, 1998;
Slamovits, 1998). A simple contouring technique was chosen rather than setting a 50% 
threshold between the optic nerve signal and background similar to studies on the spinal 
cord (Losseff et al., 1996b) because the sequence had some T2 -weighting. The 
threshold in diseased optic nerves might therefore tend to be higher than healthy optic 
nerves leading to an underestimate of optic nerve area in diseased optic nerves. Each 
measurement was carried out three times over the course of one week. The FSE images 
were assessed for the presence, distribution and length of any optic nerve lesions.
3.1.3 Statistical methods
Statistical analysis was performed using the ‘SPSS 9.5 for Windows’ statistical package 
(SPSS Inc., Chicago, 111., USA). To assess measurement reproducibility the within- and 
between-subject SD and, hence coefficient of variation (CV) and reliability coefficients, 
were obtained from random effects analysis of variance (Bland & Altman, 1996a; Bland
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& Altman, 1996b; Bland & Altman, 1996c). The acquisition-reacquisition 
reproducibility was calculated similarly from the measurements produced from the two 
series of images in the 18 control subjects who had repeat imaging. Paired and 
independent samples t tests were used for the group analyses as appropriate. Analysis 
of correlations was by Spearman’s rank correlation.
3.1.4 Results
The mean cross-sectional area of the diseased optic nerve was 11.2 (SD 2.3)mm2 and 
that of the contralateral healthy nerve 12.9 (SD 1.8)mm2 (p=0.006 compared with the 
diseased nerve) (Table 3.2, Figure 3.1 and Figure 3.2). The optic nerve mean area in the 
control group was 12.8 (SD 1.9)mm (Figure 3.2). This was significantly larger than 
that of the diseased nerve (p=0.014), but not significantly different from the 
contralateral healthy nerve area (p=0.93).
No.
Snellen visual acuity Optic nerve mean area 
(mm2)
FSE image lesion 
length (mm)
Humphrey mean 
deviation (dB)
Diseased
nerve
Healthy
nerve
Diseased
nerve
Healthy
nerve
Intra­
orbital Total
Diseased
nerve
Healthy
nerve
1 6/36 6/9 12.6 13.9 21 30 -5.80 -2.53 *
2 6/5 6/5 9.0 10.5 21 24 -4.23 -2.76 *
3 6/6 6/5 8.2 11.2 24 27 -2.65 -1.65 *
4 6/5 6/5 10.9 13.2 3 3 -1.76 -1.12*
5 6/6 6/5 9.6 12.0 12 12 -3.24 -1.18 *
6 6/6 6/6 12.1 12.3 15 24 -4.82 i oo *
7 6/5 6/5 10.8 13.0 12 21 -3.96 -6.71 *
8 6/9 6/5 10.0 10.3 15 15
9 6/6 6/6 7.3 12.7 0 12 -4.44 -6.37 *
10 6/12 6/5 12.8 14.0 0 18 -2.81 -0.19 f
11 6/18 6/9 9.1 15.1 12 21 -8.71 -4.15t
12 6/5 6/5 15.7 16.7 9 18 +0.4 -0.04 t
13 6/9 6/5 14.7 13.2 12 27 -2.96 -1.47 t
14 6/9 6/5 12.1 13.0 9 9 -1.62 -3.32 f
15 6/9 6/5 12.3 9.7 15 15 -2.81 -2.08 t
16 6/18 6/6 10.5 12.4 18 27 -5.31 -0.54 f
17 6/9 6/6 13.5 15.3 9 9
Table 3.2: Subject, Snellen visual acuity, optic nerve mean area, FSE image lesion
length in the affected optic nerve and Humphrey mean deviation. * = 
30-2, f = 24-2.
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Figure 3.1: Scatter graph illustrating mean optic nerve area in affected optic nerves
(n=17 eyes), the contralateral optic nerves in the patients (n=17 eyes), 
and control optic nerves (n=30, mean o f each eye).
Diseased Healthy Control mean
n=17 n=17 n=30
Group
Figure 3.2: Coronal sTE fFLAIR image demonstrating right optic nerve atrophy
(arrowed) in a 34 year old man (subject 2) two years after right optic 
neuritis.
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There was a significant negative correlation between time since onset o f the optic 
neuritis and the size o f the affected optic nerve, expressed as the ratio o f the mean area 
o f the affected optic nerve over the mean area o f the unaffected nerve (rs= -0.59, 
/?=0.012) (Figure 3.3).
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Figure 3.3: The relationship between time since onset o f the optic neuritis and the
size o f the diseased optic nerve, expressed as the ratio o f the mean area 
o f the diseased optic nerve over the mean area o f the healthy 
contralateral optic nerve (rs— -0.59,/?=0.012).
The measurement reproducibility results are given in Table 3.3. All patients had a high 
signal lesion in the affected optic nerve on T2 -weighted FSE images. There was no 
correlation between the total lesion length or intra-orbital lesion length and the area of 
the diseased optic nerve (Table 3.2). Five o f the subjects had lesions in the contralateral 
optic nerve. In two o f these cases, subjects 13 and 15, the contralateral nerve was 
smaller than the clinically diseased optic nerve (Table 3.2), but overall the ratio o f nerve 
size (clinically affected versus contralateral nerve) was not significantly different 
between the groups with or without a contralateral optic nerve lesion (data not shown).
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(a)
variable
mean area 
(mm2)
within- 
subject SD
95% reference 
rangea
CV
(%)
reliability
coefficientb
diseased
nerves 11.2 0.75 ± 1.47 6.7 0.90
healthy
nerves 12.9 0.76 ± 1.49 5.9 0.85
control left 
nerves 12.9 0.82 ± 1.61 6.4 0.83
control 
right nerves 12.8 0.65 ±1.27 5.1 0.90
(b)
variable
mean area 
(mm2)
within- 
subject SD
95% reference 
range3
CV
(%)
reliability
coefficient
control left 
nerves 12.5 0.89 ±1.74 7.1 0.75
control 
right nerves 12.5 1.09 ±2.13 8.7 0.71
Table 3.3: Measurement reproducibility for the different subgroups.
(a) Measure-remeasure.
(b) Acquisition-reacquisition.
a1.96 x within-subject SD. 95% of measurements are expected to lie within this 
departure from the true value.
bThe proportion of total variance due to between-subject variation. Under assumptions 
which are plausible here, one minus this value is the proportion of variation due to 
measurement error.
There was no significant difference in optic nerve area between patients with clinically 
isolated optic neuritis and those with CPMS or CDMS, between those with normal and 
abnormal brain imaging (data not shown), or between patients with poor or good 
recovery of visual acuity (Miller et al., 1988). However, only four patients had a visual 
acuity of worse than 6/9 (Table 3.2).
Visual field data was available for 15 patients (Table 3.2). There was no significant 
difference in the mean deviations between the two eyes and there was no correlation 
between Humphrey mean deviation and mean area of the diseased optic nerve. Five of 
the patients had significant Humphrey mean deviations in the contralateral (clinically
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unaffected) eyes, defined as -3.0dB (Beck et al., 1993b), two of whom had lesions in 
the corresponding nerve, subjects 6 and 11.
3.1.5 Discussion
The sTE fFLAIR sequence provides good suppression of fat and excellent suppression 
of CSF, high spatial resolution and a relatively short acquisition time. This has enabled 
measurement of optic nerve area with sufficient reproducibility to show optic nerve 
atrophy following a single episode of unilateral optic neuritis.
Measurement of optic nerve area following optic neuritis has been attempted before, 
using manual methods from STIR images (Youl et al., 1996). This sequence has the 
disadvantages of producing high signal from CSF obscuring the edge of the optic nerve 
and the inclusion of optic nerve sheath. The figure for optic nerve area was about 20% 
higher than with the sTE fFLAIR method (mean areas ranging from 14.1mm2 to 
16.8mm2). FSE images have been previously assessed for optic nerve atrophy by 
manual measurement of nerve diameter in papilloedema and autosomal dominant optic 
atrophy but as with STIR, high signal from CSF within the nerve sheath mitigates 
against accurate delineation of the nerve itself (Mashima et al., 1996; Votruba et al., 
2000). Formal measures of reproducibility were not included in these studies. A SPIR- 
FLAJR sequence has recently been described which demonstrated optic nerve atrophy 
following optic neuritis although again this was a qualitative study (Jackson et al., 
1998).
The presence of high signal lesions and visual field abnormalities in the clinically 
asymptomatic contralateral optic nerves has been previously described (Miller et al., 
1988; Beck et al., 1993b) and is likely to reflect clinically silent foci of demyelination. 
Previous studies have also reported the presence of prolonged VEP latencies from the 
contralateral healthy eye (Miller et al., 1988; Brusa et al., 1999).
In post mortem studies the area of the optic nerve in normal adults has varied from 6.75 
to 12.79mm2 depending on the technique and which part of the nerve was studied 
(Donaldson & Bolton, 1891; Sylvester & Ari, 1961; Dolman et al., 1980; Rimmer et al.,
1993). The discrepancy with the in vivo figures presented here, which are larger, could
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be related to post mortem change and shrinkage in the fixation process. It could also 
reflect the fact that the post mortem areas were measured in a true coronal plane, 
whereas due to the angle and tortuosity of the nerve, the in vivo images may have been 
oblique to the nerve on some of the slices. Movement artefact may increase the 
apparent nerve area on imaging. Also, the semi-automated contouring method requires 
checking to make sure that other orbital structures, eg extra-ocular muscles, are not 
included in the outline when the nerve lies close to them. The manual correction may 
produce an over-estimation of the area by the inclusion of partial volume pixels.
The observation that the degree of atrophy is related to the disease duration is 
interesting. It suggests that atrophy is continuing, possibly as a result of low-grade 
axonal degeneration due to reduced survival capabilities of axons that exist in a 
persistently demyelinated state (Scolding & Franklin, 1998; McGavem et al., 2000), or 
because of Wallerian degeneration distal to axonal damage in the primary lesion. The 
presence of axonal transection was striking in a recent pathological study of acute 
inflammatory multiple sclerosis plaques (Trapp et al., 1998). Atrophy of the brain due 
to Wallerian degeneration does not appear radiologically until some months following 
other central nervous system lesions such as infarcts which cause axonal loss (Kuhn et 
al., 1989), and this may explain the apparent progressive atrophy demonstrated here. 
The continuing atrophy is less likely to result from the recurrent sub-clinical optic nerve 
demyelination that is known to occur in multiple sclerosis (Feinsod & Hoyt, 1975) as 
this would be expected to affect both eyes and hence the contralateral optic nerve would 
be expected to diminish in size as well. In this study there was no overall significant 
difference in area between the contralateral optic nerves in patients and control optic 
nerves even though the patients were significantly older than the controls.
It has been shown here that a good recovery of visual acuity and Humphrey mean 
deviation is possible despite a significant degree of optic atrophy (mean 13% loss of 
optic nerve cross-sectional area). This suggests that there is redundancy in the anterior 
visual pathway or that significant cortical re-modelling of visual function has taken 
place. fMRI data suggest that an altered cortical response to visual stimulation can 
occur following an attack of optic neuritis (Rombouts et al., 1998; Werring et al., 2000).
Studies o f  Optic Nerve Atrophy Following Optic Neuritis 93
Although this sequence has detected atrophy in the clinically diseased optic nerve 
following unilateral optic neuritis, the reproducibility of this method is not as high as for 
the studies of cerebral and spinal cord atrophy (Losseff et al., 1996a; Losseff et al., 
1996b). The likely reasons for this are related to the smaller size of the optic nerves and 
greater liability for movement artefact.
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3.2 Continuing optic nerve atrophy following optic neuritis: A serial magnetic
resonance imaging study
3.2.1 Introduction
Atrophy of the brain and spinal cord occur in MS and are thought to be due 
predominantly to axonal loss (Losseff & Miller, 1998). In cross-sectional MRI series 
the degree of detected atrophy has been found to correlate well with measurements of 
disability (Losseff & Miller, 1998; Liu et al., 1999). Short-term serial studies have 
demonstrated progressive atrophy, although poor correlations with changes in disability 
have been found (Stevenson et al., 1998; Fox et al., 2000). Longer follow-up improves 
the correlation with change in clinical status (Losseff & Miller, 1998; Rudick et al.,
1999). The previous chapter described a reproducible technique to measure orbital 
optic nerve mean area using a fat saturated sTE fFLAIR sequence which removes the 
high signal from both orbital fat and CSF in the sheath of the optic nerve. Optic nerve 
atrophy was demonstrated following optic neuritis and the degree of atrophy related to 
time since onset of the illness. The present report extends the observations of the 
previous chapter with a serial study to assess the degree of optic nerve atrophy that 
occurred over a one-year period in a cohort of patients following optic neuritis and to 
investigate the effect of atrophy on visual function. Using optic neuritis as a model, the 
study has implications for the effect of lesions in MS.
3.2.2 Patients and methods
Ten patients (six following one episode of optic neuritis, whom also featured in the 
previous study, two following two episodes in one eye and two following episodes in 
both eyes) were recruited from Neurology clinics at Addenbrooke’s Hospital, 
Cambridge, UK. Six of the patients had CDMS, one had CPMS and three had clinically 
isolated optic neuritis (CIS) (Poser et al., 1983). The patients’ median age was 44 
(range 25-55) years with a median time since the first episode of optic neuritis of 19.5 
(range 3-252) months. Only one of the patients had corticosteroids in the acute phase of 
the optic neuritis. No patients received immunomodulatory therapy, either before or 
during the period of study. Ethical approval was obtained for the study from the joint 
ethics committee of the Institute of Neurology and the National Hospital for Neurology
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and Neursurgery; informed consent in writing was obtained from each subject, 
according to the Declaration of Helsinki. Visual acuity using Snellen charts and 
pattem-reversal VEPs were recorded at baseline and after one year. Visual acuity was 
classed as poor (<6/9) or good (^6/9) (Miller et al., 1988). There were no further 
episodes of optic neuritis in any of the patients during the follow-up period.
MRI was performed on a Signa 1.5-T imager (General Electric, Milwaukee, Wise., 
USA). The optic nerves were imaged with the sTE fFLAIR sequence (coronal-oblique, 
TR=2740ms, TE=16ms, TI=1072ms, NEX 6, ETL 6, matrix size 512x384, 24x18cm 
FOV, 3mm contiguous slices, acquisition time 13.5 minutes) and the brain was imaged 
with a dual echo FSE sequence (axial-oblique TR=2400ms, TEef 15/105ms, NEX 2, 
ETL 8, matrix size 256x256, 24x18cm rectangular FOV, 5mm contiguous slices). 
Imaging was performed at baseline and again at one year.
Between imaging sessions care was taken to accurately reposition the imaging field of 
view. In particular, the line from the anterior commissure to the posterior commissure 
on sagittal localiser images was used to ensure that the subjects’ head angles were the 
same at each session.
The optic nerve images were analysed on Sun workstations (Sun Microsystem, 
Mountain View, CA., USA) using the Displmage display tool (Plummer, 1992). The 
mean cross-sectional area of the intra-orbital portion of each optic nerve was calculated 
by an observer blinded to patient identity from five consecutive 3mm slices anteriorly 
from the orbital apex using a computer-assisted contouring technique as previously 
described (Chapter 3.1). Each measurement was carried out on three separate occasions 
so that the reproducibility of the measurement could be calculated. The hard copy brain 
images were assessed for any lesions at baseline and any new brain lesions after one 
year.
3.2.3 Statistical methods
Statistical analysis was performed using the ‘SPSS 9.5 for Windows’ statistical package 
(SPSS Inc., Chicago, 111., USA). To assess measurement reproducibility the within- and 
between-subject SDs and, hence CV and reliability coefficients, were obtained from
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random effects analysis of variance (Bland & Altman, 1996a; Bland & Altman, 1996b; 
Bland & Altman, 1996c). Paired and independent samples t tests were used for the 
group analyses as appropriate. Analysis of correlations was by Spearman’s rank 
correlation.
3.2.4 Results
The measurement reproducibility results are given in Table 3.4:
variable
mean area 
(mm2)
within- 
subject SD
95% reference 
range3
CV
(%)
reliability
coefficientb
baseline
diseased
nerves
11.1 0.67 ±1.31 6.0 0.94
1-year
diseased
nerves
10.2 1.14 ±2.23 11.2 0.82
baseline
healthy
nerves
12.9 0.67 ± 1.31 5.2 0.89
1-year
healthy
nerves
12.6 0.95 ± 1.86 7.5 0.82
Table 3.4: Measurement reproducibility for the different subgroups.
al .96 x within-subject SD. 95% of measurements are expected to lie within this 
departure from the true value.
l  # w
The proportion of total variance due to between-subject variation. Under assumptions 
which are plausible here, one minus this value is the proportion of variation due to 
measurement error.
At baseline the mean area of the diseased optic nerves was 11.1 (SD 2.7)mm compared 
to 12.9 (SD 2.0)mm2 for the healthy nerves (p = 0.1). Patients with CDMS or CPMS 
had smaller optic nerves than patients with CIS although the difference was not 
significant and the patients with MS also had a longer interval from onset of optic 
neuritis (data not shown). Seven diseased optic nerves had poor visual acuity and these 
were significantly smaller than the healthy optic nerves (p=0.02) (Figure 3.4).
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/? = 0.02
p = 0 .
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Figure 3.4: The relationship between optic nerve mean area at baseline and visual
acuity for diseased eyes with poor recovery o f visual acuity (<6/9) and 
good recovery o f visual acuity ( >  6/9), compared with healthy eyes.
Both the baseline VEP amplitude (rs=0.65,/?=0.02) (Figure 3.5) and VEP latency (rs=  
-0.61,/?=0.04) correlated significantly with the mean area o f diseased optic nerves but 
not healthy optic nerves.
The mean area o f diseased optic nerves decreased significantly over one year from 11.1 
(SD 2.7)mm2 to 10.2 (SD 2.4)mm2 (p = 0.01) (Figures 3.6 and 3.7) whereas the healthy 
optic nerves did not change significantly (12.9 [SD 2.0]mm2 to 12.6 [SD 2.0]mm2,/? = 
0.6). After one year the difference in area between all diseased and healthy optic nerves 
became significant (p=0.04). There was a negative correlation between time since onset 
of the optic neuritis and change in mean area over time (rs=-0.81,/?=0.001).
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0 2 4 6 8 10
Visual evoked potential amplitude (pV)
3.5: Graph demonstrating the relationship between diseased optic nerve mean
area at baseline and visual evoked potential amplitude (r=0.65,/?=0.02).
Baseline 1 year
Time point
Figure 3.6: Change in optic nerve mean area over one year for optic nerves
previously affected by optic neuritis. Baseline mean area 11.1mm2, year 
one mean area 10.2mm2 (/?=0.01).
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Figure 3.7: sTE fFLAIR images o f the optic nerves o f a 35 year old man. Left: five
months after the onset o f left optic neuritis (nerve arrowed). Right: one 
year later.
All patients had at least one lesion on brain imaging at baseline. Three patients had new 
brain lesions after one year. There was no difference in the progression o f optic nerve 
atrophy between this group and the group with no new lesions. No patient had 
worsening visual acuity over this period despite the decreases in optic nerve mean area. 
There were no significant differences between the baseline and year-one VEP latencies 
and amplitudes in both symptomatic and asymptomatic optic nerves (data not shown).
3.2.5 Discussion
This study revealed that progressive atrophy occurs in optic nerves previously affected 
by optic neuritis. The correlation between the optic nerve mean area and VEP 
amplitude, and the suggestion that smaller optic nerves have worse visual acuities, 
provide indirect evidence that the observed atrophy is due to axonal loss although 
demyelination o f axons with conduction block has also to be considered. The inverse 
correlation between time since onset of optic neuritis and extent o f continuing atrophy 
indicates that the rate o f atrophy is decreasing with time. In cases with a shorter time 
from onset, resolution o f inflammation and oedema may contribute to the decrease in 
size o f the optic nerve. However, the baseline measurement already showed a smaller 
nerve than in controls, suggesting that there was not much residual inflammation or 
oedema at this time. The prolonged and slowly evolving atrophy may reflect continuing 
axonal loss in a persistently demyelinated lesion or Wallerian degeneration secondary to 
axonal transection at the time o f the optic neuritis (Perry & Anthony, 1999). It is 
unlikely to reflect further episodes o f subclinical optic neuritis as these should equally
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affect the contralateral optic nerves. These nerves showed no significant change in area 
after one year.
The lack of correlation between changes in optic nerve area and clinical data over the 
year may reflect the short period of follow-up and the relative insensitivity of Snellen 
charts for detecting change in visual acuity. Another possibility is that functional 
reorganisation in the visual system has occurred to preserve visual acuity (Werring et 
a l , 2000).
A mean 8% decrease in optic nerve area was recorded over the one-year follow-up 
period. This is greater than that seen in one-year serial studies on other areas of the 
central nervous system. Stevenson et al. (1998) showed a mean 3.2% decrease in spinal 
cord area in a mixed MS population and Simon et al. (1999) detected a 4.9% decrease 
in corpus callosum area in patients with RRMS. Studies using whole brain measures 
have showed smaller percentage decreases, 0.8% in brain volume (Fox et al., 2000) and 
0.7% in brain parenchymal fraction (Rudick et a l , 1999). These differences may be 
explained by the fact that the lesion in optic neuritis involves a greater proportion of the 
total optic nerve compared to lesions in the brain and spinal cord and hence may cause 
greater proportional atrophy.
The present study findings suggest that atrophy may evolve over several years 
following inflammatory demyelinating lesions in the central nervous system, albeit at a 
diminishing rate. This temporal dissociation between the initial lesion and the 
subsequent development of atrophy has important implications for interpreting the latter 
in natural history studies and treatment trials. Study of the effects of optic neuritis can 
therefore help in understanding the pathophysiology of MS. In a later chapter a 
prospective serial study will be described which will follow a cohort of patients from 
onset of optic neuritis in order to clarify the temporal evolution of atrophy and its 
relationship to other MRI, VEP and clinical measures.
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3.3 Corticosteroids do not prevent optic nerve atrophy following optic neuritis
3.3.1 Introduction
Corticosteroids shorten the period of functional impairment following relapses in optic 
neuritis and MS, however they have not, thus far, been shown to affect the final level of 
function compared with placebo (Brusaferri & Candelise, 2000). There has been recent 
interest in the use of corticosteroids as neuro-protective agents by their effect of 
decreasing NO production by mononuclear cells (Compston & Coles, 2002). NO is 
toxic to axons in vitro (Smith et al., 2001). Pulsed corticosteroid treatment has been 
reported to reduce the development of cerebral atrophy, a putative marker of neuronal 
loss (Miller et al., 2002), over a five-year period in relapsing remitting MS (Zivadinov 
et al., 2001). Optic nerve atrophy has been shown to develop following optic neuritis 
(Youl et al., 1996). This study assesses whether a single course of IVMP during an 
attack of acute optic neuritis prevents the development of optic nerve atrophy following 
optic neuritis. MRI data from a recent randomised placebo-controlled trial of IVMP in 
acute optic neuritis were retrospectively evaluated (Kapoor et al., 1998).
3.3.2 Patients and methods
The design, conduct and clinical results of the trial have been previously reported 
(Kapoor et al., 1998). Briefly, 66 patients with a first episode of acute unilateral optic 
neuritis within 30 days of onset were enrolled into the study. The median duration of 
symptoms before randomisation was eight days (range 1-30). Six of the patients had 
CDMS, another 14 had CPMS and the rest had clinically isolated optic neuritis. They 
had their optic nerves imaged with a STIR sequence (TR 2500ms, TE 40ms, TI 175ms, 
matrix 256x128, FOV 16cmxl6cm, 2 excitations, 5mm contiguous slices) and were 
then randomised to receive either lg/day IVMP for three days or intravenous saline. 
Re-imaging was performed six months later. In addition, at six months, a detailed 
clinical assessment was performed including Snellen visual acuity, contrast sensitivity 
using the Pelli-Robson chart, 30-2 Humphrey visual field examination and colour vision 
using the FM 100 Hue test. Normal values were taken to be a visual acuity of 6/6 or 
better, contrast sensitivity of 1.65 or better, Humphrey mean deviation of -3dB or higher 
and the total error score of the FM 100 of less than 110 (Optic Neuritis Study Group,
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1991; Steel & Waldock, 1998). Whole field and central field pattern-evoked VEPs 
were also recorded.
Only images that were acquired on a Signa 1.5T imager (General Electric, Milwaukee, 
WI) were available. Some early patients in the study were imaged on a Picker 0.5T 
imager and these images were not available for study. In total, images from 45 patients 
at baseline and 59 (30 given IVMP and 29 given placebo) patients after six months were 
examined. The images were transferred onto workstations (Sun Microsystems, 
Mountain View, CA). Mean optic nerve area was measured by an observer blinded to 
image identity, treatment group and acquisition order from two consecutive 5mm orbital 
slices from the orbital apex forwards using a semi-automated contouring technique as 
previously described (Chapter 3.1). Each measurement was carried out three times 
independently of each other. In a previously reported study of a different patient cohort, 
five consecutive 3mm orbital slices from an sTE fFLAIR sequence were measured 
(Chapter 3.1). It was not possible to measure a 15mm segment in all subjects from the 
STIR images as in some patients the most anterior slice occurred at the point that the 
nerve sheath dilated as it attached on the back of the globe leading to an artificially 
increased area; hence a 10mm segment was measured. This was less of a problem with 
the previous study because the sTE fFLAIR sequence suppresses the signal from CSF. 
The presence of high signal lesions in the measurement area was noted and lesion 
lengths at baseline and six-months were recorded from the data of the original study, 
measured by an experienced neuroradiologist (Kapoor et al., 1998).
3.3.3 Statistical methods
The presence of nerve swelling at baseline and atrophy at six -months was assessed in 
terms of the ratio: diseased optic nerve area/healthy optic nerve area at the respective 
time points. Null hypotheses of ratio=l were examined by paired t-tests on log nerve 
areas. The possible influence of a lesion in the measured portion of the nerve was 
examined by regression of log ratios on the presence of a lesion and its length. The 
association between atrophy and corticosteroid use was assessed by regression of the 
log ratio of six-month diseased optic nerve area/six-month healthy optic nerve area and 
six-month diseased area/baseline diseased optic nerve area on an indicator of 
corticosteroid use, adjusting for relevant baseline optic nerve area. The influence of the
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presence of a baseline lesion was assessed by an interaction term. All paired tests or 
analyses involving both time points used only patients available at both time points. 
Associations between diseased optic nerve area at six months and VEP variables were 
assessed by linear regression on log diseased optic nerve area at six months; clinical 
variables were dichotomised about the threshold for the normal ranges and similarly 
assessed by logistic regression. To assess measurement reproducibility the within- and 
between-subject SD (and hence CV and reliability coefficients) were obtained from 
random effects analysis of variance (Bland & Altman, 1996a; Bland & Altman, 1996b; 
Bland & Altman, 1996c).
3.3.4 Results
Measurement reproducibility results are given in Table 3.5. At baseline optic nerve 
mean area was 18.4 (SD 3.8)mm2 in diseased optic nerves and 17.8 (SD 3.6)mm2 in 
healthy optic nerves (n=45). The estimated geometric mean ratio (diseased nerve 
area/healthy nerve area) was 1.035 (95% Cl 0.96, 1.11; p=0.33). At baseline, high 
signal was present in the measurement area in 36/45 patients. The presence of a lesion 
did not affect the ratio, however the degree of swelling increased by 7.5% (95% Cl 
3.3%, 11.7%; /?=0.001) for each slice that a high signal lesion was visible on.
After six months optic nerve mean area was 16.4 (SD 3.8)mm2 in diseased optic nerves 
and 17.4 (SD 3.5)mm2 in healthy optic nerves (Figure 3.8) (n=59). The estimated 
geometric mean ratio (diseased nerve area/healthy nerve area) was 0.93 (95% Cl 0.87, 
0.99; p=0.02). A lesion was present in 56/59 patients in the orbital portion measured at 
this time point. Neither the lesion length at baseline or six-months correlated with the 
degree of atrophy. There was no evidence of association between any of the clinical 
and VEP variables and six-month diseased nerve area.
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variable
mean
(mm2)
within- 
subject SD
95% reference 
range3
CV
(%)
reliability coefficient 
(95%CI)b
acute 
diseased 
nerve area
18.4 1.13 ±2.21 6.4 0.92 (0.88, 0.96)
acute 
healthy 
nerve area
17.8 1.21 ±2.37 6.8 0.89 (0.84, 0.94)
6-month 
diseased 
nerve area
16.4 0.76 ± 1.49 4.6 0.96 (0.95, 0.98)
6-month 
healthy 
nerve area
17.4 1.11 ±2.18 6.4 0.91 (0.87, 0.95)
Table 3.5: Measurement reproducibility for the different subgroups.
al .96 x within-subject SD. 95% of measurements are expected to lie within this 
departure from the true value.
bThe proportion o f total variance due to between-subject variation. Under assumptions 
which are plausible here, one minus this value is the proportion o f variation due to 
measurement error.
Figure 3.8: STIR MRI demonstrating optic nerve swelling at baseline (left) and optic
nerve atrophy after six months (diseased nerve arrowed) in a 27 year old 
man with right optic neuritis.
The mean area o f diseased optic nerves at six months in the IVMP group was 15.9 (SD 
3.9)mm2 (n=30) compared with 16.9 (SD 3.8)mm2 in the placebo group (n=29). The 
ratio o f six-month diseased/six-month healthy optic nerve area was 6.8% lower in the 
IVMP group than in the placebo group (95% Cl, 16.1% lower, 3.6% higher, p= 0 .19). 
The ratio o f six-month diseased optic nerve area/baseline diseased optic nerve area was 
0.8% lower in the IVMP group than in the placebo group (95% Cl 14.8% lower, 15.5%
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higher, p=0.92). Neither the MS status nor the duration of symptoms before treatment 
was instigated affected these ratios.
3.3.5 Discussion
This technique was able to demonstrate optic nerve atrophy following optic neuritis 
with good reproducibility as witnessed by the high reliability coefficients. The area 
measurements are greater than those produced from sTE fFLAIR images as the 
measurements from the STIR images include the nerve sheath. Even though the 
measurements were of the optic nerve-sheath complex atrophy was still detected after 
six-months. At the time that the images were acquired during the trial the sTE fFLAIR 
sequence had not been developed and STIR was the preferred sequence for optic nerve 
lesion identification.
A study using sTE fFLAIR in a more chronic cohort of optic neuritis patients 
demonstrated that increasing optic nerve atrophy was associated with worse vision and 
decreased VEP amplitudes (Chapter 3.2). The lack of correlation between the clinical 
outcome measures and optic nerve mean area in the present study may be due to 
functional reorganization in the visual system in the early recovery process (Werring et 
al., 2000), potentially achieved by utilising redundant optic nerve capacity (Frisen & 
Quigley, 1984). This plasticity may fail over time and this may be one explanation for 
the development of late clinical progression in MS.
There is no evidence from these data that a course of IVMP prevents the short-term 
development of optic nerve atrophy following acute optic neuritis. This is consistent 
with the lack of long-term functional benefit seen due to IVMP in both this and other 
studies.
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Chapter 4 Recovery Following Acute Optic Neuritis
The following three sections detail the clinical, electrophysiological and quantitative 
MRI findings in a cohort of patients recruited with a first episode of acute unilateral 
optic neuritis to try and elucidate the mechanisms underlying initial visual impairment 
and subsequent recovery.
4.1 Visual recovery following acute optic neuritis: A clinical, electrophysiological
and MRI study.
4.1.1 Introduction
As has been discussed, optic neuritis is one of the most common causes of acute visual 
loss in young adults living in temperate latitudes (Jin et al., 1998). It has an incidence 
of 1-5 per 100,000/year (Rodriguez et al., 1995; Jin et al., 1998; MacDonald et al.,
2000). It may occur in isolation but there is a well known association with MS. 
Approximately 40-75% of patients affected by optic neuritis go on to develop MS 
(Francis et al., 1987; Rodriguez et al., 1995; Ghezzi et al., 1999).
Although most patients make good recoveries from optic neuritis, about 10-15% of 
patients are left with significant visual impairment (Perkin & Rose, 1979; Beck, 1998). 
The degree of recovery does not seem to be related to age, gender, ethnicity, concurrent 
presence of multiple sclerosis, or abnormalities on brain MRI (Beck et al., 1994). 
Generally, patients who are worst affected initially have a poorer prognosis, mainly 
related to the fact that recovery starts from a lower level compared with those who are 
mildly affected. Recovery however, is still possible. Of 66 patients presenting with a 
visual acuity of counting fingers or worse on entry to the ONTT, 61% recovered to 6/6 
or better (Beck et al., 1994). In another study, of 10 patients who presented with no 
light perception in the affected eye and a final diagnosis of demyelinating optic neuritis, 
six recovered to 6/9 or better (Slamovits et a l, 1991).
Corticosteroid therapy hastens recovery following acute optic neuritis and acute MS 
relapses. However, in all of the clinical trials to date no effect on final function has 
been demonstrated (Brusaferri & Candelise, 2000). IVIG was proposed to enhance
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remyelination in order to promote recovery and to protect denuded axons from 
degeneration, however, in a randomised trial of 55 MS patients with persistent visual 
acuity loss after optic neuritis it did not significantly affect visual outcome (Noseworthy 
et al., 2001).
Optic neuritis provides a useful model for study of MS relapses in general because it 
mirrors the natural history of relapse and recovery in MS. Also visual function can be 
measured accurately, electrophysiological tests provide insights into the effects on 
conduction in the visual pathways and MRI techniques with fat saturation enable the 
lesion in optic neuritis to be detected and studied (Gass et al., 1996; Beck, 1998; Brusa 
et al., 2001).
Gadolinium “enhancement” on MRI is a consistent feature in acute optic neuritis (Youl 
et al., 1991; Kupersmith et al., 2002). Its presence, an indicator of acute inflammation 
(Katz et al., 1993), is associated with impairment of vision that improves on 
disappearance of the enhancement (Youl et al., 1991). The length of the initial 
enhancing lesion however, was not shown to be related to the prognosis for recovery in 
one study that used a standard dose of gadolinium (O.lmmol/kg) (Kupersmith et al., 
2002).
This study reports the prospective follow-up of a cohort of patients who were recruited 
at presentation with a first attack of acute unilateral optic neuritis. Assessment was 
made using serial visual tests, electrophysiology, conventional and triple-dose 
gadolinium-enhanced MRI to examine which factors might be important in predicting 
prognosis for visual recovery. Triple-dose gadolinium (0.3mmol/kg) was chosen as it 
was known to increase the sensitivity for detecting enhancing brain lesions in MS by 
66-75% compared with the use of single-dose (Filippi et al., 1996; Silver et al., 1997). 
This study assessed whether the potential for increased sensitivity for detecting the 
acute inflammatory lesion could lead to an improved ability for predicting prognosis 
based on the initial lesion length and the time that enhancement could be detected on 
serial imaging.
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4.1.2 Patients and methods
Thirty-three patients with their first episode of acute unilateral optic neuritis within four 
weeks of onset of visual symptoms were recruited from the Neuro-Ophthalmology 
clinic of Moorfields Eye Hospital. The diagnosis of acute optic neuritis was based on 
previously agreed clinical criteria (Compston et al., 1978). For the purposes of this 
study, patients under 18 years of age were excluded as being unable to consent to take 
part in the study and an upper age limit was put at 55 years of age as long as the rest of 
the clinical picture was consistent with acute optic neuritis. Patients were assessed for 
the diagnosis of MS according to the Poser criteria (Poser et al., 1983). Patients with 
MS were eligible for the study as long as this was their first presentation with optic 
neuritis. Ethical approval was obtained for the study from the joint ethics committee of 
the Institute of Neurology and the National Hospital for Neurology and Neursurgery; 
informed consent in writing was obtained from each subject, in accordance with the 
Declaration of Helsinki
The demographics and clinical features of the patients are listed in Table 4.1. All 33 
patients were assessed at baseline. Follow-up assessment was scheduled to occur two, 
four, eight, twelve, 26 and 52 weeks later. Twenty patients were assessed serially 
according to the above schedule (with some missing sessions) and twenty-two were 
assessed at one-year (Table 4.2).
Clinical assessment (at each visit)
Visual acuity
Best spectacle or pinhole-corrected visual acuity was measured using a retro-illuminated 
ETDRS chart and recorded as the 4m logMAR visual acuity (Ferris III et al., 1982). 
When no letters could be correctly identified a score of 1.7 was assigned (Optic Neuritis 
Study Group, 1991). A visual acuity of 0.0 or better (equivalent to Snellen 6/6) was 
considered normal (Optic Neuritis Study Group, 1991; Steel & Waldock, 1998) and a 
poor recovery was assigned if the visual acuity at the last assessment was +0.2 or 
greater (equivalent to < Snellen 6/9) (Bradley & Whitty, 1967; (Miller et al., 1988).
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No. Age Gender Side Status
Delay
-days* Pain
Pain on eye 
movement Phosphenes
1 30 <J R CPMS 12 Yes No No
2 29 6 L CIS 15 Yes Yes No
3 43 9 L CIS 14 Yes Yes Yes
4 38 ? L CIS 23 Yes Yes Yes
5 25 9 L CIS 7 Yes Yes No
6 26 9 L CIS 11 Yes Yes No
7 53 9 L CIS 18 Yes Yes No
8 25 cJ L CIS 9 Yes Yes No
9 47 9 R CPMS 24 No No Yes
10 41 6 L CDMS 17 Yes No No
11 24 9 R CIS 14 Yes Yes No
12 33 9 R CIS 12 Yes Yes Yes
13 28 9 R CDMS 13 Yes Yes Yes
14 46 6 L CIS 10 Yes Yes No
15 34 8 L CIS 10 Yes Yes Yes
16 30 9 R CPMS 11 Yes Yes No
17 27 9 R CIS 15 Yes Yes No
18 40 (J R CIS 15 Yes Yes No
19 29 9 R CIS 8 Yes Yes Yes
20 19 9 R CDMS 21 Yes Yes No
21 22 8 R CIS 13 Yes Yes No
22 44 8 R CIS 18 No No No
23 27 9 R CIS 19 Yes Yes No
24 49 9 L CPMS 12 Yes Yes Yes
25 35 9 R CIS 9 No No Yes
26 23 9 R CIS 15 Yes Yes No
27 31 <J R CIS 10 Yes Yes No
28 23 9 R CIS 16 Yes Yes No
29 45 9 L CIS 14 Yes Yes No
30 22 9 L CPMS 11 Yes Yes No
31 39 9 R CIS 13 Yes Yes No
32 25 2 L CIS 13 Yes Yes Yes
33 27 ? L CIS 13 No No Yes
Table 4.1: Patient characteristics.
* Delay is the time since onset of visual symptoms to baseline session.
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No.
Session (weeks)
Comments0 2 4 8 12 26 52
1 S
2 s ✓ S Healthy eye recurrences after 3 + 12 months
3 S s ✓ ✓ S Corticosteroid treatment
4 y ✓ ✓ S ✓ No gadolinium-enhanced imaging
5 s No gadolinium-enhanced or brain imaging
6 ✓ ✓ S
7 V ✓ S
8 s ✓ S s
9 No gadolinium
10 ✓ ✓ S V Congenital colour anomaly
11 v' s ✓ No gadolinium
12 ✓ s
13
14 ✓ ✓ s No gadolinium after baseline due to 
thrombophlebitis
15 v' ✓ ✓ ✓ V ✓ No gadolinium after baseline due to 
thrombophlebitis
16 ✓ s V Healthy eye recurrence after 6 months
17 ✓ ✓ s s
18 ✓
19 ✓ ✓ ✓ s s
20 ✓
21 s s Bilateral recurrence of optic neuritis after 3 
months, treated with corticosteroids
22 ✓ ✓ s
23 s
24 V s v'
25 ✓ S s s
26
27
28 ✓ ✓ V V s Corticosteroid treatment
29 ✓ s
30 No gadolinium
31 s
32
33
Table 4.2: Sessions that patients attended.
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Visual field
The central 30° of the visual field was analysed using the 30-2 program on the 
Humphrey field analyser (Allergan-Humphrey Inc., San Leandro, CA, USA). Wide- 
angle lenses were used to correct refractive errors where necessary. The overall visual 
field mean deviation was compared with a reference field derived from control data 
provided by the manufacturer. A mean deviation of -35dB was assigned when vision 
was too poor to attempt the test (Kupersmith et al., 2002). A mean deviation greater 
than or equal to -3.00dB was regarded as normal (Optic Neuritis Study Group, 1991; 
Wakakura et al., 1999b) and a poor recovery was assigned if the mean deviation at the 
last assessment was less than or equal to -6.00dB (Keltner et al., 1993).
The serial results from the above two parameters were chosen for detailed analysis 
because they give continuously variable measures that are amenable to statistical 
analysis.
Colour vision
Colour vision was assessed at each visit using the first 17 of the Ishihara 
Pseudoisochromatic Colour Plates 38 plates edition (Kanehara & Co. Ltd., Tokyo, 
Japan). Colour vision was scored as normal if 15 or more plates were correctly read 
(Fleishman et al., 1987). In addition, at the one year visit, the FM 100 Hue test was 
performed in each eye (Farnsworth, 1943). It was not performed earlier for reasons of 
time and the poor performance of patients when visual acuity is poor (Katz, 1995). A 
square root of the error score of 10.5 or less was considered normal (Optic Neuritis 
Study Group, 1991).
Contrast sensitivity
Contrast sensitivity was assessed using standard Pelli-Robson charts at a distance of lm 
(Pelli et al., 1988). A score of 1.65 log units or higher was considered normal (Steel & 
Waldock, 1998).
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Pupillary reaction
The presence of an RAPD was assessed using Levatin’s swinging torch test (Levatin, 
1959; Cox e ta l, 1981).
Fundus examination
Fundus examination with an ophthalmoscope was performed and the presence of optic 
disc swelling or pallor commented upon.
Electrophysiological assessment of both diseased and healthy eves 
(at baseline, four, 12, 26 and 52 weeks)
VEP recording was done in a darkened room with the patient comfortably seated and the 
head supported. The patients wore appropriate corrective lenses when necessary. Five 
recording electrodes were attached to the scalp with paste in a symmetric lateral chain 
5cm above the inion with an inter-electrode distance of 5cm. A sixth electrode was 
located 2.5cm above the inion. The common reference electrode was at Fz (10-20 
System). Impedances were reduced to <5kl2 by prior skin preparation. The 
amplification band-pass was 0.16-lkHz and the sampling rate was 2kHz for 250ms after 
each stimulus. VEPs were recorded to reversal of achromatic checks on a computer 
monitor screen with a refresh rate of 100 Hz, each check subtending 40' at the eye. The 
brightness of the light checks was 60cd/m2 and of the dark checks 4cd/m2. Whole field 
VEPs were recorded at a viewing distance of 88cm so that the screen subtended 28° 
horizontal x 20° vertical. Central field recordings with a circular screen whose radius 
subtended 4° at the eye were also taken. The interval between reversals was 909ms. 
Two averages of 100 responses were made for whole field and three for central field 
VEPs, and these were averaged together after assessment of their consistency. The 
amplitude, measured from the preceding peak of opposite polarity, and latency of the 
P I00 peaks were recorded. The results were compared with age-matched laboratory 
controls.
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Conventional imaging (at baseline and one-year)
The optic nerves were imaged with a coronal-oblique fat suppressed dual echo FSE 
(TR=2300ms, TEef=58/145ms, 2 excitations, echo-train length 16, matrix size 512x384, 
24x18cm rectangular FOV, 3mm contiguous slices) sequence (n=33 at baseline, n=22 at 
one-year). Brain imaging was also performed with an axial-oblique dual echo FSE 
(TR=2000ms, TEef=19/95ms, 2 excitations, echo-train length 8, matrix size 256x256, 
24x18cm rectangular field of view, 5mm contiguous slices) sequence (n=32 at baseline, 
n=22 at one-year).
Between imaging sessions care was taken to accurately reposition the imaging field of 
view. In particular, the line from the anterior commissure to the posterior commissure 
on sagittal localiser images was used to ensure that the subjects’ head angles were the 
same at each session.
An experienced radiologist (Dr K. A. Miszkiel), who was blinded to the lesion side and 
severity of visual loss, identified lesions on the proton density weighted FSE images at 
baseline and one year (in separate sessions), and determined their length as the number 
of consecutive slices involved multiplied by 3mm. The baseline brain FSE images were 
classified as abnormal if any lesions typical for demyelination were identified. 
Dissemination in space of the brain lesions was commented on according to the Barkhof 
criteria (although gadolinium-enhanced brain images were not acquired) (Barkhof et al., 
1997). The one-year images were assessed for the presence of any new lesions. Both 
sets of brain images were also evaluated for the presence of any optic radiation lesions. 
The brain images were then analysed on Sun workstations (Sun Microsystem, Mountain 
View, CA., USA) using the Displmage display tool (Plummer, 1992). The total brain 
and optic radiation lesion areas were calculated using a semi-automated contouring 
technique for the marked lesions as previously described (Grimaud et al., 1996).
Triple-dose gadolinium-enhanced imaging (at baseline and until enhancement ceased)
Before and after administration of 0.3mmol/kg intravenous dimeglumine gadopentate 
(triple-dose gadolinium) the patients’ optic nerves were imaged with a coronal-oblique 
fat-saturated Ti-weighted spin echo (TR 600ms, TE 20ms, 1 excitation, 256x192
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matrix, 24x18cm FOV, 16 contiguous 3mm slices) sequence in 28 patients at baseline. 
The radiologist, blinded as above, identified and determined the length of any 
enhancing optic nerve lesions on the images. Serial imaging was performed on 15 of 
the patients after 2, 4, 8 and 12 weeks and gadolinium administered until enhancement 
was deemed to have ceased. The duration of enhancement was noted.
4.1.3 Statistical methods
VEP and imaging data were considered as continuous variables; colour vision on 
Ishihara charts and contrast sensitivity scores were considered as binary variables 
dichotomised about the normal values. Visual field mean deviation and logMAR visual 
acuity were considered as both continuous and binary variables dichotomised about the 
poor recovery thresholds.
Associations at fixed times
Linear regression was used to investigate associations between pairs of quantitative 
variables at fixed times, with additional predictor terms to assess interactions and 
confounding. Where Normality of residuals could not be assumed, non-parametric bias- 
corrected bootstrap Cl were obtained using 1000 replicates (Carpenter & Bithell, 2000). 
T-tests or (where Normality could not be assumed) Wilcoxon Rank Sum tests were used 
to compare quantitative variables across two groups, and Pearson chi-square tests for 
associations between pairs of binary variables. Correlations were assessed using 
Pearson correlation coefficients.
Associations over multiple time points per subject
To investigate associations between pairs of quantitative variables across multiple time 
points, variance components regression models were used, estimating both within and 
between subject variation (Baltagi, 1995). Bootstrap inference was used when residuals 
showed some deviation from Normality.
As visual recovery appeared to approach an eventual recovery value, accordingly this 
was fitted using an exponential model which was able to fit this type of curve flexibly,
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and which captured useful features of the trajectory by means of three estimated 
parameters, a, p, ^(Snedecor & Cochran, 1989): 
y-j = <*j + Pj exp(-»%) + Eij Sij ~N(0, a2)
y tj is the acuity score for the zth assessment of they'th subject, and ty is the time from 
onset at the zth assessment of subject j\ sy is the error term, assumed Normally 
distributed with mean 0, variance o2
a, is the asymptote, or ‘eventual’ recovery level, for subject j;
pj is the extent of improvement in acuity from baseline to asymptote;
Yj controls the trajectory shape for subject j;
Further: -$ # is  the estimated gradient at baseline, the ‘initial recovery gradient’,
(\lyj)\n{Pjl[r - aj\) is the estimated time to reach acuity score r, and (l/#)ln(l/[l - d\) is 
the estimated time to achieve fraction d of the total extent of recovery Pj, for subject j. 
Since this type of non-linear model is difficult to fit in a multilevel context, the model 
was fitted for each subject separately giving subject-specific estimates, in particular, 
subject-specific eventual recovery levels (the predicted asymptote from the model, 
rather than the level at last assessment), initial recovery gradients, and times to achieve 
fractions of total recovery; these were then summarised or used in conventional 
regression models to investigate determinants of the trajectory. Bootstrap inference was 
used due to the non-Normal distribution of subject-specific estimates.
4.1.4 Results
Baseline Status
The patients’ clinical characteristics and baseline visual and imaging results are given in 
Tables 4.3-4.5.
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Baseline characteristics Frequency
Time since onset Median =13 days, Range = 7-24
Age Median = 30 years, Range = 19-53
Gender Male = 10 (30.3%), Female = 23 (69.7%)
Side Left = 15 (45.5%), Right = 18 (54.5%)
Clinical status CDMS = 3 (9.1%), CPMS = 5 (15.1%), CIS = 25 (75.8%)
Pain Present = 29 (87.9%), Absent = 4 (12.1%)
Pain on eye movement Present = 27 (81.8%), Absent = 6 (18.2%)
Pain before visual loss Present =11 (33.3%), Absent = 22 (66.7%)
Phosphenes Present =11 (33.3%), Absent = 22 (66.7%)
RAPD Present = 32 (97%), Absent = 1 (3%)
Swollen disc Present =19 (57.6%), Absent = 14 (42.4%)
Table 4.3: Baseline clinical status.
Test Median Range No. (%) abnormal
logMAR acuity 
(and Snellen equivalent)
+1.02
(6/60)
+1.70 to -0.06 
(NPL to 6/5)
30 (90.9%)
30-2 Humphrey mean 
deviation (dB)
-20.00 -35.00 to -2.47 32 (97%)
Ishihara plates correct 
out of 17 (n=32)*
1 Oto 16 30 (93.8%)
Pelli-Robson contrast 
sensitivity
0.75 Oto 1.65 32 (97%)
VEP whole field 
amplitude (/zV)
2.1 Oto 18.1 n/a
VEP whole field latency 
(ms)
129.3 99.6 to 158.0 29 (87.9%)
(inc. 9 flat responses)
VEP central field 
amplitude (fiV) (n=32)t
1.3 0 to 8.6 n/a
VEP central field 
latency (ms) (n=32)f
134.1 99.6 to 165.7 31 (96.9%)
(inc. 13 flat responses)
Table 4.4: Baseline clinical and electrophysiological results for diseased eyes.
* Colour vision not tested in one subject due to a congenital colour anomaly, 
t  One central field YEP not measured.
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Imaging finding Frequency
Lesion length on FSE Median = 24mm, Range = 9-3 9mm
Canalicular involvement on 
FSE
Present = 31 (93.9%), Absent = 2 (6.1%)
Lesion length on Gd- 
enhanced Ti CSE (n=28)
Median = 30mm, Range = 0-3 9mm
Canalicular involvement on 
Gd-enhanced Ti CSE (n=28)
Present = 27 (96.4%), Absent = 1 (3.6%)
Duration of enhancement 
(n=16)*
Median = 62 days, Range = 0-113 days
Abnormal baseline brain 
imaging on FSE (n=32)
Present = 23 (71.9%), Absent = 9 (28.1%) 
Dissemination in space = 6 (18.8%)t
Baseline brain lesion areas 
(n=32)
Median = 66.4mm2, Range = 0-1829.1mm2
Optic radiation lesions on FSE 
(n=32)
Present = 9 (28.1%), Absent = 23 (71.9%)
Optic radiation lesion areas 
(n=32)
Median = 0, Range = 0-349.8mm2
Table 4.5: Imaging results at baseline.
* Including one patient with no enhancement at baseline.
X 5/6 patients with dissemination in space had CPMS or CDMS whereas 3 patients with 
CPMS did not have dissemination in space.
The symptomatic lesion on optic nerve FSE images was identified in all 33 cases with a 
median length of 24mm (range 9-39mm). Canalicular involvement was seen in all but 
two patients. Two patients showed chiasmal high signal at baseline and one patient had 
high signal in the contralateral healthy nerve but had no previous history of optic 
neuritis in this eye. In this case the vision measures in this eye were entirely normal, 
however the VEP central field latency was borderline abnormal at 111.8ms.
The symptomatic optic nerve lesion was identified on the enhanced images in 27/28 
cases at baseline (Figure 4.1). The median lesion length at baseline was 30mm (range 
0-3 9mm) with no chiasmal enhancement seen. Canalicular involvement was present in 
all but one case. Both pain on eye movement and optic disc swelling were related to the 
presence of enhancement of the anterior orbital optic nerve (p=0.04 and p=0.01 
respectively). Seventeen patients had enhancement in the slice immediately posterior to 
the globe, 16 of whom had pain on eye movement and 13 of whom had optic disc
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swelling (11 patients did not have anterior orbital enhancement, seven o f whom had 
pain on eye movement and three o f whom had optic disc swelling).
Figure 4.1: Triple-dose gadolinium-enhanced fat-saturated Ti-weighted image o f a
42 year old woman 14 days from onset o f acute left-sided optic neuritis 
(diseased optic nerve arrowed).
The lesion length on the baseline FSE images did not correlate significantly with 
logMAR visual acuity, visual field mean deviation or any o f the VEP parameters.
There was an association at baseline between lesion length on the triple-dose 
gadolinium-enhanced images and logMAR visual acuity (r=0.38, p=0.044), visual field 
mean deviation (r=-0.57, p=0.002) and VEP central field amplitude (r=-0.41, p=0.035).
Three patients received corticosteroids. The decision to treat with corticosteroids was 
made independently o f the patients’ involvement in the study. One patient was treated 
due to a slow recovery, one patient due to persistent pain and a slow recovery and the 
last patient was treated after bilateral recurrence o f optic neuritis four months after the 
first episode.
One-year status
The one-year clinical and electrophysiological results are given in Table 4.6. Three 
patients had recurrences o f optic neuritis in the year (1 patient with 2 episodes in 
contralateral eye, 1 patient with 1 episode in contralateral eye and 1 patient with
Recovery Following Acute Optic Neuritis 119
bilateral recurrence) and three other patients had relapses of MS. Twelve patients had a 
persistent RAPD and 21 had developed a pale optic disc.
Test Median Range No. (%) abnormal
logMAR acuity 
(and Snellen equivalent)
-0.08
(6/5)
+0.62 to -0.2 
(6/25 to 6/4)
7 (33.3%)
4 (19.0%) poor recovery
30-2 Humphrey mean 
deviation (dB)
-4.04 -13.78 to -1.00 13 (61.9%)
7 (33.3%) poor recovery
Ishihara plates correct 
out of 17 (n=20)*
15.5 1 to 17 10 (50.0%)
Pelli-Robson contrast 
sensitivity
1.50 0.9 to 1.65 11 (52.4%)
FM 100 hue square root 
of error score (n=20)*
8.94 34.12 to 4.90 9 (45%)
VEP whole field 
amplitude (jiV)
8.0 1.5 to 35.9 n/a
VEP whole field latency 
(ms)
117.1 96.7 to 160.0 17(81.0%)
VEP central field 
amplitude (fiV)
5.5 1.0 to 16.8 n/a
VEP central field 
latency (ms)
115.2 95.3 to 171.1 19 (90.5%)
Table 4.6: Clinical and electrophysiological outcome at one year for diseased eyes
(n=21 - one excluded due to bilateral recurrence of optic neuritis).
* Colour vision not tested in one subject due to a congenital colour anomaly
There was no association between baseline logMAR visual acuity, visual field mean 
deviation, FSE lesion length, brain or optic radiation lesion load and one year logMAR 
visual acuity or visual field mean deviation.
There was an association between baseline gadolinium-enhanced lesion length and 
visual outcome. The final recovery level in visual acuity was estimated to be worse by 
0.02 (95% Cl: 0.003, 0.04; p=0.03) logMAR units for every additional 3mm increase in 
baseline gadolinium-enhanced lesion length. However, there was a suggestion of non- 
linearity. The difference appeared to be mainly between patients with relatively short 
baseline lesions (lowest quartile, mean lesion length 14.0mm), and others. The final 
recovery level was 0.18 (99% Cl: 0.02, 0.44; p<0.01) logMAR units lower between this 
lowest quartile and the other patients (Figure 4.2). This difference was not effectively
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altered when adjusting for baseline logMAR score (p<0.01) indicating that the 
association between lesion length and outcome was independent o f the baseline visual 
impairment.
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Figure 4.2: logMAR recovery over time by quartiles o f baseline triple-dose
gadolinium-enhanced lesion length.
(a) Patients in the first quartile.
(b) Patients in quartiles 2-4.
The final recovery level in visual field mean deviation was estimated as lower by 
0.27dB (95% Cl: 0.03, 0.60; p=0.03) for every additional 3mm increase in initial 
gadolinium-enhanced lesion length. However, there was evidence again that this 
relationship was not linear. The difference again appeared to be mainly between 
patients in the lowest quartile o f lesion length and the others. The final recovery level 
was 2.55dB higher (99% Cl: 0.22, 5.49; p<0.01) between this lowest quartile and the 
other patients (Figure 4.3). The other quartiles were not significantly different from each 
other. This difference was only slightly attenuated when adjusting for baseline visual 
field mean deviation to 2.26dB (97% Cl: 0.03, 5.69; p=0.03).
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Figure 4.3: 30-2 Humphrey visual field mean deviation recovery over time by
quartiles o f baseline triple-dose gadolinium-enhanced lesion length.
(a) Patients in the first quartile.
(b) Patients in quartiles 2-4.
Six patients reported that their vision had returned to normal. Both logMAR visual 
acuity score and visual field mean deviation were poor predictors o f  “normal” vision at 
outcome. The presence o f normal levels of contrast sensitivity (p=0.034, Wilcoxon 
rank sum), Ishihara colour vision (p=0.013, Wilcoxon rank sum) and having no RAPD 
(p=0.002, Pearson chi-squared) were however associated with self-reported normality. 
Patients reporting normal vision also had lower Famsworth-Munsell square root o f total 
error scores than those reporting abnormal vision (7.61 versus 15.64, 95% Cl for 
difference in means o f 8.03: 13.68, 3.06; p<0.001).
The median duration o f gadolinium enhancement was 63 days (range 0-113 days). The 
duration o f enhancement was associated with the initial gadolinium-enhanced lesion 
length, with five additional days o f  enhancement for each 3mm increase in baseline 
lesion length (r=0.56, p=0.024). The duration o f enhancement was not however 
associated with visual outcome. The groups who had only baseline gadolinium- 
enhanced imaging and those who had serial enhanced imaging were well-matched in 
terms o f initial visual impairment and initial lesion lengths.
The one-year imaging results are presented in Table 4.7.
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One year imaging Frequency
Lesion length on FSE (n=21)* Median = 30mm, Range = 9-45mm
Canalicular involvement on 
FSE (n=21)*
Present = 20 (95.2%), Absent = 1 (4.8%)
New brain lesions on FSEJ Present = 11 (50.0%), Absent =11 (50.0%)
Brain lesion areas Median = 54.5mm2, Range 0-767.3mm2
New optic radiation lesions on 
FSE
Present = 4 (18.2%), Absent =18 (81.8%)
Optic radiation lesion areas Median = 0, Range = 0-318.2mm2
Table 4.7: One year imaging results (n=22).
* One excluded due to bilateral recurrence of optic neuritis.
J No gadolinium enhanced brain imaging performed so dissemination in time could not 
be explored.
At one-year the median FSE lesion length was 30mm (range 9-45mm) and significantly 
longer than at baseline (mean change = 6.29mm, p=0.002). No new patients had 
chiasmal high signal at one year. No new high signal lesions were seen in the 
contralateral healthy optic nerves apart from those cases where new clinical events 
occurred. There was no association between one-year FSE lesion length, brain or optic 
radiation lesion load and one-year logMAR visual acuity or visual field mean deviation.
Visual recovery curves
logMAR acuity
From the whole cohort, 18 patients recovered to a logMAR acuity of less than +0.2, 
four did not (not including the patient with bilateral recurrence). This included a patient 
who recovered to logMAR +0.02 after 41 days and then was lost to follow-up. The 
median time to achieve 50% of the extent of eventual recovery was 11.1 days (95% Cl:
8.3, 54.2) in patients with good recoveries and 17.1 days (96% Cl: 9.7, 39.1) in patients 
with poor recovery. The 75th centile time to achieve 50% of eventual extent of 
recovery in patients with good recovery was 46.6 days (95% Cl: 11.1,131.2). The
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estimated mean gradient at the start o f recovery was -0.393 logMAR units per day in the 
patients with good recoveries and -0.002 logMAR units per day in poor-recovery 
patients (difference in mean gradients: 0.392, 95% Cl: 0.03, 1.094; p=0.01). An 
illustration o f the logMAR recovery curves for patients with good and poor eventual 
recoveries is given in Figure 4.4.
0=poor eventual recovery group
l=good eventual recovery group
0 400100 200 300
Days from symptom onset
Figure 4.4: logMAR visual acuity recovery over time according to eventual recovery
status
30-2 Humphrey visual field mean deviation
From the whole cohort, 15 patients recovered to a mean deviation o f greater than 
-6.0dB, seven did not (not including the patient with bilateral recurrence). This cohort 
includes a patient who recovered to -2.93dB after 41 days and then was lost to follow- 
up. Two patients had their recovery status classified discordantly by the logMAR and 
visual field scores. The median time to achieve 50% of the extent o f eventual recovery 
was 16.25 days (95% Cl: 8.4, 35.2) in patients with good recoveries and 37.7 days (96% 
Cl: 15.4, 96.7) in patients with poor recovery. The 75th centile time to achieve 50% of  
eventual extent o f recovery in patients with good recovery was 25.3 days (95% Cl 17.1,
38.1). The estimated mean gradient at the start o f recovery was 4.60dB units per day in 
the patients with good recoveries and 0.99dB per day in poor-recovery patients 
(difference in mean gradients: 3.61, 95% Cl 0.01, 9.08; p=0.02). An illustration o f the 
visual field mean deviation recovery curves for patients with good and poor eventual 
recoveries is given in Figure 4.5.
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Figure 4.5: 30-2 Humphrey visual field mean deviation recovery over time
according to eventual recovery status.
The quartile with shortest gadolinium-enhanced lesion length at baseline also had a 
borderline significant steeper gradient of Humphrey recovery than patients with longer 
lesions. The estimated mean gradient of recovery in shortest quartile was 7.94dB per 
day steeper than the estimated gradient in the remaining patients (95% Cl 0, 22.63; 
P=0.05). The effect o f initial lesion length on logMAR recovery was in the appropriate 
direction but not significant.
VEP data
There was no association between any of the baseline VEP variables and visual 
outcome. Patients with a good recovery o f visual field mean deviation did though, have 
increased whole and central field amplitudes throughout the recovery process compared 
with patients with poor recovery. The mean differences between good- and poor- 
recovery patients were 5.02/iV (95% Cl 0.33, 9.71; p=0.036) for whole field amplitude 
and 2.29/xV (95% Cl 0.29, 4.56; p=0.047) for central field amplitude (Figure 4.6).
There was however, no association between VEP latency and visual field recovery and 
between any VEP variable and logMAR recovery status.
The quartile with shortest gadolinium-enhanced lesion length at baseline had borderline 
significant higher time-averaged central field amplitude VEPs by a mean 2.26/fV, 95% 
Cl 0.03, 4.50; P=0.048) than longer lesion patients.
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Figure 4.6: VEP central field amplitude over time according to eventual recovery
status
Vision scores, averaged over time, tended to be better in patients with higher time- 
averaged whole and central field VEP amplitudes (see Table 4.8); moreover, within 
patients, at different times, better vision scores were associated with higher VEP 
amplitudes and lower central field latencies (Table 4.8).
VEP variable
logMAR 
visual acuity 
within 
subjects 
(change per 
unit)
logMAR 
visual acuity 
between 
subjects 
(change per 
unit)
Visual field 
mean 
deviation 
within 
subjects (dB) 
(change per 
unit)
Visual field 
mean 
deviation 
between 
subjects (dB) 
(change per 
unit)
Whole field 
amplitude 
(unit = l/iV  rise)
-0.07 
(-0.1,-0.04) 
pO.OOl
-0.03 
(-0.05, -0.01)
p=0.011
+1.23 
(0.69, 1.76) 
pO.OOl
+0.50
(0.11,0.89)
p=0.015
Whole field 
latency 
(unit = lm s rise)
No association No association No association No association
Central field 
amplitude 
(unit =ljuV rise)
-0.09 
(-0.14, -0.05) 
pO.OOl
-0.07
(-0.11,-0.02)
p=0.005
+1.73 
(0.85, 2.62) 
pO.OOl
+1.21 
(0.42, 2.01) 
p=0.005
Central field 
latency 
(unit = lm s rise)
+0.02
(0.01,0.03)
pO.OOl
No association -0.14 
(-0.23, -0.37) 
p 0 .0 0 7
No association
Table 4.8: The within and between subject relationships (95% bootstrap Cl)
between VEP parameters and both logMAR acuity and visual field mean 
deviation taking all available time points into account.
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4.1.5 Discussion
Gadolinium enhancement of the optic nerves has been shown to correlate with the 
degree of expansion of the extracellular space and amount of inflammatory infiltrate in 
animal studies of experimental allergic encephalomyelitis with optic nerve involvement 
(Guy et al., 1992). The initial enhanced lesion length in optic neuritis appeared to be 
important in our study in determining the amount of initial visual impairment 
confirming previous observations (Kupersmith et al., 2002). This is consistent with 
acute inflammation causing conduction block in the optic nerve (Youl et al., 1991).
One previous study, which was a retrospective review of 93 patients out of a cohort of 
107 who were followed to six-months after onset of optic neuritis did not find an 
association between acute enhancing lesion length or location and outcome (Kupersmith 
et al., 2002). The use of triple-dose gadolinium in the present study was associated with 
an apparent high sensitivity for detecting the acute lesion in optic neuritis, although a 
comparative study with single-dose gadolinium was not performed. There was also an 
association, independent of baseline visual impairment, between the acute enhancing 
lesion length and outcome, although this was mostly due to patients with short 
inflammatory lesions having a good prognosis for recovery. This result suggests that 
the initial extent of inflammation has some importance in determining prognosis. It was 
not however possible to do quantitative measurements on the degree of enhancement 
apart from measuring lesion length. Canalicular involvement was thought previously to 
result in a poor prognosis (Miller et al., 1988), but it was almost universal in this study, 
probably due to the increased sensitivity of the technique, and so no conclusions can be 
drawn.
Optic neuritis can usually be diagnosed on clinical grounds, however when there is 
clinical uncertainty imaging can also help in confirming the diagnosis and in ruling out 
other diagnoses such as a compressive lesion (Chapter 1). Routine use of triple-dose 
gadolinium for diagnostic imaging would have large cost implications and is not 
warranted in suspected optic neuritis. However, in future treatment trials of novel 
therapies in the acute phase to improve visual outcome in acute optic neuritis, use of 
triple-dose gadolinium may help in selecting patients who are more likely to have a 
poor prognosis.
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Both optic disc swelling and pain on eye movement were related to the presence of 
enhancement of the optic nerve in the slice immediately posterior to the globe. The 
presence of optic disc swelling is consistent with local blood-nerve barrier breakdown 
with associated inflammation and oedema, although hold up of axonal transport and 
venous congestion may also contribute. The anterior optic nerve is the most mobile 
portion of the nerve and inflammation here may therefore be more likely to cause pain 
on eye movement. The observation of the presence of pain with orbital optic nerve 
enhancement was also made by Fazzone et a/. (2003). 94.3% of patients with orbital 
enhancement experienced pain compared with only 32% of patients with enhancement 
confined to other portions of the optic nerve.
The duration of enhancement was longer than seen in previous studies. In nine out of 
11 patients given single-dose gadolinium optic nerve “enhancement” using STIR MRI 
had ceased by a mean of 34.2 days since onset (Youl et al., 1991). MS lesions have 
been shown to enhance for a mean 2.4±1.6 weeks in one study using triple-dose 
gadolinium (Tortorella et al., 1999) and 3.7±1.9 weeks in another using single-dose 
gadolinium (Silver et al., 1999). The longer duration that was observed here (median 
63 days) may be due to the use of triple-dose rather than single dose gadolinium or this 
study being on symptomatic lesions which may have been more pathologically severe 
than the asymptomatic lesions studied in the brain serial triple-dose gadolinium imaging 
studies. The duration of enhancement did not influence outcome in this study, although 
there was a relationship between initial lesion length and duration of enhancement.
The use of arbitrary standards to determine if visual acuity and visual field scores had 
returned to normal vision did not always reflect the patients’ views on whether their 
vision had returned to normal. The presence of normal contrast sensitivity and colour 
vision scores was associated with having subjectively normal vision at outcome; 
however these parameters are less amenable to statistical analysis compared with 
logMAR acuity and visual field mean deviation as they are not continuously variable.
The lesion on FSE images appeared to lengthen over the year. Possible explanations are 
Wallerian degeneration becoming apparent radiologically (Simon et al., 2000), or 
extension of the primary demyelinating lesion. However, the absolute increase in lesion 
size was small (a mean of two slices on coronal imaging).
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The baseline level of visual impairment appeared to be a poor predictor of visual 
outcome, but the visual field recovery curves showed a greater differentiation in shape 
between patients with good and poor recoveries, in particular regarding the initial 
gradient of recovery. 75% of patients, who recovered to a mean deviation of greater 
than -6.0dB, achieved half their recovery by 25 days. However, the confidence interval 
suggests this figure could have been as late as 40 days. It would be more desirable to 
give the 95% centile figure but this was not possible in this relatively small cohort.
The crucial period in recovery does appear to be within the first two months after onset. 
In one series, the mean period of recovery to Snellen 6/6 acuity, amongst those who 
reached this level, was 8.1 weeks and this was not affected by the severity of visual 
impairment at presentation (Perkin & Rose, 1979). Bradley and Whitty (1967), 
observed that vision had improved to normal (defined as Snellen acuity of 6/9 or better) 
in half after one month, and in three-quarters by six months. The recovery was slower 
in those with poor vision at onset (6/60 or worse). In the ONTT recovery of visual 
acuity was nearly complete by five weeks after onset of symptoms (Beck, 1998). 
Further, albeit slower, recovery has been seen up to one year following onset of the 
disease (Brusa et al., 2001). It may be that a poor prognosis is fixed early on and is 
related to the intensity of the initial inflammatory process causing more extensive acute 
demyelination and axonal damage (Ferguson et al., 1997; Trapp et al., 1998). The 
slower recovery curves in these patients may then reflect attempts at repair with 
expression of new sodium channels on persistently demyelinated axons (Smith & 
McDonald, 1999) and cortical adaptation in the presence of axonal loss or persistent 
conduction block through demyelination (Werring et al., 2000), rather than just 
resolution of inflammation and its effects on relatively normal axons which is 
associated with rapid recovery of vision (Youl et al., 1991). It is interesting that 
corticosteroids speed up recovery without influencing outcome, probably reflecting their 
effect on suppressing inflammation. The association between lower VEP amplitudes 
and poorer vision during recovery suggests that the loss of functioning neural channels 
presents a bar to recovery. This would imply that axonal loss is important, although 
persistent conduction block in demyelinated fibres could give a similar picture. To 
counter such processes, neuroprotective or remyelination treatments may be required to 
improve visual outcome. Targeting of treatment to those with a poor prognosis will be
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required. Also, if treatment is introduced too late then it may not influence outcome. 
Whilst these findings should be confirmed in a larger cohort they do suggest that the 
one- to two-month time window may be appropriate to identify those patients with a 
poorer prognosis. These patients may then be candidates for novel therapies. Some of 
these therapies may be invasive, such as cell-based remyelination requiring surgical 
introduction of the cells, emphasising the need for appropriate patient selection.
In conclusion, this study suggests that factors that are associated with a better prognosis 
are having a short acute lesion on triple-dose gadolinium-enhanced imaging, higher 
VEP amplitudes and a steeper gradient of the initial improvement in vision. These 
observations may have implications for the timing and strategy for implementing new 
treatments to improve visual outcome in optic neuritis, and potentially also for treatment 
of MS relapses in general, although it is less easy to define the symptomatic lesion in 
other parts of the CNS (Behan et al., 2000). Also, lesions elsewhere may not be as 
easily accessible as the optic nerves are if cell-based remyelination therapies were to 
become available.
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4.2 Serial magnetisation transfer imaging in acute optic neuritis
4.2.1 Introduction
As has been discussed in Chapter 2.3.9 MT imaging provides a means by which tissues 
can be examined in more detail (Wolff & Balaban, 1989), going beyond the more 
conventional MRI Ti and T2 characteristics (McGowan, 1999; Barker, 2000; Van 
Buchem & Tofts, 2000). Use of MT allows the otherwise invisible “bound” water 
associated with myelin sheaths to be examined. It also provides a means of producing 
quantitative images by calculating parameters related to the degree of exchange between 
bound and free protons; in particular the MTR.
Taken together the studies detailed in Chapter 2.3.9 suggest that:
(i) Early changes due to Wallerian degeneration may be associated with an early rise in 
MTR, possibly due to exposure of myelin fragments to extracellular tissue increasing 
the exchange of magnetisation.
(ii) Low MTR results from a decreased capacity for exchange due to oedema, 
demyelination and gliosis.
(iii) Axonal degeneration combined with demyelination results in even greater falls in 
MTR.
(iv) Remyelination may result in restoration of MTR.
The temporal evolution of MTR changes after an acute attack of optic neuritis and the 
relationship with imaging, clinical and electrophysiological parameters has not been 
previously studied. This report presents the results of a prospective serial study of optic 
nerve MTR using a high resolution 3D GE sequence in the above cohort of patients with 
acute unilateral optic neuritis. The key aims of the present study are:
(i) To quantify the MTR changes over time due to a symptomatic acute inflammatory 
demyelinating lesion.
(ii) To determine if the MTR changes over time mirror the electrophysiological and 
histopathological observations which suggest demyelination followed by remyelination 
in acute MS lesions. It would be desirable to confirm by imaging the 
electrophysiological observation of remyelination in the recovery process (Brusa et al.,
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2001); such an outcome would support using MTR as a tool to investigate remyelination 
in the optic nerve and elsewhere in the CNS.
(iii) To explore whether the MTR measures either acutely, or during recovery, are 
associated with the degree of visual recovery.
4.2.2 Patients and methods
Twenty-nine patients with their first episode of acute unilateral optic neuritis (10 males, 
19 females, median age 30 years, range 19-53 years), as part of the cohort described 
above, were recruited from the Neuro-Ophthalmology clinic, Moorfield’s Hospital, 
London. The median delay from onset of visual symptoms to the first examination was 
13 days (range 7-24 days). Three of the patients had CDMS, five had CPMS and 21 
had clinically isolated optic neuritis (Poser et al., 1983). All the patients were examined 
acutely and most after 2, 4, 8,12,26 and 52 weeks (n=21, with some missing time 
points for some of the patients).
MRI was performed on a Signa 1.5-T imager (General Electric, Milwaukee, Wise., 
USA). The patients had their optic nerves imaged with a coronal 3D GE sequence (TR 
23.1ms, TE 5.6ms, NEX 2, flip angle 12°, 256x192 matrix, 19x14.25cm FOV, in-plane 
resolution 0.75x0.75mm, 60x1.5mm contiguous slices, acquisition time 18mins) both 
with and without a pre-pulse to saturate the broad resonance of immobile 
macromolecular protons (offset frequency 2kHz, equivalent on-resonance flip angle 
500°) and a fat-saturated dual echo FSE sequence (coronal-oblique, TR 2300ms, 
TEeffective 58/145ms, ETL 8, NEX 2, 512x384 matrix, 24x18cm FOV, in-plane 
resolution 0.5x0.5mm, 16x3mm interleaved contiguous slices, 1 lmin acquisition time).
In addition, 24 of the patients had their optic nerves imaged at baseline before and after 
intravenous administration of 0.3mmol/kg dimeglumine gadopentate (triple-dose 
gadolinium) with a coronal-oblique fat-saturated Ti-weighted spin echo sequence (TR 
600ms, TE 20ms, 1 excitation, 256x192 matrix, 24x18cm FOV, 16 contiguous 3mm 
slices, 3min acquisition time). An experienced radiologist (Dr K.A. Miszkiel), blinded 
to the lesion side and severity of visual loss, identified and measured the length of any 
enhancing optic nerve lesions on the post-gadolinium images. Serial imaging following 
triple-dose gadolinium was performed on 15 of the patients after 2, 4, 8 and 12 weeks
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until enhancement was deemed to have ceased. The duration of enhancement was 
noted.
Twenty-seven control subjects (11 male, 16 female, median age 32 years, range 21-58 
years) were also imaged. Eight of the controls were imaged once, four were imaged 
twice and 15 were imaged on three separate occasions spread out over the course of one 
year. Control subjects had to be free of significant ophthalmological or neurological 
disease and were recruited by the use of advertising posters.
A quadrature birdcage head coil was used as both transmitter and receiver coil.
Subjects were asked to close their eyes and avoid any deliberate eye movements during 
image acquisition. Between imaging sessions care was taken to accurately reposition 
the imaging field of view. In particular, the line from the anterior commissure to the 
posterior commissure on sagittal localiser images was used to ensure that the subjects’ 
head angles were the same at each session.
At each visit the patients were examined. Best visual acuity with appropriate spectacle 
or pinhole correction was measured using a retro-illuminated ETDRS chart and 
recorded as the 4m logMAR visual acuity (Ferris III et al., 1982). When no letters 
could be correctly identified a score of 1.7 was assigned (Optic Neuritis Study Group, 
1991). The central 30° of the visual field was analysed using the 30-2 program on the 
Humphrey field analyser (Allergan-Humphrey Inc., San Leandro, CA, USA). Wide- 
angle lenses were used to correct refractive errors where necessary. The overall visual 
field mean deviation was compared with a reference field derived from control data 
provided by the manufacturer. A mean deviation of -35dB was assigned when vision 
was too poor to attempt the test (Kupersmith et al., 2002). The above two parameters 
were chosen because they give continuously variable measures that are amenable to 
statistical analysis.
In addition, at baseline, 4, 12 and 52 weeks whole-field and central-field pattem- 
reversal VEPs were measured on each patient (Chapter 4.1) (Brusa et al., 2001). Ethical 
approval was obtained for the study from the joint ethics committee of the Institute of 
Neurology and the National Hospital for Neurology and Neursurgery; informed consent
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in writing was obtained from each subject, in accordance with the Declaration of 
Helsinki.
From the images, MTR was calculated on a voxel-by-voxel basis from the expression: 
lOOx(Mo-Ms) / Mo pu where Ms and Mo represent signal intensities with and without 
the saturation pulse respectively. The calculated MTR maps (Figure 1) were displayed 
on workstations (Sun Microsystem, Mountain View, CA, USA) using the Displmage 
display tool (Plummer, 1992).
4.2.3 Segmentation methodology
For segmentation of the optic nerves on the images to give the mean MTR previous 
studies relied on manual placement of an ROI of 4-8 pixels within the nerve (Thorpe et 
al., 1995; Boorstein et al., 1997; Inglese et al., 2002). As has been discussed this has 
the potential for poor reproducibility, loss of information if there is swelling of the optic 
nerves and partial volume effects from surrounding CSF and orbital fat if there is optic 
nerve atrophy. These changes are known to occur in the natural history of optic neuritis 
(Figure 4.7) (Youl et al., 1996).
An evaluation of different segmentation techniques was performed to decide on the 
most optimum method to carry forward to the major study. Ten control datasets with 
repeat imaging and five patient datasets both acutely and after one year were selected 
for preliminary analysis. No automatic segmentation method exists for the optic nerve 
due to its small size and the close approximation to the brain in its intracranial portion 
and the extra-ocular muscles near the orbital apex (Figure 4.8).
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Figure 4.7: Baseline-52 week MTR maps o f the orbital optic nerve in a patient with
acute left-sided optic neuritis demonstrating change in optic nerve size 
over time (arrowed).
Figure 4.8: Optic nerve MTR maps from a control with optic nerves arrowed,
a) chiasm. b) intracranial,
c) intracanalicular. d) orbital.
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A preliminary study was performed using the object strength method (Tofts et al., 
1997). The total excess intensity o f the optic nerve in the orbit however was lower than 
in the canalicular and cranial portions because the background orbital fat had greater 
signal intensity than the air and bone surrounding the more posterior parts o f the nerve 
(Figure 4.9). This methodology was not therefore explored further.
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Figure 4.9: Total excess intensity from MTR maps versus position along the optic
nerve for five randomly selected optic nerves. Note the sharp decrease in 
excess intensity which occurs upon entering the orbit.
Threshold-based contouring was tried, comparing a fixed threshold o f lOpu, which was 
the threshold set for a previous MT study in the spinal cord to exclude partial volume 
pixels (Rovaris et al., 2000), with a more conservative 30pu. These two thresholds 
were compared for both reproducibility and the ability to detect changes occurring in 
both the acute and chronic phase o f optic neuritis. The analysis was performed by a 
blinded observer on the MTR maps, as the intraorbital optic nerve could not be 
identified on the M0 images due to high signal and chemical shift artefact from orbital 
fat (Figure 4.10). The signal from fat was suppressed on the MTR maps due to its low 
MTR. Some manual correction was needed particularly for the intracranial optic nerve, 
as the brain was often included in the initial ROI generated.
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Figure 4.10: Orbital Mo image demonstrating high signal from orbital fat obscuring
the optic nerves.
The measurement reproducibility o f the two segmentation thresholds in given in Table 
4.9 from random effects analysis o f variance (Bland & Altman, 1996a; Bland & 
Altman, 1996b; Bland & Altman, 1996c) and the results in patients and controls is in 
Tables 4.10.
(a)
Threshold 
and side
Mean
(pu)
Within- 
subject SD
95% reference 
range3
CV
(%)h
Reliability
coefficient0
lOpu
left 44.1 0.65 ± 1.27 1.5 0.93
lOpu
right 42.7 0.65 ± 1.27 1.5 0.82
3Qpu
left 48.8 0.22 ±0.43 0.5 0.98
30pu
right 47.9 0.50 ±0.98 1.0 0.99
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(b)
Threshold 
and side
Mean
(pu)
Within- 
subject SD
95% reference 
range3
CV
(%)
Reliability
coefficient15
lOpu
left 42.7 1.28 ±2.51 3.0 0.58
lOpu
right 42.7 1.14 ±2.23 2.7 0.62
30nu
left 47.8 1.27 ±2.49 2.7 0.44
30pu
right 47.8 1.03 ±2.02 2.2 0.67
Table 4.9: Measurement reproducibility for the different subgroups.
a) Measure-remeasure for 10 randomly selected datasets.
b) Acquisition-reacquisition for 10 controls.
a 1.96 x within-subject SD. 95% of measurements are expected to lie within this 
departure from the true value.
bThe proportion of total variance due to between-subject variation. Under assumptions 
which are plausible here, one minus this value is the proportion of variation due to 
measurement error.
Threshold
MTR (pu)
Control mean Acute optic neuritis Optic neuritis after 
1 year
10 pu 42.7 43.6 
p=0A v. control
40.1
/?=0.01 v. control 
/?=0.08 v. acute
30 pu 47.4 48.5 
p=0.4 v. control
45.9
p=0.04 v. control 
p=0.\ v. acute
Table 4.10: Optic nerve MTR in patients and controls, comparisons using paired and
independent samples t tests as appropriate.
This sequence produces high quality MT images and the fixed threshold contouring 
enables the measurement of MTR with both high reproducibility and sensitivity to 
detecting disease effects. The high reproducibility is a result of the segmentation using
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fixed thresholds which are less dependent on the initialisation point and also because 
they are based on mean results over a number of slices. The lOpu threshold required 
more manual correction and potentially included more partial volume pixels, 
particularly in the orbit, as the background is not as uniform as in the spinal cord. The 
results suggest that changes in MTR due to optic neuritis can be measured, at least in 
the chronic phase, although this will need confirming in a larger cohort of patients. The 
30pu threshold segmentation technique was more reproducible and is potentially more 
immune to partial volume effects and therefore the results will be more robust. Its use 
in the whole cohort of patients will now be considered.
4.2.4 Optic nerve segmentation
An observer, experienced in interpreting optic nerve images but blinded to subject 
identity and acquisition order, segmented the optic chiasmata and the optic nerves, from 
all the slices on which the nerves were visible, using threshold-based contouring with 
the threshold fixed at 30pu. The measurements made on the baseline imaging of the 
controls, plus 20 of the patients’ scans (selected at random), were repeated so that the 
measurement reproducibility could be assessed.
Lesions were identified on the acute FSE images (intrinsically registered to the MT 
images as they were acquired together) by the radiologist (Dr. K. Miszkiel) and from 
their coordinates the part of the nerve occupied by a lesion could be identified on the 
MTR maps. The mean lesion and post-lesion MTR (ie the MTR in the section of the 
nerve between the lesion and the optic chiasm) could then be calculated. Formal co­
registration was not possible due to the small size of the optic nerves and the fact that 
the nerves can move (semi-) independently of the surrounding tissue. Instead, at each 
subsequent time-point the same parts of the nerve were identified by using the optic 
chiasm as the reference point and counting the same number of slices from the anterior 
part of the chiasm.
In controls the optic nerve mean MTR varied with slice position from the optic chiasm 
reaching a peak in approximately the location of the optic canal (Figure 4.11).
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Figure 4.11: Mean MTR according to slice position from the optic chiasm anteriorly
in controls. Error bars show (V2/2) x 95% confidence intervals. For 
first 16 slices n=27, for subsequent slices n = 26, 25, 23, 22, 20, 15, 11, 
6, 4 and 2, respectively, reflecting the variation in length o f the optic 
nerve in different individuals.
For analysis o f lesion and post-lesion MTR, the ratio o f the symptomatic optic nerve 
lesion mean MTR or post-lesion mean MTR to the corresponding part o f  the healthy 
contralateral optic nerve mean MTR was therefore used because the lesion length and 
position along the optic nerve varied between patients. This also had the effect o f  
smoothing out any effects due to varying movement artefact between sessions, as any 
movement artefact due to head motion and conjugal eye movements tends to affect both 
eyes equally.
4.2.5 Statistical methods
To assess measurement reproducibility the within- and between-subject standard 
deviations (and hence CV and intraclass correlation coefficient) were obtained from 
random effects one way analysis o f variance (Bland & Altman, 1996a; Bland & Altman, 
1996b; Bland & Altman, 1996c). Variations in MTR variables over time were 
examined using random intercept (Goldstein, 1995) regression models with fixed linear 
and quadratic terms in time (there was no evidence that random slopes in time improved 
the fit). Baseline (time 0, the day o f onset o f  visual symptoms) and 365 day values were 
estimated from these models, and patient versus control difference in gradient assessed, 
including a subject status by time interaction term. Time to nadir (minimum o f the
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quadratic curve) and value at nadir were functions of the linear and quadratic 
parameters, for which Cl were obtained using a non-parametric bias-corrected bootstrap 
with 1000 replicates (Carpenter & Bithell, 2000). Bootstrap Cl were also obtained 
where Normality of regression residuals could not confidently be assumed. Simple 
regression was used to examine relationships between ‘time-averaged’ variables (with 
one value per subject averaged over available time points); a subject status indicator 
was used to compare patients and controls (this is equivalent to a t-test). Eventual 
visual recovery levels were estimated for each patient as asymptotes of exponential 
models in time (Snedecor & Cochran, 1989). All analyses were carried out in Stata 7.0 
(Stata Corporation, College Station, Texas, USA) except for random slopes models 
which were examined in MLwiN 1.10 (Centre for Multilevel Modelling, Institute of 
Education, London, UK).
One patient had bilateral recurrence of optic neuritis after 12 weeks and 2 patients had 
recurrences in their previously healthy contralateral optic nerves, one patient at both 12 
and 52 weeks and one patient at 26 weeks. The data collected on these subjects after 
these events were excluded from the analysis.
4.2.6 Results
Measurement reproducibility figures (CV ranges 0.3-0.5%) are given in Table 4.11.
The estimated mean MTR in control optic nerves at baseline was 47.8pu (95% Cl 47.4,
48.2). This value showed no evidence of a systematic change according to the date of 
acquisition, nor was there evidence that mean MTR in controls changed significantly 
over one year: the estimated rate of change over the year was -0.00065pu/day (95% Cl 
-0.0024, 0.0011), p=0.462. The time-averaged mean MTR in controls was 47.7pu (95% 
Cl 47.5, 48.0) (Figure 4.12).
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MTR
variable
Mean
(pu)
Within- 
subject SD
95% reference 
rangea
CV
(%)
Reliability coefficient 
(95%CI)b
Controls:
Mean 47.8 0.17 ± 0 .34 0.4% 0.98 (0.96, 0.99)
Optic
chiasm
48.4 0.21 ±0.41 0.4% 0.99 (0.98, 1.00)
Patients: 
Diseased 
optic nerve 
Healthy 
optic nerve 
Optic 
chiasm
45.9
47.7
46.7
0.21
0.17
0.18
+ 0.41 
±0.33  
± 0.36
0.5%
0.3%
0.4%
0.99 (0.98, 1.00) 
0.99 (0.99, 1.00) 
0.99 (0.98, 1.00)
Table 4.11: Measurement reproducibility for the different subgroups.
al .96 x within-subject SD. 95% of measurements are expected to lie within this range 
of the true value, if  the variable is approximately Normally distributed. 
bThe proportion o f total variance due to between-subject variation (with 95% 
confidence intervals). Under assumptions which are plausible here, one minus this 
value is the proportion o f variation due to measurement error.
55'
0 100 200 300 400
Days since first imaging
Figure 4.12: Mean MTR in controls over time with fitted line shown in bold.
The estimated mean MTR from healthy contralateral optic nerves from patients at 
baseline was 47.9pu (95% Cl 47.5, 48.3). The gradient o f change over one year was 
+0.00092pu/day (95% Cl -0.0012, 0.0030), p=0.383, again suggesting that there was no 
significant change in MTR in the healthy contralateral eyes over one year. There was 
no evidence o f  any difference in time-averaged mean MTR between the healthy
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contralateral nerves and controls (patient - control difference in means = 0.2813, 95% 
Cl -0.2843, 0.8470, p=0.323).
The characteristics o f mean MTR in diseased optic nerves and lesion MTR ratio are 
illustrated in Figures 4.13 and 4.14 and given in Table 4.12. The significant positive 
quadratic coefficients indicate a U-shape: an initial decline in MTR reaching a nadir at 
about 240 days followed by a slight increase. The estimated 365 day values remained 
significantly less than both baseline and control values although the increases compared 
with the nadir values were not significant (as shown by the appropriate 95% confidence 
limits).
Figure 4.13: Mean MTR over time for whole o f diseased optic nerves with fitted
curve in bold.
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Figure 4.14: Ratio o f MTR of the lesion: corresponding portion o f healthy
contralateral optic nerve over time with fitted curve in bold.
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Estimated 
time “0” 
value 
(95% Cl)
Linear 
coefficient3 
(95% Cl) 
P value
Quadratic 
coefficient 
(95% Cl) 
P value
Time to 
nadirb 
(95% CI)C
Nadir value 
(95% CI)c
Estimated 
365 day 
value 
(95% Cl)
Diseased 
optic nerve 
MTR, pu
47.4 
(46.8,48.1)
-0.027
(-0.035,
-0.019)
P 0 .0 0 1
5.7x10° 
(3.6 xlO'5, 
7.8 xlO'5) 
PO.OOl
239 
(216, 277)
44.2 
(43.7,44.8)
45.1 
(44.4, 45.8)
Ratio of 
diseased: 
healthy 
optic nerve 
MTR
0.99 
(0.97, 1.00)
-0.00051
(-0.00072,
-0.00030)
PO.OOl
lxlO'6 
(5x1 O'7, 
1.6X10-6) 
PO.OOl
246
(214,313)
0.92 
(0.91, 0.94)
0.94 
(0.92, 0.95)
Ratio o f  
lesion: 
healthy 
optic nerve 
MTR
0.98 
(0.97, 1.00)
-0.00058
(-00083,
-0.00033)
PO.OOl
1.2x10'6 
(5.6x1 O'7, 
1.8x1 O'6) 
PO.OOl
241
(215,289)
0.91 
(0.90, 0.93)
0.93 
(0.91, 0.95)
Table 4.12: Whole optic nerve and lesion MTR results in patients.
aLinear coefficient can be interpreted as the rate of daily decline at time “0”. 
bDays from time “0” (day of onset of visual symptoms). 
cBootstrap derived confidence intervals.
At the first assessment there was no significant difference in MTR between diseased 
optic nerves and control optic nerves (mean MTR in patients 47.3pu, mean MTR in 
controls 47.7, difference -0.4, 95% Cl -1.2, 0.4, p=0.354). There was however a 
significant difference in the time-averaged mean MTR from diseased optic nerves and 
control optic nerves (46.2pu versus 47.7pu, difference in means -1.5, 95% Cl -0.8, -2.1,
p=0.0001).
The mean MTR ratios from post-lesion segment of diseased optic nerves and the mean 
MTR results from the optic chiasmata are given in Table 4.13. A linear model gave the 
best fit for these two variables and indicated a decline in both over time. In controls 
there was no evidence of change of chiasmal MTR over time (gradient -0.0013pu/day, 
95% Cl -0.0038, 0.0012, p=0.304). However, there was no statistical evidence of a 
difference in gradient between patients and controls, probably through insufficient 
power. At first assessment the chiasmal MTR was significantly less in patients than 
controls (47.1pu versus 48.3pu, p=0.023). There was also a significant difference 
between patients and controls for the time-averaged mean chiasmal MTR (46.8pu 
versus 48.0pu, p=0.004); and the 365 day estimated value for patients (46.0pu, 95% Cl
45.3, 46.8) was lower than the control time-averaged mean (48.0pu, 95% Cl 47.3, 48.7).
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Estimated time 
“0” value 
(95% Cl)
Linear coefficient3 
(95% Cl)
Estimated 365 
day value 
(95% Cl)
Ratio of post­
lesion: healthy 
optic nerve MTR
0.98 
(0.97, 0.99)b
-9x1 O'5 
(-1.5x10-4, -3xl0'5)b
p=0.01b
0.95 
(0.93, 0.96)b
Chiasmal 
MTR, pu
47.2 
(46.7, 47.7)
-0.0033 
(-0.0058, -0.0007) 
p=0.013
46.0 
(45.3, 46.8)
Table 4.13: Post-lesion and chiasmal MTR results from patients.
aThis is interpreted as the estimated rate of change per day in the MTR variable.
bBootstrap derived confidence intervals and P-value.
The relationship between the MTR variables and the clinical variables was complex. 
There was no linear relationship between any of the diseased optic nerve MTR variables 
and logMAR acuity or visual field mean deviation at baseline or one year. Although 
there appeared to be an association within patients between the MTR variables and 
vision (with the MTR variables appearing to fall as vision improved), this seemed to be 
an artefact of time: once time was entered into the model, the within-person MTR 
versus vision relationship lost statistical significance. However, eventual visual 
recovery level was improved in patients with higher time-averaged ratios of 
diseased:healthy optic nerve MTR; this was true for the whole optic nerve, for the lesion 
segment and for the post-lesion segment (Table 4.14).
There was no evidence of association between the acute lesion length (measured on 
either FSE or triple-dose gadolinium enhanced images) and any of the MTR variables. 
The median duration of gadolinium enhancement was 63 days (range 0-113 days). 
Again, the duration of enhancement was not associated with any of the MTR variables.
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Ratio
Linear coefficients3 
(95% CI)b 
P-value
Visual field mean 
deviation recovery, dB
logMAR visual acuity 
recovery
Diseased optic nerve: 0.95 -0.05
healthy (0.49, 1.57) (-0.01, -0.08)
optic nerve MTR p<0.001 p=0.007
Lesion: 0.46 -0.03
healthy optic nerve (0.08, 099) (-0.002, -0.08)
MTR p=0.04 p=0.02
Post-lesion: 0.79 -0.03
healthy optic nerve (0.46,1.12 (-0.003, -0.07)
MTR pO.OOl p=0.03
Table 4.14: The relationship between time-averaged MTR ratios and visual recovery
level.
aInterpreted as estimated change in eventual visual recovery level for each 0.01 rise in
time-averaged MTR ratio.
bBootstrap derived confidence intervals.
There were no significant direct linear relationships by cross-sectional analyses between 
the MTR variables and electrophysiological measurements. There was evidence that 
patients with higher time-averaged MTR values had shorter time-averaged VEP 
latencies. Whole field latency was lower by 5.3ms (95% Cl 0.2, 10.3, p=0.043) and 
central field latency was lower by 6.1ms (95% Cl 1.5, 10.7, p=0.012) (Figure 4.15) per 
lpu rise in time-averaged diseased optic nerve MTR. There were no associations 
between time-averaged amplitude results and any time-averaged MTR variables.
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Figure 4.15: Time-averaged VEP central field latencies versus time-averaged diseased
optic nerve MTR values.
4.2.7 Discussion
The use o f a fixed threshold o f 30pu enabled the optic nerves to be segmented with high 
reproducibility, although it should be noted that as the results reflect the mean MTR 
over the whole optic nerve, variations will tend to be, to an extent, smoothed out. The 
high threshold was chosen to exclude partial volume voxels which in patients might be 
expected to have a differential effect later in the study where optic nerve atrophy might 
be developing. This may also have limited the proportionate decrease in MTR values 
seen compared with previous studies in both MS and optic neuritis, by minimising the 
risk of a spurious reduction in MTR due to partial volume effects with inclusion o f CSF 
in the optic nerve sheath. However, absolute MTR values between studies should not 
be directly compared as they vary according to the imager and sequence used.
The mean MTR in the healthy optic nerve varied with slice position, being highest in 
the optic canal, probably due to the more densely packed structure o f the optic nerve 
within the confines o f the bony canal (Figure 4.11). The decline in the orbital portion 
may be due to a looser structure as well as movement artefact in this portion o f the optic 
nerve. There was also variation in length o f the optic nerve between individuals leading 
to larger confidence intervals at the most anterior slices.
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A quadratic model was used for both diseased optic nerve MTR and lesion MTR ratio 
because inspection of the raw data suggests that, on average, both declined to nadirs at 
around 240 days followed by small increases (Table 4.12, Figures 4.13 and 4.14). The 
one-year values however, were not significantly higher than the nadir values.
At the onset of optic neuritis, when visual impairment was at its worst, MTR values 
were unchanged. This finding is in contrast with acute brain lesions in MS where there 
is a rapid initial decrease in MTR. The normal MTR value in acute optic neuritis may 
result from a balance of two factors. Firstly, in the first two weeks after axonal 
transection, “acute” Wallerian degeneration may transiently increase MTR, probably 
due to increasing exposure of myelin fragments (Lexa et al., 1994). Secondly, 
breakdown of the blood-optic nerve barrier, depicted using gadolinium enhancement, 
results in an inflammatory cellular infiltrate and an element of vasogenic oedema; the 
increase in interstitial fluid will decrease MTR. The optic nerve has a more compact 
structure with subdivision into fascicles of axons by fibrous septa and a surrounding 
optic sheath (Williams et al., 1989). Vasogenic oedema may therefore be limited in the 
optic nerve, lessening the initial effects of oedema on MTR changes in the nerve. In 
comparison, acute MS lesions in the brain may show much larger initial reductions in 
MTR values (Dousset et al., 1998; Silver et al., 1998) because there is a much greater 
amount of interstitial fluid due to vasogenic oedema.
During the most rapid phase of visual recovery mean MTR was gradually declining. 
This decline did not reach a nadir until about 8 months. This discordance suggests that:
(i) There are factors leading to early visual recovery that are not reflected using MTR.
(ii) A continuing breakdown in tissue structure is occurring for several months 
following visual recovery.
The initial rapid recovery of vision may have been due to:
(i) Disappearance of inflammatory mediators of conduction block (e.g. nitric oxide) 
(Youl e ta l,  1991).
(ii) Insertion of sodium channels along the inter-nodal membrane to restore axonal 
conduction (Moll et al., 1991; Felts et al., 1998).
(iii) Early remodelling of visual function and utilising redundant capacity at the level of 
central synaptic networks (Frisen & Quigley, 1984; Werring et al., 2000).
None of these processes may have had a material effect on MTR.
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The optic nerve mean MTR also continued to decline beyond when gadolinium 
enhancement, indicating inflammation, was last detected. The continued decline in 
MTR might be due to:
(i) Ongoing demyelination, as reflected by the relationship between time-averaged MTR 
and mean VEP central field latency.
(ii) Gradual clearance of myelin breakdown products (that continue to act as structural 
elements whilst present) resulting either from initial inflammatory myelin breakdown 
per se (Adams et al., 1989) or as part of the prolonged degenerative phase of Wallerian 
degeneration (Lexa et al., 1994).
The decline in MTR occurred for much longer in this study than studies of MS brain 
lesions (Dousset et al., 1998; Silver et al., 1998) possibly due to the different 
ultrastructure of the optic nerve compared with white matter tracts in the brain slowing 
clearance of myelin debris. In this context, it is noteworthy that in a rat optic nerve 
model of Wallerian degeneration myelin debris could be detected 22 months post­
enucleation (Ludwin, 1990).
The decline in MTR appeared to reach a nadir after about 8 months, which may reflect 
arrest of demyelination and clearance of myelin debris. Remyelination in the lesion 
may have contributed to the subsequent trend for MTR to increase, a view supported by 
the significant relationship observed between time-averaged MTR and mean VEP 
central field latency. However, further follow up is needed to determine whether or not 
the increase in MTR is significant and sustained.
Over the whole period, lower time-averaged MTR ratios were associated with poorer 
visual outcome, which suggests that, although the relationship between MTR and vision 
is complex, the longer the time during which the diseased nerve MTR was lower than 
that of its fellow nerve (implying tissue disruption most likely due to demyelination and 
axonal loss) the worse the prognosis.
The continued linear decline in post-lesional and chiasmal MTR is probably solely due 
to Wallerian degeneration in the axons transected in the acute inflammatory lesion. The 
initial post-lesional MTR was not abnormally high, unlike what was seen in the case in 
the experimental transection study by Lexa et al. (1994), possibly due to inflammation 
in these regions not apparent on conventional imaging depressing MTR slightly. Also,
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Wallerian degeneration is likely to be much less extensive in the optic nerve following 
optic neuritis, than in the above lesion study, probably affecting only about 10% of 
fibres compared with the 100% nerve section model.
If, in future trials of remyelination therapies, the optic nerves are chosen, then optic 
nerve MT imaging in combination with conventional imaging, VEP and clinical 
measures may be useful in assessing the response to treatment. The potential advantage 
of using optic nerve MT imaging to assess optic nerve structure over VEP measurement 
is the ability to visualise the optic nerves and to assess different parts of the optic nerve, 
including both the lesion and post-lesion segments. Electrophysiological measures can 
only give an indication of conduction in the whole optic pathway which may be 
influenced by changes in the optic tract, lateral geniculate body and optic radiation. 
MTR measures may also have a role in detecting remyelination of MS lesions elsewhere 
in the CNS.
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4.3 A serial MRI study following optic nerve mean area in acute optic neuritis
4.3.1 Introduction
A reproducible technique to measure orbital optic nerve mean cross-sectional area was 
described in Chapter 3.1 and 3.2 using a fat-saturated sTE fFLAIR sequence which 
removes the high signal from both orbital fat and CSF in the sheath of the optic nerve. 
Optic nerve atrophy was demonstrated following optic neuritis and the degree of 
atrophy related to time since onset of the illness. Serial follow-up in a subgroup of 
patients demonstrated ongoing atrophy some years following the acute event in many of 
the patients. Poor baseline visual acuity (p=0.02), decreased VEP amplitudes (rs=0.65, 
p= 0.02) and increased latencies (rs=-0.61,/>=0.04) were associated with the degree of 
atrophy.
Although atrophy measures are widely used to monitor the course of MS, the 
mechanisms of progressive atrophy and axonal loss are not well understood. One 
potential mechanism for the development of ongoing atrophy is Wallerian degeneration 
due to axonal damage in focal MS lesions. This may result from inflammatory and 
post-inflammatory mechanisms. Axonal transection and loss has been shown to occur 
in acute inflammatory MS lesions (Ferguson et al., 1997; Trapp et al., 1998). However, 
axons are potentially vulnerable for a long time, perhaps months or years, in the post 
inflammatory lesion, if there is persistent demyelination and/or exposure to excitatory 
neurotoxic molecules including nitric oxide and glutamate (Smith & McDonald, 1999). 
In the brain and spinal cord, measures of atrophy, in general, correlate only modestly 
with lesion load measures but it is difficult to explore the relationship between atrophy 
and lesions in these regions of because it is not possible to study the effects of 
individual lesions within their relevant fibre tract (Miller et al., 2002). As has been 
discussed, optic neuritis offers a unique opportunity to investigate individual 
inflammatory lesions and the consequences that they have for tissue volume loss.
This study focuses on the above cohort of patients recruited prospectively with their 
first episode of acute optic neuritis. The key aims of this study are:
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(i) To quantify the extent of tissue volume changes due to an individual acute 
inflammatory demyelinating lesion within its fibre tract, previously observed to be 
swollen acutely and atrophied chronically.
(ii) To determine the time course of atrophy developing as a result of individual lesions.
(iii) To explore if any of the acute imaging, clinical or electrophysiological measures 
may help in predicting the likelihood of optic nerve atrophy developing: identifying 
such factors may help in selecting patients where therapies to prevent atrophy are most 
needed.
(iv) To determine whether the extent of early swelling or later atrophy are related to 
clinical, imaging or electrophysiological measures.
(v) To determine if there is any relationship between MTR, a putative marker for 
myelination and axonal integrity (Chapters 2.3.9 and 4.2) in the optic nerve and the 
development of optic nerve atrophy, in particular if higher MTR values, implying less 
demyelination, are associated with less atrophy development.
4.3.2 Patients and methods
Twenty-nine patients with their first episode of acute unilateral optic neuritis (10 males, 
19 females, median age 30 years, range 19-53 years), as part of the cohort described 
above, were recruited from the Neuro-Ophthalmology clinic, Moorfields Hospital, 
London. The median delay from onset of visual symptoms to the first examination was 
13 days (range 7-24 days). Three of the patients had CDMS, five had CPMS and 21 
had clinically isolated optic neuritis (Poser et al., 1983). All of the patients were 
examined acutely and then 21 were followed-up after 2,4, 8,12, 26 and 52 weeks (with 
some missing time points for some of the patients). Ethical approval was obtained for 
the study from the joint ethics committee of the Institute of Neurology and the National 
Hospital for Neurology and Neurosurgery; informed consent in writing was obtained 
from each subject, in accordance with the Declaration of Helsinki.
MRI was performed on a Signa 1.5-T imager (General Electric, Milwaukee, Wise., 
USA). The patients’ optic nerves were imaged with the sTE fFLAIR (coronal-oblique, 
TR=2740ms, TE=16ms, TI=1072ms, NEX 6, ETL 6, matrix size 512x384, 24x18cm 
field of view, in-plane resolution 0.47x0.47mm, 3mm interleaved contiguous slices, 
acquisition time 13.5 minutes) sequence, a fat-saturated FSE (coronal-oblique, TR
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2300ms, TEef 58/145ms, ETL 8, NEX 2, 512x384 matrix, 24x18cm field of view, in­
plane resolution 0.47x0.47mm, 3mm interleaved contiguous slices, 1 lmin acquisition 
time) sequence and a three-dimensional GE (coronal, TR 23.1ms, TE 5.6ms, NEX 2, 
flip angle 12°, 256x192 matrix, 19x14.25cm field of view, in-plane resolution 
0.74x0.74mm, 60x1.5mm contiguous slices, acquisition time 18mins) sequence both 
with and without a pre-pulse to saturate the broad resonance of immobile 
macromolecular protons (offset frequency 2kHz, equivalent on-resonance flip angle 
500°). From these images, MTR was calculated on a voxel-by-voxel basis from the 
expression: 100x(Mo-Ms) / Mo pu where Ms and Mo represent signal intensities with 
and without the saturation pulse respectively.
In addition, 24 of the patients had their optic nerves imaged at baseline before and after 
intravenous administration of 0.3mmol/kg dimeglumine gadopentate (triple-dose 
gadolinium) with a coronal-oblique fat-saturated Ti-weighted spin echo (TR 600ms, TE 
20ms, 1 excitation, 256x192 matrix, 24x18cm field of view, in-plane resolution 
0.94x0.94mm, 16 interleaved contiguous 3mm slices) sequence. An experienced 
radiologist (Dr. K. A. Miszkiel), blinded to the lesion side and severity of visual loss, 
identified and measured the length of lesions on FSE images and any enhancing optic 
nerve lesions on the post-gadolinium Ti-weighted images. Serial imaging following 
triple-dose gadolinium was performed on 15 of the patients after 2, 4, 8 and 12 weeks 
until enhancement was deemed to have ceased. The duration of enhancement was 
noted.
Thirty-two control subjects (14 male, 18 female, median age 31 years, range 21-58 
years) were also imaged. Ten of the controls were imaged once, six were imaged twice 
and 16 were imaged on three separate occasions spread out over the course of one year. 
Control subjects had to be free of significant ophthalmological or neurological disease 
and were recruited by the use of advertising posters.
A quadrature birdcage head coil was used as both transmitter and receiver coil.
Subjects were asked to close their eyes and avoid any deliberate eye movements during 
image acquisition. Between imaging sessions care was taken to accurately reposition 
the imaging field of view. In particular, the line from the anterior commissure to the
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posterior commissure on sagittal localiser images was used to ensure that the subjects’ 
head angles were the same at each session.
At each visit the patients were examined. Best visual acuity with appropriate spectacle 
or pinhole correction was measured using a retro-illuminated ETDRS chart and 
recorded as the 4m logMAR acuity (Ferris III et al., 1982). When no letters could be 
correctly identified a score of 1.7 was assigned (Optic Neuritis Study Group, 1991).
The central 30° of the visual field was analysed using the 30-2 program on the 
Humphrey field analyser (Allergan-Humphrey Inc., San Leandro, CA, USA). Wide- 
angle lenses were used to correct refractive errors where necessary. The overall field 
mean deviation was compared with a reference field derived from control data provided 
by the manufacturer. A mean deviation of -35dB was assigned when vision was too 
poor to attempt the test (Kupersmith et al., 2002). The above two parameters were 
chosen because they give continuously variable measures that are amenable to statistical 
analysis. In addition, at baseline, 4, 12 and 52 weeks whole-field and central-field 
pattem-reversal VEPs were measured on each patient (Chapter 4.1) (Brusa et al., 2001).
The images were displayed on Unix workstations (Sun Microsystem, Mountain View, 
CA, USA) using the Displmage display tool (Plummer, 1992). The mean cross- 
sectional area of the intra-orbital portion of each optic nerve was calculated by an 
experienced observer blinded to image identity and acquisition order from five 
consecutive 3mm slices anteriorly from the orbital apex from the sTE fFLAIR images 
using a computer-assisted contouring technique as described in Chapter 3.1. The 
measurements were repeated from all of the controls’ baseline imaging and 20 of the 
patients’ images selected at random so that the measurement reproducibility could be 
calculated. The same observer segmented the whole optic nerves from the MTR maps 
using threshold-based contouring with the threshold fixed at 30pu, as performed in 
Chapter 4.2.
One patient had bilateral recurrence of optic neuritis after 12 weeks and 2 patients had 
recurrences in their previously healthy contralateral optic nerves, one patient at both 12 
and 52 weeks and one patient at 26 weeks. The respective data from these time points 
and after have been discarded.
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4.3.3 Statistical methods
To assess measurement reproducibility the within- and between-subject standard 
deviations (and hence CV and intraclass correlation coefficient) were obtained from 
random effects one way analysis of variance (Bland & Altman, 1996a; Bland & Altman, 
1996b; Bland & Altman, 1996c).
Paired t-tests were used to assess differences between diseased and healthy contralateral 
optic nerve mean areas at fixed time points. Two sample t-tests were used for the 
comparison between diseased and control optic nerve mean areas both at fixed time 
points and for ‘time-averaged’ values (mean for each patient over available time points). 
Variation in healthy nerve area over time was examined using random intercept and 
fixed slope regression models (Goldstein, 1995) with linear term in time (there was no 
evidence that random slopes improved fit). Patient indicator x time interaction terms 
were used to assess patient versus control differences in gradients over time.
Patient-specific baseline and one year rates of decline and eventual levels of diseased 
optic nerve area were estimated by fitting exponential models in time (Snedecor & 
Cochran, 1989) for each patient, since multilevel non-linear models are difficult to fit. 
CIs and p-values for these estimates were obtained using a non-parametric bias- 
corrected bootstrap with 1000 replicates (Carpenter & Bithell, 2000). Figures 4.18 and 
4.19 were generated using exponential models fitted to all patient data.
Linear regression was used to investigate associations at fixed time points between 
atrophy and other quantitative variables (VEP, visual acuity), and between time- 
averaged variables. Where Normality of residuals could not be assumed bootstrap 
confidence intervals and corresponding p-values were obtained; where outliers were 
present Spearman rank coefficients are reported.
All analyses were carried out in Stata 7.0 (Stata Corporation, College Station, Texas, 
USA) except for random slopes models which were examined in MLwiN 1.10 (Centre 
for Multilevel Modelling, Institute of Education, London, UK).
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4.3.4 Results
Measurement reproducibility figures are given in Table 4.15. There was no evidence of 
a systematic change in mean area from controls according to the date of acquisition.
Variable Mean
(pu)
Within- 
subject SD
95% reference 
range3
CV
(%)
Reliability 
coefficient 
(95% CI)b
Controls:
Mean 13.5 0.55 ±1.07 4.0% 0.90 (0.84, 0.97)
Patients: 
Diseased 
optic nerves
13.6 0.65 ± 1.26 4.8% 0.96 (0.93, 0.99)
Healthy optic 
nerves
12.7 0.67 ± 1.31 5.3% 0.84 (0.70, 0.97)
Table 4.15: Measurement reproducibility for the different subgroups.
a1.96 x within-subject SD. 95% of measurements are expected to lie within this range
of the true value, if the variable is approximately Normally distributed.
b= The proportion of total variance due to between-subject variation. Under
assumptions which are plausible here, one minus this value is the proportion of
variation due to measurement error.
Control mean areas
At baseline the mean area of control optic nerves was 13.6 (SD 1.8)mm2. There were 
no significant differences between right or left optic nerves or in optic nerve mean area 
between males and females. The control mean area at 52 weeks was 13.1 (SD 1.8)mm2 
to give a time-averaged mean of 13.5 (SD 1.6)mm2 and gradient of change of 
-0.001mm2/day (95% Cl -0.003, 0.001; p=0.36).
Patients: Baseline mean areas
At baseline the mean area of diseased optic nerves was 16.1 (SD 3.1)mm2, 20.1% 
higher than the 13.4 (SD 2.0)mm2 for healthy contralateral optic nerves (mean
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difference=2.7mm2, 95% Cl 1.8, 3.7; pO.OOOl for hypothesis o f zero difference) and 
18.4% higher than the 13.6mm2 for controls (mean difference=2.5mm2 95% Cl 1.2, 3.8; 
p=0.0003).
Patients: 52 week mean areas
At 52 weeks the mean area of diseased optic nerves was 11.3 (SD 2.2)mm2, 11.7% 
lower than the 12.8 (SD 1.5)mm2 for healthy contralateral optic nerves (mean 
difference—1.5, 95% Cl -0.1, -2.8; p=0.032) and 13.7% lower than the 13.1mm2 for 
controls (mean difference—1.8, 95% Cl -0.5, -3.2; p=0.008) (Figure 4.16).
Figure 4.16: Baseline and one-year images from a 42 year-old woman with left-sided
optic neuritis. The first imaging was performed 14 days after onset of  
visual symptoms.
Patient healthy contralateral optic nerve mean area trajectories
There was no evidence o f change in area o f healthy contralateral optic nerves over time 
(gradient=-0.00072mm2/day, 95% Cl -0.0029,0.0015; p= 0.52) (Figure 4.17). There 
was also no evidence o f any difference in time-averaged values between the patients’ 
healthy contralateral optic nerves (mean 13.15 [SD 1.0]mm2) and control optic nerves 
(13.5mm2), difference 0.35mm2 (95% Cl 0.3, 1.0; p=0.32).
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Figure 4.17: Contralateral healthy optic nerve mean area over time with linear
model prediction shown in bold.
Patient diseased optic nerve mean area trajectories
The diseased optic nerve mean area declined over time, from initial swelling, to later 
atrophy. The best fitting model to describe the changes was an exponential (Figure 4.18 
for mean area and Figure 4.19 for ratio of diseased: healthy optic nerve mean area). The 
median gradient o f decline in mean area at baseline (reported as median due to three 
outliers) was -0.26mm2/day (95% Cl -0.35, -0.050). Significant ongoing decrease in 
area was still apparent after one-year. The mean gradient at 365 days was 
-0.0018mm2/day (95% Cl -0.0038, -0.00051; p<0.01 for difference from hypothesis of 
zero gradient). There was no evidence o f association between baseline diseased optic 
nerve area and outcome optic nerve area or with rate o f decline o f optic nerve area at 
either baseline or one-year.
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Figure 4.18: Diseased optic nerve mean area over time with predicted trajectory of
mean area by applying exponential model to all data points ignoring 
subject (bold line).
Days since onset o f  visual symptoms
Figure 4.19: Ratio o f diseased optic nerve: healthy optic nerve mean area over time
with predicted trajectory of mean ratio by applying exponential model to 
all data points ignoring subject (bold line).
Associations with vision
Higher baseline diseased optic nerve mean area was correlated with worse baseline 
logMAR visual acuity (rs=0.46, p=0.012) and with lower baseline visual field mean 
deviation (rs=-0.55, p=0.002). However, at 52 weeks there was no direct evidence o f
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association between vision scores and diseased optic nerve mean area. There was also 
no evidence of association between vision scores at one-year and either baseline or one- 
year gradients of decrease in diseased optic nerve mean area.
Associations with YEP parameters
There was no evidence of association between baseline, rates of decline or one-year 
diseased optic nerve mean areas and any of the baseline, one-year or time-averaged 
VEP variables.
Associations with lesion lengths
The median baseline gadolinium-enhanced lesion length was 30mm (range 0-39mm) 
and the median duration of enhancement was 63.5 days (range 0-113 days). The 
baseline diseased optic nerve mean area was 0.2mm2 (95% Cl 0.08, 0.3; p=0.001) 
higher for every additional 1mm of gadolinium-enhanced lesion length. However there 
was no association between baseline lesion length and initial or one-year rate of decline 
of optic nerve mean area, or one-year optic nerve mean area.
There was borderline evidence that the initial rate of decline in diseased optic nerve 
mean area was related to the length of time that enhancement was detected for, but not 
the one-year rate of decline: the baseline gradient of decline was less steep by 
3.5mm2/day for each day that enhancement was detected for (95% Cl 0.00099, 8.40; 
p=0.05).
The median baseline lesion length on FSE images was 21mm (range 9-39mm). There 
was no evidence of association between baseline lesion lengths on FSE images and 
baseline diseased optic nerve mean area or initial rates of decline of diseased optic nerve 
mean area. There was borderline evidence that the one-year rate of decline in diseased 
optic nerve mean area was less steep in the shortest quartile of baseline lesion length 
than in patients with longer lesions by 0.0019mm2/day (95% bootstrap Cl 8.6x10'5, 
0.0044; p=0.045).
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Associations with M TR values
The MTR results have been previously reported (Chapter 4.2). There was some 
evidence that higher one-year diseased optic nerve mean area values were associated 
with higher baseline mean optic nerve MTR values. The one-year mean area was 
higher by 0.47mm2 (95% bootstrap Cl 0.022, 0.92; p=0.045) per lpu rise in baseline 
mean MTR. There was a stronger association between one-year optic nerve mean area 
and time-averaged optic nerve MTR. The one-year mean area was higher by 0.76mm2 
(95% bootstrap Cl 0.29, 1.13; p=0.009) per lpu rise in time-averaged optic nerve MTR 
(Figure 4.20). However, there was no evidence o f a direct association between one-year 
optic nerve mean area and one-year optic nerve mean MTR values.
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Figure 4.20: The relationship between one-year optic nerve mean area and time-
averaged mean MTR.
4.3.5 Discussion
By prospectively studying a cohort o f patients with acute optic neuritis using multiple 
MRI sequences, detailed clinical tests and VEPs, and in particular using the sTE 
fFLAIR sequence and a computer-assisted contouring technique to segment the optic 
nerves, it has been possible to extend the previous observations that optic nerve atrophy 
occurs following optic neuritis, and may continue to develop over several years. The 
measurement CV figures for optic nerve area were o f the order o f 5%, however the 
reliability coefficiency figures o f approximately 0.9 suggest that the technique is 
reproducible, with 90% o f the variability due to inter-subject variability and only 10%
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due to measurement error (see Table 4.15). The reproducibility is not as good as for 
atrophy studies in the brain or spinal cord, reflecting the small size of the optic nerves 
and the greater potential for movement artefact. Higher resolution sequences or higher 
field imagers may help in future studies, although the former would be at the expense of 
increasing the acquisition time (Barker, 2000). At present, the sTE fFLAIR sequence 
presents the best compromise between high resolution and an acceptable acquisition 
time.
This study confirms, quantitatively, that optic nerve swelling occurs in acute optic 
neuritis, followed by the development of optic nerve atrophy over time. The results 
suggest an average increase in optic nerve mean area at baseline of approximately 20%. 
Optic nerve swelling on MRI had been previously thought to be a rare occurrence in 
acute optic neuritis and if swelling was present then it was recommended that a glioma 
or meningioma should be suspected (Comblath & Quint, 1997). The present study is in 
agreement with other studies (Youl et al., 1996; Kapoor et al., 1998) which suggest that 
optic nerve swelling is actually common in acute optic neuritis. This swelling is 
probably due to acute inflammation with inflammatory cell infiltrates and vasogenic 
oedema. The observations that the amount of swelling was related to the lesion length 
on the gadolinium-enhanced images and the less steep decline in optic nerve mean area 
with increasing duration of enhancement support this conclusion, since the gadolinium 
enhancement has been shown to correlate with pathological features of inflammation in 
MS (Katz et al., 1993; Bruck et al., 1997). This study also supports the previous 
observation that acute inflammation causes impairment of vision (Youl et al., 1991), 
with an association between the extent of acute optic nerve swelling and the degree of 
visual impairment in the acute phase.
The degree of initial swelling or acute enhancing lesion length was not associated with 
the degree of atrophy at one year, although there was a suggestion that the patients who 
had short acute FSE lesions had a decreased rate of continuing development of atrophy 
after one year. There was also an association between time-averaged optic nerve MTR 
and one-year optic nerve mean area. The presence of higher average MTR values 
implies less acute oedema and demyelination, although the degree of axonal integrity 
also contributes. The two mechanisms of Wallerian degeneration of axons previously 
discussed in Chapter 4.2, namely: transection in the acute inflammatory lesion and later
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axonal death in persistently demyelinated axons; probably both contribute to the 
development of optic nerve atrophy which occurred over the year of follow up. More 
prolonged follow-up may help to determine if remyelination, inferred from increasing 
mean MTR values and shortening of VEP latencies, confers protection against 
continuing axonal degeneration, as measured by ongoing atrophy development. If this 
is the case then therapies to induce remyelination might be appropriate for 
neuroprotection.
The lack of association between the optic nerve mean area and visual impairment after 
one year could reflect the fact that few patients had substantial visual impairment and 
that the overall extent of tissue loss was small (mean decrease in area 12%). It is 
probable that the remaining axonal fibres are sufficient to enable restoration of vision 
once the phase of conduction block during acute inflammation has passed. Recovery of 
vision may also, in part, be due to central adaptation. This has been suggested by a 
functional MRI study of patients who recovered back to normal vision following optic 
neuritis and in whom there was activation involving extra-striate cortical regions 
(Werring et al., 2000). Some of this reorganisation may be achieved by utilising 
redundant optic nerve capacity (Frisen & Quigley, 1984).
The data suggest that the decline in mean area from initial swelling to later atrophy 
followed an exponential curve. More prolonged follow-up will be undertaken to 
determine whether optic nerve atrophy continues to occur over several years, as 
suggested by the previous small study (Chapter 3.2). This previous study and another 
that has been published (Inglese et al., 2002) suggest that in patients seen some years 
following optic neuritis there is an association between the degree of atrophy and visual 
impairment. Although it is hard to directly compare studies, the degree of tissue loss 
was not much greater than reported in the present study at one year. It may be that 
further episodes of optic neuritis (that could have been asymptomatic) had occurred 
leading to more demyelination and conduction block, or that failure of remyelination of 
the initial lesion with persistent demyelination may have predisposed, over time, to 
secondary axonal degeneration (Scolding & Franklin, 1998; McGavem et al., 2000). In 
this case a small decrease in the number of critical macular axons may affect the ability 
of the visual system to compensate. The failure to compensate as axonal degeneration 
slowly but relentlessly occurs is one potential explanation for the development of
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secondary progression in MS. Although progressive significant visual impairment is 
unusual in MS, evidence for progressive atrophy of the optic nerve over a long period of 
time would support the concept that progressive axonal loss may follow acute 
inflammatory demyelination.
In the brain and spinal cord measures of atrophy in MS reflect the global effects of the 
disease, which includes both old and new lesions and normal-appearing tissues. The 
observation here of swelling in the acute inflammatory lesion and atrophy in the more 
chronic post inflammatory lesion suggest that the concurrent presence of lesions of 
differing ages, as is often seen in the brain of patients with relapsing forms of MS, may 
introduce noise when using the measure of progressive brain atrophy as surrogate 
markers of axonal loss. The present observations support the study of optic neuritis as a 
model for the development of atrophy following inflammatory demyelinating lesions.
A further implication of the present study is that disease modifying therapies for 
preventing acute inflammation have the potential to decrease the extent of tissue 
damage and axonal loss in MS. It also suggests that acute treatments during the 
inflammatory episode which prevent or reduce subsequent tissue loss should be sought.
It was reported above (Chapter 3.3) that high dose IVMP failed to prevent optic nerve 
atrophy following an attack of optic neuritis consistent with the lack of long-term 
functional benefit from the therapy. Novel therapies for acute MS relapses are therefore 
required. In future treatment trials of such agents, inclusion of patients with optic 
neuritis and the use of combined clinical, electrophysiological and quantitative MRI 
measures including optic nerve size would be useful in assessing the response to 
treatment.
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Chapter 5 Conclusions
The studies in this work have shown that optic neuritis is indeed a good model for the 
study of the effects of inflammatory demyelinating lesions. The lesion affects a defined 
pathway, with obvious clinical symptomatology that usually causes patients to present 
early. The effects on vision can be quantified reproducibly and VEP studies give an 
indication about how conduction in the optic pathways has been affected. This work 
has built on previous MRI studies on optic neuritis.
The acute lesion in optic neuritis is almost invariably associated with gadolinium 
enhancement, especially if triple-dose gadolinium is given. The finding of associations 
between the lesion length on triple-dose gadolinium-enhanced images and logMAR 
visual acuity (r=0.38, p=0.044), visual field mean deviation (r=-0.57, p=0.002) and VEP 
central field amplitude (r=-0.41, p=0.035) are in support of the view that the acute 
inflammatory lesion causes conduction block in the optic nerve (Youl et al., 1991). 
There was also an association, not seen in a previous study using single-dose 
gadolinium (Kupersmith et al., 2002), between the acute enhancing lesion length and 
outcome, although this was mostly due to patients with short inflammatory lesions 
having a good prognosis for recovery. The measurement of lesion length is a fairly 
crude way of determining the degree of acute inflammatory change as it does not reflect 
the signal intensity (“brightness”) changes in the optic nerve due to gadolinium leakage. 
One possible solution is to look at the relative change before and after gadolinium in the 
Ti properties of a tissue. This has been used in studies in the brain (Silver et al., 2001), 
but requires registration of the pre- and post-gadolinium enhanced images. Due to the 
small size of the optic nerves this was not possible using current methodology. It may 
be feasible in future with if resolution can be improved, perhaps by using higher field 
imagers or new phased array receiver coils.
The baseline level of visual impairment in the study in Chapter 4.1 appeared to be a 
poor predictor of visual outcome, but the visual field recovery curves showed a greater 
differentiation in shape between patients with good and poor recoveries, in particular 
regarding the initial gradient of recovery. In combination with the observation that 
initial enhanced lesion length was associated with the final recovery level it may 
suggest that a poor prognosis is fixed early on. There has been a suggestion that the
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reason that corticosteroids do not influence outcome, or the development of optic nerve 
atrophy as observed in Chapter 3.3, is that they are given too late to prevent acute 
axonal damage (Compston & Coles, 2002). Trials of corticosteroids in the hyperacute 
phase of optic neuritis would be required to test this hypothesis. Optic nerve imaging 
may be useful in helping select those patients who might be predicted to have a poor 
prognosis. It was previously thought that canalicular involvement led to a worse 
outcome (Miller et al., 1988), although this has not been borne out in subsequent studies 
(Kapoor et al., 1998; Kupersmith et al., 2002) and it was almost universal in the study 
in Chapter 4.1, probably due to the increased sensitivity of the technique. The results in 
Chapter 4.1 suggest that patients with short lesion on triple-dose gadolinium enhanced 
imaging have a better prognosis, independent of the level of baseline visual impairment. 
Triple-dose gadolinium enhanced imaging may therefore be useful in selecting patients 
for future optic neuritis treatment trials, although the cost implications will bar its use in 
routine clinical practice.
Optic neuritis can usually be diagnosed on clinical grounds (Chapter 1). The principal 
use of MRI in these patients is to assess the brain for asymptomatic demyelinating 
lesions. This can then give an indication for the likely risk of subsequent MS (Optic 
Neuritis Study Group, 1997a; Optic Neuritis Study Group, 2003) and may drive the 
decision to initiate DMDs, although they are not currently licensed for this indication in 
the United Kingdom. In clinical practice, optic nerve MRI is most useful in ruling out 
other pathologies, especially if the clinical presentation is atypical (Chapter 1).
The results from the optic nerve MTR study (Chapter 4.2) were interesting in that 
initially the MTR in the diseased optic nerves were unchanged, in contrast to the 
situation in brain MS lesions. This may have been partly due to the ultrastructure of the 
optic nerve with its subdivision into fascicles (Williams et al., 1989) limiting vasogenic 
oedema, although it has been demonstrated the swelling of the optic nerve does occur 
during acute optic neuritis (Chapter 4.3). The inflammatory infiltrate may also be more 
cellular which would tend to increase the number of sites for exchange of magnetisation 
(thus maintaining or increasing MTR). The subsequent prolonged decline followed by 
stabilisation and a small (but not significant) upturn may reflect slow clearance of 
myelin debris followed by remyelination. Studies with prolonged follow-up of patients 
with optic neuritis suggest that significant shortening of VEP latencies, implying
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remyelination, occurs for 2-3 years (Brusa et al., 1999; Brusa et al., 2001). It is 
interesting to note that in these studies and in the study in Chapter 4.1, vision scores 
were not associated with VEP latencies but were associated with VEP amplitudes. This 
supports the view that vision requires functional axonal channels. These are affected 
initially by acute inflammation causing conduction block, and subsequently by the 
degree of axonal damage. Demyelination may not prevent visual recovery as has been 
discussed in Chapter 1.
Optic nerve atrophy measures may be most influenced by the degree of axonal damage. 
The studies in Chapters 3 and 4.3 suggest that atrophy is a consistent feature following 
optic neuritis. The measurement reproducibility figures were not as good as for studies 
of brain and spinal cord atrophy, due to the difficulties of imaging the optic nerves as 
outlines. However, the reliability coefficients of ~0.9 imply that most of the variation 
was due to inter-subject variability rather than measurement variability, thus the 
measure provides a meaningful biological outcome. Improvements in the imaging 
sequence for measuring optic nerve size should be possible in future. The ideal imaging 
sequence for this purpose should combine short acquisition time with high spatial 
resolution, high SNR and CSF and fat suppression. 3D double inversion recovery or 3D 
fast FLAIR sequences may give some improvements over the current 2D sequence. If 
so, it may be possible to re-format the images in other planes and so obtain images 
orthogonal to the nerve. An automated method to segment the nerves could also be 
considered. A method using a B-Spline active surface technique has been proposed 
(Coulon et al., 2000). This has been tried in the spinal cord and gives good 
reproducibility results (Hickman et al., 2003). The technique appeared however to be 
less sensitive at detecting small changes than existing semi-automated threshold 
contouring, both in the spinal cord (Hickman et al., 2003) and when tested in the optic 
nerve on the sTE fFLAIR images (S.J. Hickman, unpublished observations). Further 
developments to active surface techniques are awaited.
There was no association between optic nerve mean area and vision scores in the 
patients studied with a short interval after the attack of optic neuritis (median 21 months 
in Chapter 3.1, six months in Chapter 3.3 and up to 12 months in Chapter 4.3) 
suggesting that initially the visual system can compensate for the damage to the afferent 
system, through redundancy in the system and/or more active reorganisation of cortical
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response. In the cohort studied with a longer interval which had patients up to 252 
months after their first attack of optic neuritis there was an association between optic 
nerve mean area and vision scores, in that the optic nerves with poor visual recovery 
(<6/9) were significantly smaller than healthy optic nerves (p=0.02). The ability to 
compensate may have been affected by either further attacks of optic neuritis that may 
have been subclinical or by ongoing loss of critical macular axonal fibres. The visual 
system may be able to compensate in the short-term but may fail over a longer period.
It is also possible that the full extent of atrophy that results from an acute 
inflammatory/demyelinating lesion does not emerge for a long time (i.e. more than one 
year) because of protracted and slow clearance of debris associated with Wallerian 
degeneration.
The cohort of patients from the studies in Chapter 4 is being followed-up after both two 
and three years. This will help to show if the observation of prolonged shortening of 
VEP latencies, implying remyelination, in previous studies can be repeated. It will also 
be interesting to see if the small upturn in MTR in the optic nerves between 240 days 
and one-year after onset of optic neuritis in the study of Chapter 4.2 is sustained, or 
even progressive. If the association remains between VEP latency and optic nerve MTR 
then it supports the use of MTR as a tool to measure remyelination in vivo, especially as 
therapies to promote remyelination have been proposed (Compston & Coles, 2002).
The association between time-averaged optic nerve MTR and one-year optic nerve 
mean area is interesting (Chapter 4.3). It implies that more pronounced damage of optic 
nerve integrity, probably as a combination of vasogenic oedema, demyelination and 
axonal transaction, leads to more long-term tissue damage. Prolonged follow-up may 
help to determine if remyelination, inferred from increasing mean MTR values and 
shortening of VEP latencies, may confer protection against continuing axonal 
degeneration, as measured by ongoing atrophy development. The amount of ongoing 
axonal degeneration is likely to be small as the long-term visual outcome following 
optic neuritis is very good (Optic Neuritis Study Group, 2004). Poor visual outcome 
(and increasing optic nerve atrophy as seen in Chapter 3.2) usually occurs due to 
recurrent attacks of optic neuritis.
The use of arbitrary standards to determine if vision had returned to normal did not 
always reflect the patients’ views on whether their vision had returned to normal in
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Chapter 4.1. Pelli-Robson contrast sensitivity and Ishihara colour vision scores 
appeared to be more discriminatory however these parameters are less amenable to 
statistical analysis compared with logMAR acuity and visual field mean deviation as 
they are not continuously variable. FM 100 Hue colour vision scores seemed to be able 
to discriminate between good subjective recovery and not as well as providing a 
continuously variable score for statistical analysis. The test however takes a long time 
to perform (-15 minutes per eye) and is unreliable when vision is worse than 6/60 
(Katz, 1995), as is common in the acute stages of optic neuritis. Future methods of 
testing could include rarebit perimetry which appears to be more sensitive for detecting 
optic nerve damage by being able to probe for damage within receptive fields (Frisen, 
2002; Frisen, 2003). It also has the advantage of being very fast to perform (one minute 
for each pass, although multiple passes are usually performed). Psychophysical testing 
may be useful in differentiating between magnocellular and parvocellular damage. In 
optic neuritis and MS the parvocellular pathway is thought to be affected more (Wall, 
1990; Caruana et al., 2000; Evangelou et al., 2001). Again, psychophysical testing is 
time consuming (60-75 minutes) and may not be able to distinguish between 
preferential damage to either system where there is profound visual loss. Chromatic 
(particularly red) perimetry could be considered (Frisen, 2002).
At present results of quantitative imaging studies can only be correlated with tests of 
visual function or of electrical conduction to validate them. Radiological-pathological 
studies are useful and have been performed successfully in the brain and spinal cord 
(van Waesberghe et al., 1999; De Groot et al., 2001; Mottershead et al., 2003).
Autopsy MRI of the optic nerves has not previously been performed. Any tissue would 
have to be carefully handled and due to the small size of the optic nerves and post 
mortem or fixation artefacts may have a profound influence on the results. There would 
not however be difficulties with orbital fat or CSF, nor movement artefact. Acquisition 
times post mortem can be much longer than could be tolerated in vivo and so higher 
spatial resolution would be possible. Another way of trying to assess the degree of 
axonal damage in the optic nerves, which is possible in vivo, is to image the RNFL. 
Atrophy of fibres of the RNFL has been described in MS (Frisen & Hoyt, 1974). 
Recently attempts have been made to try and quantify this loss. Two techniques that 
have been employed are scanning laser polarimetry (SLP) (Steel & Waldock, 1998) and 
ocular coherence tomography (OCT) (Parisi et al., 1999; Drexler et al., 2001). These
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can both give an indication of the thickness of the nerve fibre layer and have both been 
applied in patients following optic neuritis. Steel and Waldock (1998) found evidence 
of RNFL loss in 29/33 eyes previously affected by optic neuritis, although there was no 
correlation between SLP scores and other clinical tests. Parisi et al. (1999) measured 
RNFL thickness with OCT in 14 patients with MS who had had previous optic neuritis. 
Mean overall RNFL thickness was lll.ll±11.87/m i in 14 control eyes, 82.73±10.73/mi 
in clinically healthy eyes from MS patients and 59.79±10.80/mi in eyes previously 
affected by optic neuritis (p<0.01 compared with both controls and clinically healthy 
eyes). RNFL thickness correlated with PERG P50 latency and P50 to N95 amplitude 
but not VEP scores. It would be interesting to combine studies using both a measure of 
axonal integrity, such as the two methods mentioned above, and quantitative optic nerve 
imaging to try and quantify the amount of damage that occurs in the axonal pathways 
both within the retina and in the optic nerve. Should such studies reveal a correlation 
between RNFL thickness and an MR measure, it would further support using that MR 
measure (e.g. atrophy) as a surrogate markers of axonal loss.
Optic nerve MRI in optic neuritis/MS has developed from initial studies with STIR that 
could give an indication of lesion length and anatomical distribution of any lesion, 
through more sensitive means of detecting abnormalities in the visual pathway using 
sequences such as fat-saturated FSE and gadolinium enhancement, to the situation now 
where techniques such as atrophy and MT imaging that have been initially employed in 
the brain and spinal cord have been applied to the optic nerve. These techniques have 
gone some way to overcome the difficulties that imaging the optic nerve causes. In 
quantitative studies, reproducibility figures have not been as high as in studies of the 
brain and spinal cord. The techniques have though been sensitive to disease effects and 
in many studies produced results that correlate with measures of visual function and 
conduction in the optic pathways. Further refinements may be possible using higher 
field strengths or more sensitive coils. Another class of imaging technique that is being 
developed for optic nerve imaging is DWI as outlined in Chapter 2. DWI offers the 
potential to offer pathologically specific imaging with measures that are thought to be 
sensitive to changes in nerve structure, particularly axonal disruption. Further studies in 
optic neuritis using DWI are awaited.
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In conclusion, quantitative MRI of the optic nerves in optic neuritis can help to give 
insights into the evolution of the condition. Optic neuritis is a model for MS relapses in 
general. In future treatment trials of novel therapies that aim to improve outcome 
following MS relapses optic neuritis would be a useful testing ground. In such trials 
optic nerve MRI with some of the techniques outlined in this work could be used to 
screen patients and in assessing response to treatment. With further developments in 
MR technology, it is possible to foresee that future studies of the optic nerve, using 
advanced MRI, VEP and clinical evaluation, will not only define reliable imaging 
markers for specific pathological features in optic neuritis and MS, but will also 
elucidate the pathophysiological mechanisms for functional recovery and its failure.
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